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ABSTRACT 
ERIN KALTENBRUN: Molecular Determinants of Tbx20 Activity during 
Cardiac Development 
(Under the direction of Dr. Frank L. Conlon) 
 
 The formation of the heart is a complex process that requires the 
combinatorial activity of a number of critical cardiogenic transcription factors that 
function to drive distinct gene subprograms in the developing heart. Tbx20 is a 
potent activator of cardiac gene expression, and has also been shown to act as a 
transcriptional repressor in the heart. Precise regulation of Tbx20 expression levels 
and activity is crucial for normal heart development, as alterations in Tbx20 levels 
and activity lead to a spectrum of cardiac defects in humans and in animal models. 
Despite the importance of Tbx20 in heart development, very little is known about 
how Tbx20 expression is regulated in the heart. Further, the mechanisms by which 
Tbx20 acts to regulate its target genes are not understood. Here we explore the 
Tbx20 transcription network, both at the gene and protein level, to identify critical 
determinants of Tbx20 activity during heart development.  
 
 We have identified a crucial role for BMP signaling in maintaining Tbx20 
cardiac expression during cardiac chamber maturation. This regulation is mediated 
by a minimal 334 bp regulatory element that is sufficient to drive cardiac expression 
 iii 
of Tbx20 in Xenopus, zebrafish, and mouse, indicating that this regulatory pathway 
is evolutionarily conserved among vertebrates. To begin to decipher how Tbx20 
regulates its target genes, we have undertaken a proteomic screen of Tbx20 
transcription complexes, both in human cells and mouse embryonic stem cell-
derived cardiomyocytes. These studies resulted in the identification of a broad 
chromatin remodeling network that includes both co-activators and co-repressors. 
Specifically, Tbx20 directly recruits a Groucho/TLE and histone deacetylase 
repressor complex through an N-terminal eh1 domain. Additionally, Tbx20 recruits 
multiple chromatin remodelers including components of the SWI/SNF complex, the 
NuRD complex, and the INO80 complex. Collectively, these studies suggest that 
Tbx20 controls gene expression in the developing heart through selective 
association with distinct chromatin remodeling complexes. This work provides insight 
into how Tbx20 activity is regulated during cardiac development. 
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Chapter 1 
Introduction 
 
 The heart is one of the first structures to form during embryonic development, 
and cardiac precursor cells are among the first cells of the epiblast to ingress during 
gastrulation. Fate-mapping studies in mice have determined that prospective heart 
mesoderm is localized in the anterior portion of the primitive streak (Lawson et al., 
1991; Parameswaran and Tam, 1995). In the early to mid-streak stages, heart 
mesoderm progenitors begin to migrate from the anterior primitive streak to the 
anterior proximal region of the epiblast (future anterior ventral midline of the embryo) 
and come to lie underneath the head folds, forming a structure known as the cardiac 
crescent (Parameswaran and Tam, 1995; Tam et al., 1997). By the late primitive 
streak stages (E7-7.5), cells of the cardiac crescent begin to express the first 
markers of heart mesoderm including Nkx2.5, Gata4/5, Tbx5, and Tbx20 (Arceci et 
al., 1993; Komuro and Izumo, 1993; Horb and Thomsen, 1999; Carson et al., 2000).  
  
 Myocardial precursor cells undergo a number of sequential, but overlapping 
processes to become terminally differentiated cardiomyocytes. Studies have 
demonstrated important roles for a number of signaling families in early cardiac 
! 2!
specification including the BMP, FGF, Hedgehog, and Wnt families (Reifers et al., 
2000; Zhang et al., 2001; Gadue et al., 2006; Foley et al., 2007; Kattman et al., 
2011). Integration of these signals by prospective cardiac precursors during 
gastrulation and anterolateral migration triggers heart field patterning and 
commitment to a myocardial fate. Expression of Mesp1, a bHLH transcription factor, 
is transiently expressed in prospective cardiac mesoderm and is thought to act as a 
molecular switch during cardiac specification by activating many of the key genes 
within the core cardiac transcription network and repressing genes that promote 
early mesoderm and endoderm cell fates (Bondue et al., 2008). Combinatorial 
expression of the transcription factors Nkx2.5, Gata4/5, Tbx5, and Tbx20 within the 
early heart field marks cardiac progenitors. Recent work in this field supports the 
idea that these transcription factors are core components of a large regulatory 
network that drives myocardial lineage development and morphogenesis of the early 
embryonic heart. Additionally, the importance of Nkx2.5, Gata4/5, Tbx5, and Tbx20 
as critical modifiers of cardiac cell fate and morphogenesis is underscored by the 
identification of mutations within these genes that are associated with a variety of 
congenital heart malformations in humans (Basson et al., 1997; Schott et al., 1998; 
Pehlivan et al., 1999; Kirk et al., 2007). Therefore, it is critical to identify and 
understand the protein-protein interactions, transcriptional targets, and upstream 
regulators of these core cardiac transcription factors.  
 
 Here, we investigate the molecular regulators of Tbx20 expression and 
function during cardiac development. Within this cohort of core cardiac transcription 
! 3!
factors, Tbx20 is unique in that it is expressed uniformly throughout all layers 
(epicardium, myocardium, and endocardium) of the forming heart during 
development and adulthood. Additionally, this expression pattern is conserved from 
flies to humans implying a fundamental role for Tbx20 in proper heart development 
and function (Ahn et al., 2000; Griffin et al., 2000; Meins et al., 2000; Iio et al., 2001; 
Brown et al., 2003; Huang et al., 2012; Sakabe et al., 2012). We provide evidence 
that BMP signaling is required to maintain Tbx20 expression in the heart during 
cardiac chamber formation, suggesting a critical role for the BMP pathway in driving 
proper regionalization of cardiac chambers (Mandel et al., 2010). We also show that 
Tbx20 interacts with a unique transcription repression network that includes 
components of both the Nucleosome Remodeling and Deacetylase (NuRD) complex 
and Groucho/TLE co-repressors. We predict that the Tbx20 repression network is 
essential to prevent inappropriate gene activation within the developing heart. 
Finally, we have developed a novel approach to identify endogenous cardiac-
specific Tbx20 interaction partners over the course of cardiomyocyte development, 
which has resulted in the discovery of new components of the Tbx20 regulatory 
network. First, I will introduce the current understanding of relationships within the 
core cardiac transcription factor network, highlighting the roles of critical activating 
and repressing transcription factor protein complexes in specifying and maintaining 
cardiac cell fate. 
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A CORE CARDIAC TRANSCRIPTION FACTOR NETWORK  
 In addition to the core factors Mesp1, Nkx2.5, Tbx5, Tbx20, and Gata4, other 
transcription factors are expressed and have critical functions during cardiogenesis. 
In particular, MEF2 factors and SRF, additional T-box proteins including Tbx1, Tbx2, 
Tbx3, and Tbx18, as well as the homeodomain protein Isl1 have each been shown 
to be important for proper heart development (Lin et al., 1997; Wang et al., 2001a; 
Vitelli et al., 2002; Cai et al., 2003; Harrelson et al., 2004; Hoogaars et al., 2004; 
Christoffels et al., 2006). Collectively, these transcription factors act in 
interconnected pathways to regulate the expression of each other, as well as 
downstream gene targets to control heart development. The transcription factors 
Nkx2.5, Tbx5, Tbx20, Gata4, and Mef2C also physically interact with each other, 
implying that the transcriptional control of heart development is directed by 
cardiogenic transcription factors that are linked genetically and biochemically via 
large multimeric protein complexes (Figure 1.1) (Morin et al., 2000; Hiroi et al., 2001; 
Sepulveda et al., 2002; Stennard et al., 2003; Vincentz et al., 2008; Munshi et al., 
2009; Junion et al., 2012).  
 
Positive regulation of cardiac cell fate: Evidence for a Transcription Factor 
Collective 
 
 Over the last two decades, studies regarding the relationships between 
cardiac transcription factors support the notion that core cardiac transcription factors 
promote specification, proliferation, and differentiation of cardiac precursor cells, as 
well as morphogenetic movements of the primitive heart tube, via protein-protein 
interactions with other transcription factors (Figures 1.2, 1.3, 1.4, and 1.5). These 
! 5!
protein-protein interactions appear to be critical to ensure activation of multiple 
cardiac genes, and thus point to a “transcription factor collective” model in which 
cardiogenic transcription factors bind to and activate cardiac enhancers 
cooperatively. I present the following examples in support of this model: 
 
Nkx2.5  
 Nkx2.5 encodes a homeobox transcription factor that was originally cloned 
from Drosophila (msh-2, tinman) in a screen looking for new mesoderm-specific 
homeobox genes (Bodmer et al., 1990). Tinman is expressed in mesoderm 
primordium in the early embryo; however, expression later becomes restricted to the 
visceral mesoderm and the heart (Bodmer et al., 1990). Drosophila embryos with 
mutant tinman lack both heart precursor cells and differentiated heart cells indicating 
a role for tinman in heart precursor specification (Bodmer, 1993). The vertebrate 
homolog of tinman, Nkx2.5 (Csx), was independently cloned in the mouse, chick, 
fish, and frog. In all species examined, Nkx2.5 is expressed in early cardiomyocyte 
precursors (Komuro and Izumo, 1993; Lints et al., 1993; Tonissen et al., 1994; 
Schultheiss et al., 1995; Chen and Fishman, 1996). Targeted deletion of Nkx2.5 in 
the embryonic heart arrests heart tube morphogenesis and looping, resulting in 
embryonic death at E9-10 (Lyons et al., 1995). Additional studies in Xenopus 
demonstrate that XNkx2.5 overexpression results in an enlarged heart, consistent 
with a critical role for Nkx2.5 in maintenance of the heart fields (Cleaver et al., 1996). 
Interestingly, co-injection of dominant negative repressor derivatives of XNkx2.3 and 
XNkx2.5 into Xenopus embryos causes a more severe cardiovascular phenotype 
! 6!
than repression of XNkx2.5 alone with a complete loss of differentiated myocardium 
(Fu et al., 1998; Grow and Krieg, 1998). This finding suggests that there may be 
some functional redundancy among the NK/tinman family members and helps to 
explain why Nkx2.5 knockout mice are able to generate a primitive heart tube. Early 
studies defined Nkx2.5 as a transcriptional activator capable of binding novel 
homeodomain sites as well as sites that resemble serum response elements (Chen 
and Schwartz, 1995), which serve as binding sites for the MADs box transcription 
factor SRF (Treisman, 1986).  
 
  Initial studies on Nkx2.5-mediated transcriptional regulation revealed that 
Nkx2.5 interacts with a number of factors to regulate gene expression in the heart.  
Nkx2.5 interacts with Gata4 and SRF to activate cardiac alpha-actin (αCA) gene 
expression (Chen and Schwartz, 1996; Sepulveda et al., 1998; Sepulveda et al., 
2002) and interacts with Gata4 to activate atrial natriuretic factor (ANF) expression 
(Durocher et al., 1997; Lee et al., 1998; Sepulveda et al., 1998). A recent study 
demonstrated that Nkx2.5 interacts directly with the MADs box transcription factor 
Mef2c (Vincentz et al., 2008). Interestingly, allele inactivation of Mef2c results in a 
similar phenotype to Nkx2.5 deficient animals, with arrested heart looping and 
defective cardiomyocyte differentiation (Lin et al., 1997; Vong et al., 2006). Mef2c 
and Nkx2.5 also genetically interact; compound deletion of both genes results in a 
global loss of ventricular markers relative to the single mutants indicating a role for 
this complex in promoting ventricular identity (Vincentz et al., 2008). Additionally, 
Nkx2.5 has been shown to interact with the bHLH transcription factor Hand2 to 
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promote ventricular differentiation (Yamagishi et al., 2001). Nkx2.5-/-; Hand2-/- 
mutants have a single atrial chamber, and expression of Irx4, a ventricle-specific 
gene, is completely abolished, thereby suggesting that Nkx2.5 and Hand2 promote 
ventricle differentiation in part through cooperative regulation of Irx4 (Yamagishi et 
al., 2001). Aside from its role in promoting normal differentiation and morphogenesis 
of chamber myocardium, Nkx2.5 is also critical for development of the cardiac 
conduction system. Nkx2.5 dosage is directly proportional to the number of cells in 
the cardiac conduction system pointing to a role for Nkx2.5 in promoting the genetic 
conduction program (Jay et al., 2004). Nkx2.5 was later found to promote 
specification of ventricular myocytes into ventricular conduction system cells through 
a genetic interaction with Tbx5, which together cooperatively regulate Id2 and other 
conduction system genes (Moskowitz et al., 2007). Collectively, these studies 
demonstrate that interaction of Nkx2.5 with other cardiogenic transcription factors is 
critical for proper regulation of downstream cardiac genes, and subsequent 
activation of the appropriate cardiac gene program (Figure 1.2). The choice of 
protein co-factor may also provide an additional level of specificity for Nkx2.5-
mediated gene regulation. 
 
 The importance of Nkx2.5 function in establishing the early heart field is 
underscored by identification of mutations in human NKX2.5 that are associated with 
non-syndromic atrial septal defects (ASD), atrioventricular conduction abnormalities, 
ventricular septal defects (VSD), tetralogy of Fallot, double-outlet right ventricle, and 
valve diseases (Schott et al., 1998; Benson et al., 1999). All mutations characterized 
! 8!
thus far, most of which are truncations or missense mutations in the homeodomain, 
are predicted to augment DNA binding. These data suggest that the principal 
determinant of the congenital heart defects associated with NKX2.5 mutations is the 
total dosage of NKX2.5 capable of binding to DNA (Schott et al., 1998; Kasahara et 
al., 2000; Kasahara and Benson, 2004). 
 
Gata4  
 Gata4 is a member of the GATA transcription factor family, which contains 
two zinc fingers that are required for binding to the GATA binding sequence 
[(A/T)GATA(A/G)] (Molkentin, 2000). Gata4 was identified in a screen of a mouse 
embryo cDNA library searching for new GATA-binding factors and was enriched in 
heart tissue (Arceci et al., 1993). A second group independently identified Gata4 in a 
Xenopus tadpole liver cDNA library and demonstrated that Gata4 is expressed in 
presumptive cardiac ventral mesoderm (Kelley et al., 1993). In the primitive heart, 
Gata4 is expressed in the developing atria and ventricles, as well as the 
endocardium. Expression in the heart persists through gestation and after birth 
(Kelley et al., 1993; Heikinheimo et al., 1994). Early studies in cell culture models of 
cardiac differentiation suggest that Gata4 plays a role in cardiomyocyte 
differentiation (Grepin et al., 1995; Grepin et al., 1997). However, Gata-4 null mice 
form relatively normal differentiated myocardium leading to hypotheses about the 
possible redundancy of Gata4 with other Gata factors (Gata5/6 are also expressed 
in the developing heart) or with other cardiac transcription factors (Kuo et al., 1997; 
Molkentin et al., 1997). Though Gata4-/- cardiac precursors undergo differentiation, 
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the cardiomyocytes fail to migrate to the ventral midline and instead generate 
cardiac structures in the dorsolateral regions of the embryo indicating that Gata4 is 
essential for migration of the presumptive heart fields (Kuo et al., 1997; Molkentin et 
al., 1997).  
 
Gata4 acts as a potent transactivator of cardiac genes (Figure 1.3). Gata4 
physically interacts with Gata6 in the myocardium to cooperatively activate 
ANF/Nppa and B-type natriuretic peptide (BNP) transcription, providing at least one 
example in which Gata4 and Gata6 act in the same transcriptional pathway (Charron 
et al., 1999). As previously described, Gata4 interacts with Nkx2.5 on the αCA and 
ANF/Nppa promoters (Durocher et al., 1997; Shiojima et al., 1999; Small and Krieg, 
2003). Synergistic activation of ANF/Nppa by Nkx2.5 and Gata4 relies on an Nkx2.5-
binding element in the ANF/Nppa promoter, suggesting that Nkx2.5 recruits Gata4 to 
the promoter (Shiojima et al., 1999). Similarly, Gata4 has been shown to interact 
with Tbx5 and Mef2C to activate the ANF/Nppa promoter. Gata4-Isl1 complexes 
activate Mef2c expression in the second heart field, a region of cardiogenic 
mesoderm that resides anterior to the primary heart field and gives rise to the 
outflow tract and portions of the right ventricle (Morin et al., 2000; Garg et al., 2003; 
Dodou et al., 2004). Gata4 and Tbx5 also cooperatively activate expression of 
connexin 30.2 (Cx30.2), a gap junction protein required for atrioventricular node 
delay, in the conduction system (Munshi et al., 2009). Interestingly, a heterozygous 
missense mutation in human GATA4 that is associated with cardiac septal defects 
disrupts the physical interaction between Gata4 and Tbx5, underscoring the 
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importance of the GATA4-TBX5 interaction in human heart development and 
supporting the idea that disruption of the core cardiac transcription factor network 
leads to major cardiac anomalies (Garg et al., 2003). GATA4 haploinsufficiency also 
leads to congenital heart defects in humans: patients with monosomy 8p23.1 
(deletion of the distal arm of chromosome 8p) and congenital heart disease were 
found to have deletions at the GATA4 locus (Pehlivan et al., 1999). A del(8)(p23.1) 
patient who lacked cardiac anomalies did not have a GATA4 deletion, indicating that 
GATA4 deficiency directly contributes to congenital heart disease (Pehlivan et al., 
1999). 
 
Tbx5 
TBX5, a member of the T-box family of transcription factors [Brachyury (T) 
gene family], was originally identified as a gene mutated in Holt-Oram syndrome 
(HOS1) patients (Basson et al., 1997; Li et al., 1997). HOS1 is an autosomal 
dominant disorder that is characterized by cardiac and skeletal defects including 
upper limb defects, ASD, VSD, and tetralogy of Fallot (Hurst et al., 1991). Detailed 
mapping of the genomic region responsible for HOS1 revealed mutations in TBX5. 
TBX5 was subsequently found to be expressed in the human embryonic heart and 
limbs (Li et al., 1997). Interestingly, different TBX5 mutations result in distinct HOS1 
clinical features. Null mutations in TBX5 lead to defects in both the limbs and heart, 
whereas missense mutations can produce significant cardiac defects with minor 
skeletal defects or minor cardiac abnormalities with extensive limb malformations 
(Basson et al., 1999). Structural analyses of the location of TBX5 missense 
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mutations revealed that different mutations are predicted to perturb distinct target 
DNA interactions (binding to the major groove of DNA versus the minor groove), 
indicating that TBX5 may interact with DNA differently in the developing heart 
compared to the limbs (Basson et al., 1999). In vitro binding assays have identified 
an octamer sequence [AGGTGTG(A/G)] to which Tbx5 binds that is part of the 
Brachyury consensus half site (Ghosh et al., 2001; Macindoe et al., 2009). Tbx5 can 
also bind the full palindromic Brachyury binding site indicating there is some 
flexibility in Tbx5 target sequence grammar (Ghosh et al., 2001). 
 
The precise role of Tbx5 in heart development was first assessed in Xenopus, 
where Tbx5 is expressed throughout the early heart field and within the forming 
heart tube in all but the most anterior region, the bulbus cordis (Horb and Thomsen, 
1999). Inhibition of XTbx5 using a dominant negative repressor version of the protein 
results in a dose-dependent block in heart formation, highlighting a global role for 
Tbx5 in heart formation (Horb and Thomsen, 1999). In the mouse and chick, Tbx5 is 
expressed uniformly throughout the cardiac crescent. However, upon formation of 
the heart tube, Tbx5 expression becomes graded with stronger expression at the 
posterior end (Bruneau et al., 1999). In the looped heart, Tbx5 is expressed in the 
left ventricle, but not the right ventricle or the outflow tract (Bruneau et al., 1999). 
Heterozygous Tbx5+/- mice phenocopy defects seen in HOS1 patients; homozygous 
deletion of Tbx5 in the mouse results in severe hypoplasia within the posterior region 
of the heart and reduced expression of ANF/Nppa and connexin 40 (Cx40) (Bruneau 
et al., 2001). In agreement with these studies, Tbx5 physically binds Nkx2.5 and 
! 12!
Gata4 to synergistically promote ANF/Nppa expression (Bruneau et al., 2001; Hiroi 
et al., 2001; Garg et al., 2003) and modulates Cx40 expression in combination with 
Nkx2.5 and Gata4 (Linhares et al., 2004). Additionally, Tbx5 and Gata4 genetically 
interact; mice heterozygous for both alleles have atrioventricular septal defects and 
myocardial thinning, defects distinct from the isolated ASD observed in Tbx5 
heterozygotes (Maitra et al., 2009). Tbx5 also forms a complex with Mef2C on the 
alpha-cardiac myosin heavy chain (Myh6) promoter to drive Myh6 expression and 
normal heart patterning (Ghosh et al., 2009). Collectively, these studies have 
identified Tbx5 as a crucial node within the cardiac transcription network (Figure 
1.4). Recent studies have continued to investigate the functions of Tbx5 in different 
cardiac cell populations. This work has revealed an essential function for Tbx5 in 
directing ventricular and atrial septation (Takeuchi et al., 2003; Xie et al., 2012), 
specifying the proepicardium (Liu and Stainier, 2010), patterning of the conduction 
system (Moskowitz et al., 2004; Moskowitz et al., 2007), and regulating cardiac cell 
cycle progression (Goetz et al., 2006). Further studies are required to explore how 
Tbx5 intersects with other transcription factor pathways to regulate these diverse 
processes. 
 
Tbx20 
 Tbx20 (H15, Tbx12, HrT) was independently identified in human, mouse, 
zebrafish, and Drosophila as a novel T-box gene expressed in the heart (Ahn et al., 
2000; Carson et al., 2000; Griffin et al., 2000; Meins et al., 2000). Shortly thereafter, 
Tbx20 was identified in Xenopus and chick (Iio et al., 2001; Brown et al., 2003). In all 
! 13!
of these species, Tbx20 transcipts are enriched in the anterior lateral plate 
mesoderm and gradually become restricted to the cardiac primordial prior to ventral 
migration. Expression is maintained in the primary heart field throughout the process 
of migration, looping, and cardiac chamber formation. Thus, Tbx20 is expressed at 
the same time, and in many of the same regions as the transcription factors Tbx5, 
Nkx2.5, and Gata4. Morpholino knockdown of the Tbx20 protein in Xenopus 
embryos results in a loss of cardiomyocytes and unlooped hearts, but cardiac 
specification and migration proceeds normally (Brown et al., 2005). In agreement 
with these studies, deletion of Tbx20 in mice also results in a loss of 
cardiomyocytes, failure to loop, and defects in cardiomyocyte maturation and 
chamber specialization (Cai et al., 2005; Singh et al., 2005; Stennard et al., 2005; 
Takeuchi et al., 2005). Moreover, the role of Tbx20 in heart formation appears to be 
evolutionarily ancient, with Drosophila having two Tbx20 orthologues, neuromancer 
(nmr1) and neuromancer2 (nmr2), which are also referred to as H15 and midline, 
respectively. Like Tbx20, this pair of genes is required for proper development of the 
dorsal vessel, a structure thought to be homologous to the vertebrate heart 
(Miskolczi-McCallum et al., 2005; Qian et al., 2005; Reim et al., 2005). 
 
Recent studies have identified a number of patients with dilated 
cardiomyopathy, ASD, or mitral valve disease that carry mutations in TBX20. 
Additionally, upregulated TBX20 gene expression has been linked to tetralogy of 
Fallot (Kirk et al., 2007; Hammer et al., 2008; Qian et al., 2008; Posch et al., 2010). 
Of the 12 mutant forms of TBX20 associated with congenital heart disease, eight are 
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missense mutations within the T-box domain, and two are identical mutations in 
unrelated individuals. Of the remaining four TBX20 mutations, one is a missense 
mutation leading to truncation of TBX20 in the T-box domain and the other three are 
missense mutations mapping to two different regions of unknown function. 
Interestingly, one of the missense mutations in the T-box domain is a gain-of-
function mutation that enhances transcriptional activity and increases occupancy of 
DNA (Posch et al., 2010). These genetic studies imply that precise regulation of both 
TBX20 expression and transcriptional activity is critical for normal heart 
development. 
 
Similar to Tbx5, the optimal binding site for Tbx20 corresponds to a T-half-site 
(Macindoe et al., 2009). The Tbx20 binding site differs from that of Tbx5 in that it 
does not display any variation in the last nucleotide position (AGGTGTGA). 
Additionally, Tbx5 and Tbx20 exhibit different binding affinities and kinetics on T-
half-sites, thus implying that there may be some degree of T-box competition on 
cardiac gene promoters (Macindoe et al., 2009).  
 
Although T-box binding elements may predominantly control localization of 
Tbx20 to sites within the genome, the function of Tbx20 as a transcriptional activator 
or repressor likely relies on protein-protein interactions with transcription factor 
partners.  A number of studies suggest that Tbx20 physically interacts with Isl1, 
Nkx2.5, and Gata4 to positively regulate cardiac genes including ANF/Nppa 
(Stennard et al., 2003; Takeuchi et al., 2005; Singh et al., 2009). Further, Tbx20 
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transcriptional activity is enhanced in the presence of Gata4/5 and Nkx2.5 (Posch et 
al., 2010) Consistent with these data, a recent study identified GATA and NKX 
binding motifs in Tbx20-bound genomic regions. Further, these binding motifs were 
over-represented in Tbx20-bound regions associated with genes that were down-
regulated in Tbx20 knockout hearts, indicating that these genes represent targets of 
Tbx20-mediated activation (Sakabe et al., 2012). Tbx20 also interacts with Tbx5, 
and this interaction may be important for the regulation of genes associated with cell 
polarity or adhesion as depletion of Tbx20 and Tbx5 protein from Xenopus embryos 
results in severe cardiac defects compared to single morphants but cardiomyocyte 
marker expression is maintained (Brown et al., 2005). The effect of protein-protein 
interactions on Tbx20 transcriptional activity appears to be context- and dose-
dependent. For instance, in the presence of Nkx2.5 and Gata4, Tbx20 activates the 
ANF/Nppa promoter; however, in the presence of Tbx5, Tbx20 appears to repress 
ANF/Nppa activation by Tbx5 in a dose-dependent manner. These results suggest 
that Tbx20 functions as both a co-activator and co-repressor of cardiac transcription 
factors (Figure 1.5), and this decision may be based on local levels of Tbx20 as well 
as on protein partner choice (Plageman and Yutzey, 2004; Brown et al., 2005). More 
studies are needed to shed light on this discussion. In particular, very little is known 
about the role of Tbx20 as a transcriptional repressor. 
   
 The frequent occurrence of collaborative transcription factor interactions in 
heart development points to several different models for how transcription factors 
complexes bind to and activate target genes. The first model, known as the 
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“enhanceosome model” suggests that transcription factors are recruited and bind to 
the enhancer as an intact complex. In this model, the exact positioning of bound 
transcription factors within the complex is important, as the complex must bind to a 
very specific motif grammar within the enhancer (Arnosti and Kulkarni, 2005). The 
second model, called the “billboard model” presupposes that each transcription 
factor is recruited independently to the cardiac enhancer and binds to its own 
sequence motif. This model predicts that cardiac enhancers will contain individual 
binding motifs for all bound transcription factors (Arnosti and Kulkarni, 2005). A 
recent study assessed genome-wide cardiac transcription factor binding in 
cardiomyocytes, specifically examining regions bound by the factors Nkx2.5, Gata4, 
Tbx5, SRF, and Mef2A (He et al., 2011). The authors found that regions bound by 
one transcription factor were often highly enriched for binding motifs of factors that 
are known to interact with the first transcription factor. Of the chromatin regions 
bound by multiple transcription factors, many were enriched for genes that are 
expressed in a cardiac-specific manner and represent bona fide cardiac enhancers, 
confirming that binding of multiple cardiac transcription factors is predictive of 
cardiac-specific transcription (He et al., 2011). A similar study assessed genome-
wide binding sites in Drosophila dorsal mesoderm of the factors Tin (an NKX factor), 
Doc (a T-box factor), Pnr (a GATA factor), dTCF (an effector of Wnt signaling), and 
pMad (an effector of TGF-β signaling) (Junion et al., 2012). These investigators 
found that the most prominent binding signature within cardiac enhancers is the 
simultaneous recruitment of all five transcription factors. However, when they 
evaluated the motif content within the enhancers occupied by these transcription 
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factors, they found much higher enrichment of Doc and Pnr motifs compared to the 
other transcription factor motifs. These data indicate that Doc and Pnr may bind in a 
sequence-specific manner and other cardiac transcription factors may be recruited 
independently of sequence grammar (Junion et al., 2012). These studies have led to 
the development of a third enhancer model, the “transcription factor collective 
model”. This model suggests that cardiogenic transcription factors cooperatively 
activate cardiac enhancers; however, binding of the cohort of factors does not 
require a specific sequence motif. This model suggests that it may not be necessary 
for all of the factors to directly bind the enhancer. Instead, it may suffice for a subset 
of the transcriptions factors to bind their sequence motifs, which results in 
recruitment of the rest of the complex via protein-protein interactions with the DNA-
bound transcription factors. 
 
 Collectively, these studies reveal the complexity of transcription factor 
pathways within the cardiac regulatory network. Mutations in many of the core 
transcription factors in this network have been identified in humans, and these 
mutations have been linked to a variety of cardiac malformations (reviewed in Table 
A1.1). These data emphasize the importance of understanding how these 
transcription factor pathways intersect to promote normal heart development.  
Additionally, the idea that the cooperative activity of multiple cardiac transcription 
factors promotes cardiac gene expression holds great promise for regenerative 
medicine. Heart failure is a leading cause of death worldwide, due largely to the 
inability of the human heart to regenerate damaged myocardium after infarct. 
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Though recent studies have demonstrated that the adult heart retains some 
regenerative capacity, this capacity is extremely limited, and a large portion of adult 
cardiomyocytes are quiescent and incapable of generating new cardiomyocytes to 
replace injured myocardium (Bergmann et al., 2009; Kajstura et al., 2010; Walsh et 
al., 2010; Senyo et al., 2013). Recent work has demonstrated that the addition of 
Gata4, Mef2c, and Tbx5 to adult cardiac fibroblasts is sufficient to reprogram these 
cells to cardiomyocytes, in vitro and in vivo (Ieda et al., 2010; Qian et al., 2012). This 
provides additional evidence that cardiac cell fate is driven by the combinatorial 
activities of multiple core transcription factors and highlights the human health 
applications if the relationships between these factors are precisely defined. 
  
Cardiac transcription factors and chromatin remodelers: Regulation at the 
chromatin level 
 
 Cardiac transcription factors interact with a number of chromatin remodeling 
and histone-modifying factors to regulate gene expression in the developing heart. 
These interactions may promote a more accessible chromatin configuration, allowing 
transcription factors to bind and recruit activators to the locus; alternately, they result 
in recruitment of histone-modifying enzymes that alter histone-DNA contacts to 
promote a more “closed” chromatin configuration. Here, I will review some examples 
of how these types of interactions are critical for proper transcriptional regulation of 
cardiac development. 
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BAF Complexes 
 The SWI/SNF ATP-dependent chromatin remodeling complexes PBAF and 
BAF are large protein complexes that share eight common subunits. The PBAF 
complex is distinguished from BAF by the presence of the unique subunit Baf180 
(Xue et al., 2000), whereas BAF complexes contain Baf250 (Nie et al., 2000). 
SWI/SNF complexes facilitate chromatin remodeling through nucleosome 
mobilization and allow transcription factors to access the DNA template (Kwon et al., 
1994). Both SWI/SNF complexes have been demonstrated to be required for proper 
heart development (Lickert et al., 2004; Wang et al., 2004). Ablation of the PBAF 
subunit Baf180 results in hypoplastic ventricles and ventricular septal defects 
indicating that the PBAF complex is required for ventricular chamber development 
(Wang et al., 2004). Similarly, knockdown of Baf60c, a subunit common to both BAF 
complexes, results in impaired expansion of the early heart fields and defects in 
cardiomyocyte maturation (Lickert et al., 2004). Interestingly, expression of Baf60c 
with Tbx5, Nkx2.5, and Gata4 increased ANF/Nppa reporter activity compared to 
control in the presence of just the transcription factors, suggesting that BAF 
complexes may potentiate transcription factor activation of ANF/Nppa (Lickert et al., 
2004). This potentiation requires the presence of the ATPase subunit of BAF, Brg1, 
which was shown to interact with Tbx5, Nkx2.5, and Gata4 in the presence of 
Baf60c. Finally, a combination of Baf60c, Gata4, and Tbx5 can direct mouse 
mesoderm into beating cardiomyocytes, again suggesting that BAF complexes 
permit binding of transcription factors to cardiac genes (Takeuchi and Bruneau, 
2009). BAF complexes therefore interact with cardiac transcription factors to activate 
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cardiac genes, leading to the hypothesis that interactions between transcription 
factors and chromatin remodeling complexes may be a common feature of heart-
specific chromatin activation. 
  
 Several groups have characterized the role of Brg1 in cardiac gene regulation 
(Stankunas et al., 2008; Hang et al., 2010; Takeuchi et al., 2011). Endocardial-
specific deletion of Brg1 leads to trabeculation defects that arise as a result of 
derepression of the secreted matrix metalloproteinase, ADAMTS1 (Stankunas et al., 
2008). This study suggests that BAF complexes may be involved in both activation 
and repression of gene expression in the heart. Indeed, a later study examining the 
role of Brg1 in the myocardium found that Brg1 directly represses α-MHC, the MHC 
isoform that is predominantly expressed in adult heart, thereby maintaining 
myocardial cells in an embryonic state (Hang et al., 2010). The authors also showed 
that Brg1 interacts with and requires HDACs and PARPs to transcriptionally repress 
α-MHC. Interestingly, Brg1 also activates β-MHC, the MHC isoform present in 
embryonic myocardium, indicating that Brg1 regulates parallel pathways to control 
MHC isoform expression (Hang et al., 2010). It is unclear precisely how 
BAF/HDAC/PARP complexes are recruited to the MHC promoter; however, one 
potential mechanism is recruitment by DNA sequence-specific cardiac transcription 
factors. One recent study supports this hypothesis and demonstrated a genetic 
interdependence between cardiac transcription factors and BAF complexes. 
Compound heterozygous mice for Brg1 and either Tbx5, Nkx2.5 or Tbx20 all display 
profound cardiac defects compared to any of the single heterozygous mice 
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(Takeuchi et al., 2011). Additionally, Brg1 occupancy at the ANF/Nppa and Gja 
promoters was markedly reduced in a Tbx5 heterozygous background, and further 
reduced in a Tbx5; Brg1 double heterozygous background, indicating that BAF 
complex occupancy of cardiac promoters relies on interactions with cardiac 
transcription factors on the target promoter (Takeuchi et al., 2011). 
   
INO80 Complex 
 The INO80 chromatin remodeling complex is a very large protein complex 
with 11 to 16 members including the ATP-dependent helicases Ino80 and SRCAP, 
the DNA helicases Pontin (Ruvbl1, Tip49, Tip49a) and Reptin (Ruvbl2, Tip48, 
Tip49b), actin, and various actin-related proteins (Arp4, Arp5, Arp8, β-actin, Arp7, 
Arp9) (Shen et al., 2000; Jin et al., 2005). The INO80 complex alters chromatin 
accessability resulting in activation or repression of target genes (Cai et al., 2007; 
Ford et al., 2007; Klopf et al., 2009). Two members of the complex, Pontin and 
Reptin, have opposing acitivities within the INO80 complex, and this antagonistic 
relationship has been shown to play a role in cardiac growth in zebrafish (Rottbauer 
et al., 2002). An ENU-induced mutation in Reptin leads to cardiac hyperplasia and 
embryonic lethality. This mutation is an activating mutation in Reptin, increasing the 
ATPase activity of Reptin complexes, thus overriding Pontin diminution of Reptin 
activity, and increasing the transcriptional repressor activity of the complex. Mutant 
zReptin was subsequently shown to have a stronger repressive effect on β-
catenin/TCF-mediated transactivation, leading to the hypothesis that Pontin/Reptin 
complexes regulate β-catenin-mediated activation of cell cycle genes such as cyclin 
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D and c-Myc to control the balance between proliferation and differentiation in the 
developing zebrafish heart (Rottbauer et al., 2002). Further studies are needed to 
investigate the role of the INO80 complex in mammalian heart development and to 
determine how Pontin, Reptin, or other members of the INO80 complex might 
intersect with additional transcription factor pathways in the heart. 
 
Histone Deacetylases 
 HDACs are a class of histone-modifying enzymes that promote chromatin 
condensation by removing acetyl groups from conserved lysine residues of histone 
tails, resulting in transcriptional repression (Vidal and Gaber, 1991; Vidal et al., 
1991; Rundlett et al., 1996; Hassig et al., 1997; Rundlett et al., 1998). HDACs 
interact with a variety of DNA-binding transcription factors and are often components 
of larger repression complexes (Ayer et al., 1995; Heinzel et al., 1997; Zhang et al., 
1997; Wade et al., 1998). HDACs are divided into 3 classes based on their 
homology with the 3 yeast HDACs: class I HDACs consist of HDAC1, -2, -3, and-8, 
class II HDACs include HDAC4, -5, -7, and -9, and class III HDACs, which are 
termed sirtuins (Ekwall, 2005; Haberland et al., 2009). Several HDAC proteins have 
been shown to be critical for transcription repression during normal heart 
development (Zhang et al., 2002; Chang et al., 2004; Montgomery et al., 2007; 
Montgomery et al., 2008; Trivedi et al., 2008; Trivedi et al., 2010). 
 
 HDAC1 and HDAC2 have partially redundant roles in developing 
cardiomyocytes. Myocardium deletion of either HDAC1 or -2 does not result in a 
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cardiac phenotype; however, mice mutant for both HDAC1 and -2 die neonatally of 
cardiac arrhythmias and dilated cardiomyopathy (Montgomery et al., 2007). Heart 
failure in these mice likely results from upregulation of calcium channel and 
contractile genes, indicating that HDAC1 and -2 function to negatively regulate 
genes involved in calcium flux and contraction. Additional studies are needed to 
address the mechanism by which HDAC1 and -2 are targeted to cardiac genes. 
Interestingly, HDAC2 also regulates Gata4 transcriptional activity via deacetylation 
its lysine resides, suggesting that Gata4 is a non-histone target of HDAC2 in the 
heart (Trivedi et al., 2010). HDAC2 deacetylation of Gata4 requires the adaptor 
protein Hopx and results in a suppression of Gata4-dependent transactivation of 
cyclinD2 and cdk4. Consistent with the requirement for HDAC2 in Gata4-mediated 
regulation of cell cycle genes, HDAC2; Hopx knockout hearts display increased 
cardiomyocyte proliferation indicating that HDAC2, Hopx, and Gata4 interact to 
regulate myocyte proliferation (Trivedi et al., 2010). It will be interesting to determine 
if HDACs are responsible for deacetylating other transcription factors in the heart. 
 
 Myocardium-specific deletion of HDAC3 results in lethality at 3-4 months of 
age due to cardiac hypertrophy and severe defects in cardiac metabolism, 
suggesting the HDAC3 has an independent role from HDAC1/2 in cardiac function 
(Montgomery et al., 2008). HDAC3 mutant hearts display significantly upregulated 
expression of genes involved in myocardial energetics as a result of aberrant 
activation of PPARα gene targets. These data indicate that HDAC3 is recruited by 
PPARs to the promoters of metabolic genes to facilitate transcriptional repression. 
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HDAC3 may also be important for promoting postnatal cardiomyocyte proliferation, 
as myocardium-specific overexpression of HDAC3 results in increased 
cardiomyocyte proliferation and inhibition of cyclin-dependent kinase inhibitors 
(Trivedi et al., 2008). Interestingly, the effects of HDAC3 overexpression on 
cardiomyocyte proliferation are limited to birth until 2 months of age, when 
proliferation returns to normal. It is unclear whether this occurs because the neonatal 
cardiomyocytes are no longer competent to respond to proliferation cues, or is a 
result of temporal HDAC3 activity on cell cycle genes. The mechanism by which 
HDAC3 activity in the heart is regulated has yet to be determined; however, it is 
likely that HDAC3 exists as part of a larger repressive complex that is recruited 
temporally in a tissue-restricted manner by tissue-specific DNA-binding factors. 
 
 Similar to the coordinated functions of HDAC1/2, the class II HDACs HDAC5 
and -9 redundantly regulate embryonic cardiac growth and hypertrophy. Mouse 
embryos that are double null for HDAC5 and HDAC9 begin to die at E15.5 with 
ventricular septal defects and thinned ventricular walls, highlighting a role for these 
HDACs in cardiac growth (Chang et al., 2004). Mice lacking only HDAC5 or HDAC9 
are born in normal Mendelian ratios but go on to display age-dependent hypertrophy 
indicating a defect in the cardiac stress response (Zhang et al., 2002; Chang et al., 
2004). Indeed, mice mutant for either HDAC5 or -9 develop enlarged hearts in 
response to various forms of cardiac stress suggesting that HDAC5/9 are involved in 
regulating the transcriptional program governing cardiac hypertrophy. Interestingly, 
class II HDACs have been demonstrated to interact with MEF2 transcription factors 
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and these interactions result in the recruitment of HDACs to MEF2 target genes 
(McKinsey et al., 2002). In particular, one isoform of HDAC9 termed MEF2-
interacting transcription repressor (MITR) encodes a truncated form of HDAC9 that 
does not have HDAC activity but inhibits MEF2 target genes by association with 
other HDACs and transcriptional repressors (McKinsey et al., 2002). The precise 
role that HDAC-MEF2 complexes play in embryonic heart development is unclear 
and warrants investigation. 
 
Histone Methyltransferases 
 The effect of histone methylation on gene expression is context dependent 
and can both activate and repress target genes. Histone methyltransferases (HMTs) 
catalyze the transfer of methyl groups to lysine and arginine residues of histones 
(Strahl et al., 1999; Wang et al., 2001b). Typically, methylation of K4, K36, and K79 
of histone H3 results in transcriptional activation (Strahl et al., 1999; Rao et al., 
2005; Vakoc et al., 2006), whereas methylation of K9 and K27 is associated with 
transcriptional repression (Nielsen et al., 2001; Vakoc et al., 2006). Several HMTs 
have been implicated in heart development as both targets and functional partners 
of cardiac transcription factors (Gottlieb et al., 2002; Sims et al., 2002; Phan et al., 
2005; Tan et al., 2006; Nimura et al., 2009; Park et al., 2010). 
   
 The HMT Smyd1 (mBop, Bop) contains a SET domain for methyltransferase 
activity and a MYND domain, which is involved in recruitment of HDACs to mediate 
transcriptional repression (Gottlieb et al., 2002). Global knockdown of Smyd1 results 
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in embryonic death with defects in cardiomyocyte differentiation and right ventricular 
development (Gottlieb et al., 2002). Additional studies in zebrafish conclude that 
Smyd1 is required for myofibril organization and skeletal and cardiac muscle 
contraction (Tan et al., 2006). Subsequent work has placed Smyd1 expression 
downstream of Mef2c, thereby suggesting that Mef2c induction of Smyd1 is 
necessary for development of the second heart field, which gives rise to the outflow 
tract and right ventricle (Phan et al., 2005). In the heart, Smyd1 interacts with the 
muscle-specific transcription factor skNAC to regulate the transcriptional program 
governing ventricular identity (Sims et al., 2002; Park et al., 2010). Interestingly, 
expression of the Smyd1-dependent gene Hand2 is unaffected in skNAC null hearts. 
These results imply that Smyd1 regulates Hand2 and possibly other cardiac genes 
in an skNAC-independent manner, likely through interactions with other cardiac 
transcription factors. 
    
 A second HMT with implications in heart development, WHSC1 (MMSET), is 
associated with the dominant disorder Wolf-Hirschorn syndrome (WHS) (Wright et 
al., 1997; Marango et al., 2008). WHS is characterized by a constellation of 
symptoms that include growth deficiency, mental retardation, craniofacial 
abnormalities, midline closure defects, skeletal defects, and atrial and ventricular 
septal defects (Wright et al., 1997). WHSC1 has been characterized as a SET 
domain-containing HMT that trimethylates K36 of histone H3 (H3K36me3) and is 
deleted in WHS (Nimura et al., 2009). A recent study determined that allele 
inactivation of Whsc1 in the mouse recapitulates the developmental defects, 
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including congenital heart defects, observed in WHS patients (Nimura et al., 2009). 
Additionally, Whsc1 physically interacts with Nkx2.5 in embryonic hearts to 
transcriptionally repress the Nkx2.5 targets Pdgfra, Igfbp5, and Isl1, presumably via 
H3K36 trimethylation (Nimura et al., 2009). A functional interaction between Whsc1 
and Nkx2.5 was also confirmed genetically. Mice double heterozygous for Whsc1 
and Nkx2.5 display atrial and ventricular septal defects, providing additional 
evidence that Whsc1-Nkx2.5 complexes negatively modulate cardiac transcriptional 
networks. 
 
DISSERTATION GOALS 
 The interconnectivity of core cardiac transcription factors, as well as the 
interface between these transcription factors and the chromatin remodeling 
machinery of the cell represent critical relationships that ensure the proper 
specification, differentiation, and morphogenesis of cardiac cells. Therefore, defining 
the precise interactions and mechanisms of action for each core transcription factor 
is critical for a full understanding of the entire transcription network. Although 
mutation or misregulation of Tbx20 leads to a variety of cardiac defects in humans, 
mice, Xenopus, and Drosophila, very little is known about the upstream signaling 
pathways that regulate Tbx20 cardiac expression or the protein-protein interactions 
that specify Tbx20 transcriptional activity in the heart. For this reason, I sought to 
identify and characterize novel determinants of Tbx20 cardiac expression and 
activity. In Chapter 2, we identify an evolutionarily conserved cardiac enhancer that 
is necessary to direct Tbx20 expression in the heart during cardiac chamber 
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maturation. We go on to show that this enhancer is downstream of BMP signaling 
and directly bound by phospho-Smad1/5/8. Because Tbx20 is required to ensure 
proper regionalization of the chambers, this work implies a critical role for BMP 
signaling in this process. To identify and characterize Tbx20 protein-protein 
interactions that are important in Tbx20-mediated gene regulation, Chapter 3 
focuses on a proteomics-based approach to isolate Tbx20 transcription complexes 
using Human Embryonic Kidney 293 (HEK 293) cells as a model system. Here, we 
demonstrate that Tbx20 interacts with a unique transcription repression network that 
includes chromatin remodelers, Groucho/TLE co-repressors, and the cardiac T-box 
transcription factor Tbx18. In Chapter 4, we develop a method to isolate endogenous 
Tbx20 protein complexes from mouse embryonic stem cell (ESC)-derived 
cardiomyocytes and show that Tbx20 interacts with a broad chromatin remodeling 
network in cardiac progenitor cells. In the future, this methodology will be used to 
characterize the temporal and tissue-specific components of Tbx20 transcription 
complexes. Collectively, this work will enhance the understanding of the Tbx20 
transcription network during cardiac development. 
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Figure 1.1. The core cardiac transcription factor network. The core cardiac 
transcription factors Tbx20, Tbx5, Nkx2.5, Gata4, Mef2C, and Isl1 control early heart 
development through multiple protein-protein interactions with each other. These 
interactions are necessary to ensure proper transcriptional regulation of other factors 
within the network and of a variety of downstream cardiac genes (not shown).  
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Figure 1.2. The Nkx2.5 transcription network. 
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Figure 1.3. The Gata4 transcription network. 
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Figure 1.4. The Tbx5 transcription network.  
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Figure 1.5. The Tbx20 transcription network. 
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Chapter 2 
 
The BMP pathway acts to directly regulate Tbx20 in the 
developing heart 
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ABSTRACT 
 TBX20 has been shown to be essential for vertebrate heart development.  
Mutations within the Tbx20 coding region are associated with human congenital 
heart disease, and the loss of Tbx20 in a wide variety of model systems leads to 
cardiac defects and eventually heart failure.  Despite the critical role of TBX20 in a 
range of cardiac cellular processes, the signal transduction pathways that act 
upstream of Tbx20 remain unknown.  Here we have identified and characterized a 
conserved 334bp Tbx20 cardiac regulatory element that is directly activated by the 
BMP/SMAD1 signaling pathway.  We demonstrate that this element is both 
necessary and sufficient to drive cardiac-specific expression of Tbx20 in Xenopus 
and that blocking SMAD1 signaling in vivo specifically abolishes Tbx20 transcription, 
but not that of other cardiac factors such as Tbx5 and MHC, in the developing heart.  
We further demonstrate that activation of Tbx20 by SMAD1 is mediated by a set of 
novel, non-canonical, high-affinity SMAD-binding sites located within this regulatory 
element and that phospho-SMAD1 directly binds a non-canonical SMAD1 site in 
vivo.  Finally, we show that these non-canonical sites are necessary and sufficient 
for Tbx20 expression in Xenopus and that reporter constructs containing these sites 
are expressed in a cardiac-specific manner in zebrafish and mouse.  Collectively, 
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our findings define Tbx20 as a direct transcriptional target of the BMP/SMAD1 
signaling pathway during cardiac maturation.  
 
INTRODUCTION 
 A series of clinical studies has provided direct evidence of a role for T-box 
genes in heart development and human disease, as mutations in at least three T-
box genes, Tbx1, Tbx5, and Tbx20, have been linked to human congenital heart 
disease (CHD) (Kirk et al., 2007; Hammer et al., 2008; Liu et al., 2008; Qian et al., 
2008).  Specifically, mutations in Tbx20 have been associated with a wide array of 
congenital abnormalities, including dilated cardiomyopathy (DCM), atrial septal 
defects (ASD), and mitral valve disease.  Moreover, upregulation of Tbx20 has been 
reported in patients with tetralogy of Fallot (Kirk et al., 2007; Hammer et al., 2008; 
Liu et al., 2008; Qian et al., 2008).  These findings are consistent with studies of 
Tbx20 orthologues in a wide range of model systems including mouse (Tbx12/20) 
(Carson et al., 2000; Kraus et al., 2001), zebrafish (Tbx20/HrT) (Ahn et al., 2000; 
Griffin et al., 2000), chick (Iio et al., 2001), and Xenopus (Brown et al., 2003; Showell 
et al., 2006), which have shown a requirement for Tbx20 in a number of cardiac 
cellular processes.  The effects of loss of Tbx20 appear to be in part mediated 
through its endogenous role in restricting expression of Tbx2, a T-box containing 
protein required for the repression of chamber specific genes (Singh et al., 2009). 
Despite the essential role of Tbx20 in cardiac development, little is known about the 
signal transduction pathways that function upstream to regulate Tbx20 expression in 
the developing heart. 
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 Members of the bone morphogenetic protein (BMP) family and their 
downstream mediators, the SMADs, have also been shown to be required for many 
cellular events in early heart development, including cardiac progenitor specification, 
proliferation, and differentiation.  The role of BMPs in cardiac development is 
evidenced by the cardiac-associated defects in mouse mutants for components of 
the BMP pathway and by the observation that SMAD proteins, mediators of BMP 
signaling, are upregulated in response to cardiac stress or injury.  However, 
identification of a specific cellular role for any single component of the BMP pathway 
in cardiac development is frequently confounded by genetic redundancy within the 
BMP and SMAD families and temporal and spatial differences in the activities of 
individual pathway components (reviewed in Klaus and Birchmeier, 2009; Euler-
Taimor and Heger, 2006; Wijk et al., 2007).  An alternative means of dissecting the 
roles of BMPs in early heart development would be to identify the direct 
transcriptional targets of BMP signaling; however, the cardiac targets of the BMP 
pathway remain poorly characterized. 
 
 In efforts to define the direct targets of growth factor pathways in heart 
development, we have identified a 334bp regulatory element that is both necessary 
and sufficient for Tbx20 expression during cardiac chamber formation in Xenopus.  
We further show that the Tbx20 cardiac element is a direct transcriptional target of 
the BMP/SMAD1 arm of the transforming growth factor-β (TGF-β) pathway and that 
its activation is independent of the TGF-β/activin/nodal/SMAD3 pathway.  We further 
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demonstrate that Tbx20 is co-expressed with nuclear SMAD1 in cardiomyocytes 
during cardiac chamber formation and that blocking SMAD1 activity in vivo leads to 
a specific loss of cardiac Tbx20 but not other markers of cardiac tissue.  We go on to 
demonstrate that the minimal cardiac Tbx20 element contains four critical non-
canonical, high-affinity SMAD-binding sites, which are directly bound by phospho-
SMAD1 and are necessary for proper combinatorial regulation of Tbx20.  Finally, we 
demonstrate that the ability to recognize the non-canonical SMAD1 sites is not 
specific to Xenopus by showing that reporter constructs containing these elements 
are expressed in a cardiac-specific manner in zebrafish and mouse.  Collectively, 
our studies define a direct target of the BMP/SMAD1 signaling pathways in heart 
development and imply a role for BMP signaling in cardiac maturation. 
 
MATERIALS AND METHODS 
BAC Library Screen, RLM-RACE 
The ISB-1 X. tropicalis bacterial artificial chromosome (BAC) library 
(Children’s Hospital Oakland Research Institute (CHORI)) was screened with the 5’ 
terminus of the X. laevis Tbx20 coding region, and BAC DNA prepared according to 
CHORI.  DNA was initially characterized by field inversion gel electrophoresis (FIGE) 
and Southern blot analysis using a panel of Tbx20 specific probes.  The 
transcriptional start site of X. tropicalis Tbx20 was identified using the First Choice 
RLM-RACE Kit (Ambion) and 5’ RLM-RACE as described by the manufacturer using 
whole X. tropicalis embryos (N=25) as well as brain-enriched and heart-enriched 
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tissues (approximately 250 embryos for each) at stage 28. Primer sequences and 
details available upon request. 
 
Tbx20-EGFP and Xenopus Transgenesis  
Tbx20-EGFP reporter constructs were generated by introducing EGFP in-
frame into exon 1 of Tbx20 at position +142. A Tbx20-EGFP deletion series was 
generated by substituting elements of Tbx20 ranging from 471-2106bp, each 
containing a 5’ EcoRI linker and a 3’ BamHI linker, for the original 2601bp of the 
Tbx20-EGFP construct. Details and primer sequences available upon request. All 
Tbx20 reporter constructs were linearized by KpnI and transgenesis performed 
according to Kroll and Amaya (Kroll and Amaya, 1996). For each construct greater 
than 10 EGFP-positive embryos were examined from at least three independent sets 
of injections.    
 
XTbx20-EGFP Transgenic Mice 
The XTbx20(-2464)-EGFP plasmid was prepared for microinjection by 
digestion with SacII and KpnI to release the linear transgene. The transgene DNA 
was purified by agarose gel electrophoresis and injected into the pronuclei of 
C57BL/6 x DBA2 hybrid embryos at the UNC Animal Model core facility. Fertilized 
ovum were subsequently implanted into pseudo-pregnant females and offspring 
were analyzed for the presence of the transgene. Founders were identified by PCR 
analysis of tail DNA, using the following primers: 5’ CCCTATTTGATCAGCAAACG 3’ 
and 5’ CACTTCCATGGGCTGATGCT 3’. Embryos resulting from timed matings 
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between one of the male founders and a wild-type C57Bl6 female were screened for 
EGFP expression on a Leica MZ16F stereomicroscope. Animal care and animal 
experiments were in accordance with the Animal Care Committee at the University 
of North Carolina-Chapel Hill.  
 
Xenopus Embryo and Explant Culture  
Xenopus embryos were obtained and staged according to Nieuwkoop and 
Faber (Nieuwkoop and Faber, 1967). For tissue explants, tissue posterior to the 
cement gland and including the heart field was excised at stage 35/36 and cultured 
in 1X MBS (Chemicon) at 23°C until stage 40.  The cardiac explants include 
overlying pharyngeal endoderm and some foregut endoderm.  Anterior regions of 
whole embryos were excised and cultured in identical conditions as cardiac 
explants.  Explants were treated at stage 40 with either 7µM DMSO or 5µM 
dorsomorphin (also referred to as Compound C; Calbiochem) in 1X MBS for 6 hours 
at 23°C (Hao et al., 2008; Yu et al., 2008). Explants were then fixed for 2 hours at 
room temperature in either Dent’s Fix (80% MeOH in DMSO) for whole-mount 
antibody staining, MEMFA for in situ hybridization, or 4% PFA for 
immunohistochemistry. 
   
Zebrafish Embryo Culture and Transgenesis 
For transient expression in zebrafish, the Tbx20(-334) reporter construct was 
flanked by Tol2 arms in a pT2 vector for Tol2 transposase-mediated transgenesis 
(Fisher et al., 2006). Embryos were injected at the 10cell stage with 100pg of 
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capped mRNA encoding Tol2 transposase and 50-100pg of the transgene plasmid.  
Injected embryos were examined and photographed at 48 hours post-fertilization 
(hpf) on Zeiss M2Bio and Axioplan microscopes.   
 
Cell Culture and Luciferase Assays 
Transient transfections were conducted as previously described (Wang et al., 
2001). Each assay conducted in triplicate at least two times in 12-well plates using 
the following expression plasmids: Myocardin (Wang et al., 2001), SRF(Wang et al., 
2001), Mef2c (Wang et al., 2001), SMAD3 (Feng et al., 2000), SMAD4 (Feng et al., 
2000), pRK5 N-Flag Smad1 (Liu et al., 1996), pGL3-Nkx2.5 (Lien et al., 2002), 
Gata4 (Oh et al., 2004), and SM22 (Li et al., 1996). Fold induction was calculated as 
induction compared to that of reporter alone, and error bars refer to the standard 
deviation of fold induction. 
 
In Situ Hybridization and Immunohistochemistry 
In situ hybridization and immunohistochemistry were conducted as previously 
described (Goetz et al., 2006) with the following addition: anti-Phospho-
Smad1(Ser463/465)/ Smad5(Ser463/465)/ Smad8(Ser426/428) (1: 100; Cell 
Signaling). 
 
Protein-DNA Binding Assays 
For 2X coverage of the Tbx20(-334) regulatory element, 21 double-stranded, 
30 basepair, 5’-FAM oligos were designed to overlap by 15 bases beginning from 
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base -1 (Figure 2.6A) and XVent and SRF binding site oligos were designed as 
positive and negative controls respectively, based on previously published work 
(Henningfeld et al., 2000; Chang et al., 2001). All fluorescence polarization 
experiments were performed in a PHERAstar microplate reader (BMG 
Labtechnologies) with reactions performed in a 50µL volume containing 250nM 5’-
FAM oligo and increasing concentrations of GST-SMAD1 (0-7416.67nM, information 
available upon request) in 10mM Tris-HCl, pH 8.0, 100mM NaCl. Each assay was 
performed in triplicate at 25oC.  Anisotropy was measured by excitation with 
vertically polarized light, using 490nm excitation and 520nm emission filters with the 
gain optimized for maximum signal and normalized to “no protein” controls.  Data 
analysis was performed using SigmaPlot 8.0 software, and dissociation constants 
(Kd) determined for each oligo using the single rectangular I, 3 parameter equation 
y=yo + ax/(b+x) where b is equal to Kd. 
 
Chromatin Immunoprecipitation in Xenopus tropicalis Embryos 
Stage 41 embryos (n=30) were cross-linked in 1% Formaldehyde in PBS for 
60 minutes and washed in 0.125M Glycine for 10minutes and then three times in 
PBS. Embryos were homogenized in 500µL Cell Lysis Buffer (50mM Tris-HCl pH8, 
2mM EDTA, 0.1% NP-40, 10% glycerol, and protease/phosphatase inhibitors), 
centrifuged, and the pellet rinsed twice in cold PBS. Nuclei were lysed in 200µL 
Nuclei Lysis Buffer (50mM Tris-HCl pH8, 10mM EDTA, 1% SDS, and 
protease/phosphatase inhibitors) and nuclear extracts were diluted in 400µL IP 
Dilution Buffer (20mM Tris-HCl pH8, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 
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and protease/phosphatase inhibitors). ChIP extracts were sonicated three times for 
30 seconds on ice, centrifuged, and supernatants were precleared with 50µL Protein 
A/G Agarose beads (Santa Cruz Biotechnology) at 4°C for 1.5 hours. Precleared 
ChIP extracts were diluted in 400µL IP Dilution Buffer and incubated with 2µg 
antibody on a rotating wheel at 4°C overnight. 50µL of Protein A/G Agarose beads 
was added to the ChIP samples for 2 hours at 4°C, and beads were subsequently 
washed in IP Dilution Buffer, ChIP Wash Buffer (10mM Tris-HCl pH8, 1mM EDTA, 
1% sodium deoxycholate, 1% NP-40, 0.25M LiCl, and protease/phosphatase 
inhibitors), IP Dilution Buffer, and TE Buffer (10mM Tric-HCl pH8 and 1mM EDTA). 
The material was eluted in Elution Buffer (50mM Tris-HCl pH8, 10mM EDTA, and 
1% SDS) at 65°C, digested with RNase A for 3 hours at 37°C, and incubated in 0.3M 
NaCl overnight at 65°C to reverse cross links. ChIP samples were subsequently 
digested with proteinase K for 4 hours at 55°, phenol extracted, and precipitated, 
and the recovery of specific DNA sequences was determined by quantitative PCR 
using SYBR Green PCR reagents (Sigma) and an Applied Biosystems 7900 HT Fast 
Real-Time PCR machine. Anti-Phospho-Smad1(Ser463/465)/ Smad5(Ser463/465)/ 
Smad8(Ser426/428) (Cell Signaling) antibody was used. As a control for this 
procedure, ChIP was also performed on stage 9 Xenopus laevis embryos (n=50) 
with a rabbit anti-β-catenin antibody (Cocalico Laboratories; Reamstown, PA) as 
previously reported (Blythe et al., 2009). Fold enrichment relative to a no antibody 
control was calculated using the comparative CT  method (ΔΔCt). See Table S2.1 for 
primer sequences.   
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RESULTS 
A Tbx20-EGFP transgene recapitulates endogenous expression of Tbx20 in 
mid-tadpole stage embryos 
 
Given the evolutionarily conserved role for Tbx20 in heart development and 
its role in human congenital heart disease we sought to determine the regulatory 
pathways that are required for the proper spatial and temporal expression pattern of 
Tbx20. To this end, we mapped the cardiac transcriptional start site of Tbx20 and 
inserted an EGFP reporter cassette in-frame with the TBX20 translational start site 
(see Materials and Methods) in a 4116bp fragment corresponding to the 5-prime end 
of the Xenopus tropicalis (X. tropicalis) Tbx20 locus (Figure 2.1A, B).  Based on our 
observations that Tbx20 is expressed in an identical pattern in X. tropicalis and X. 
laevis (Brown et al., 2003; Showell et al., 2006), we introduced the Tbx20(-2464)-
EGFP reporter into Xenopus laevis (X. laevis) embryos by restriction enzyme-
mediated integration (REMI) transgenesis. Consistent with endogenous Tbx20 
expression, the Tbx20 reporter directed expression of EGFP to the developing heart 
and cement gland, (≥5 rounds of injections; n≥20 EGFP-expressing embryos per 
experiment; Figure 2.1C-F and Figure S2.1).  Specifically, EGFP expression was 
first observed in the cement gland at stage 24 and in the heart at stage 32.  Identical 
to endogenous Tbx20 expression, as the cells of the cement gland began to 
undergo apoptosis, expression of EGFP decreased and was completely absent by 
late tadpole stages (stages 48). In contrast, EGFP expression in the heart was 
maintained through chamber differentiation and heart looping and continued to be 
expressed until later stages of cardiac development (>stage 46; Figure 2.1C-F; data 
not shown). We did not observe EGFP expression in the heart prior to early tadpole 
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stages (stage 32) nor in any other tissue types including those which endogenously 
express Tbx20 such as the hindbrain and eye.  
 
A 334bp of regulatory element is sufficient for cardiac Tbx20 expression  
To define the minimal regulatory element necessary to drive Tbx20 cardiac-
specific expression, we generated transgenic embryos with a panel of 5-prime 
deletion constructs. Results from these injections showed that -2464bp, -1483bp, 
and -334bp Tbx20 reporters (≥3 rounds of injections; ≥20 EGFP-expressing 
embryos per experiment; Figure 2.2A-J) all recapitulated endogenous Tbx20 
expression in cardiac tissue and the cement gland at stage 46 (8/8 EGFP-
expressing embryos per construct; Figure 2.2K-P). Collectively, these data show that 
sequences 334bp upstream of the Tbx20 transcriptional start site contain elements 
that function to regulate Tbx20 cardiac expression at this stage of heart 
development. 
 
Tbx20 reporter expression is conserved in mouse and regulated by 
SMAD1/SMAD4 but not SMAD3 
 
We observed that offspring from a mouse transgenic founder carrying the 
Xenopus Tbx20(-2464)-EGFP reporter shows an expression pattern analogous to 
that observed in Xenopus with strong EGFP expression throughout the developing 
heart but not in other tissues where Tbx20 is endogenously expressed in the mouse, 
such as the hindbrain and the lateral plate mesoderm (Fig. 3A-D). Based on these 
findings we determined whether a set of murine cardiac transcription factors 
identified in the minimal 334bp Tbx20 regulatory element by ConSite, Jaspar, and 
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Transfac software, including SRF, NKX2.5, MEF2C, GATA4, SMAD1, and TBX5, 
were capable of activating Xenopus cardiac-specific Tbx20 reporters (Fig. 3E-G). Of 
the potential transcription factors, SMAD1, SRF, and the SRF co-factor myocardin 
were found to be capable of activating Tbx20 (Fig. 3E-G).  We further note that the 
334bp reporter has a greater response to SMAD1 and SRF than the 1483bp or 
2464bp elements, suggesting sequences upstream of the 334bp element can 
attenuate the response to SMAD1 and SRF. Although SRF and myocardin were 
able to induce Tbx20, upon further analysis we found that Tbx20 reporters did not 
respond to myocardin or SRF in a dose-dependent fashion and mutation of putative 
SRF binding sites had no effect on the temporal or spatial expression of the Tbx20 
reporter in vivo (data not shown).  Although we cannot formally rule out a role for 
SRF or myocardin in the regulation of Tbx20 expression, we did not analyze the 
effects of SRF or myocardin on Tbx20 expression in greater detail.  
 
To also characterize the activation of Tbx20 in response to the TGF-β family 
of signaling molecules, we tested the ability of SMAD1, a mediator of BMP signaling, 
SMAD3, a mediator of TGF-β/activin/nodal signaling, and the common SMAD, 
SMAD4, to activate Tbx20 luciferase reporters. We observed a dose-dependent 
activation of both the largest (-2464) and smallest (-334) Tbx20 regulatory elements 
with increasing amounts of SMAD1 and SMAD4 (Figure 2.3H, I, K, L). Further 
deletions of the Tbx20 upstream region to -251 and -81 greatly decreased the 
responsiveness to SMAD4 and led to an increase in EGFP in non-specific regions in 
Xenopus transgenics (Figure S2.2).  
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We further observed that SMAD3 failed to activate any Tbx20 reporter though 
it did induce expression of the SMAD3 control reporter SM22 (Figure 2.3J) (Qiu et 
al., 2003). Consistent with these findings, treatment of cells with the TGF-
β/activin/nodal small molecule inhibitor SB431542 had no effect on the induction of 
Tbx20 in response to SMAD4 (Figure 2.3M). Taken together, these results suggest 
that Tbx20 cardiac activation occurs in a SMAD1-dependent, SMAD3-independent 
manner which is at least in part, mediated by sequences that lie between -81bp and 
-334bp upstream of the Tbx20 cardiac transcriptional start site.  
 
Tbx20 and SMAD1 are co-localized during cardiac chamber formation 
Upon activation of the BMP signaling pathway, SMAD1 is phosphorylated and 
translocates to the nucleus where it binds DNA and regulates transcription of 
neighboring genes (reviewed in (Kretzschmar and Massague, 1998; Massague et 
al., 2005)). To determine if SMAD1 is nuclear localized and co-expressed with 
Tbx20 in cardiac tissue and therefore, could function endogenously to regulate 
Tbx20 expression, we serial sectioned X. laevis hearts (stage 46) and examined 
Tbx20 expression by in situ hybridization. On adjacent sections we examined 
phospho-SMAD1 expression and its cellular localization by immuno-histochemistry. 
Our results demonstrate that at these stages Tbx20 and phospho-SMAD1 are co-
expressed throughout the myocardium of the developing heart including the 
ventricle, the atria, the outflow tract, and the truncus arteriosus (Figure 2.4A-F).   
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SMAD signaling is required for the maintenance of Tbx20 expression in vivo 
To verify that BMP signaling regulates Tbx20 expression in vivo we 
determined the effects of inhibiting SMAD1 activation on Tbx20 expression. In order 
to bypass the requirements for SMAD1 during the early stages of embryogenesis we 
made use of the SMAD1 inhibitor Dorsomorphin and a tissue explant assay 
(Langdon et al., 2007; Hao et al., 2008; Yu et al., 2008; Fukuda et al., 2009). As 
reported for tissue culture cells (Langdon et al., 2007; Hao et al., 2008; Yu et al., 
2008; Fukuda et al., 2009), treatment of stage 40 anterior explants with 
Dorsomorphin clearly show that Dorsomorphin blocks the nuclear localization of 
SMAD1 (Figure 2.5A-F; A’-F’) and completely inhibits the expression of Tbx20 in the 
developing heart as compared to controls (Figure 2.5G, H, K, L). Moreover, the 
effects of blocking SMAD1 are specific to the cardiac expression of Tbx20 as we see 
little change in expression of Tbx20 in the hindbrain (Figure 2.5I, J). Furthermore, 
SMAD1 inhibition has little to no effect on other cardiac markers including MHC, 
tropomyosin, and Tbx5 (Figure 2.5M-P; Figure S2.3). Taken together these results 
strongly imply that the BMP pathway signals through SMAD1 to directly regulate the 
cardiac expression of Tbx20 in vivo. 
 
SMAD activation of Tbx20 occurs through direct binding of SMAD1 
To identify the specific endogenous SMAD1 binding sites within the minimal 
334bp Tbx20 cardiac regulatory element, and to accurately determine the binding 
affinity of SMAD1 to the respective elements, we used fluorescence polarization 
assays. Double stranded, 30bp, 5’ carboxyfluorescein-labeled oligos overlapping by 
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15bp were designed across the 334bp Tbx20 cardiac regulatory element for full 2x 
coverage (Figure 2.6A).  Based on the premise that oligos tumble more slowly in 
solution when bound by protein as compared to unbound oligos, we combined 
fluorescent oligos with increasing concentrations of GST-SMAD1 fusion protein to 
evaluate the changes in light depolarization, as anisotropy.  From the anisotropy 
data, we plotted binding curves and calculated dissociation constants (Kd(mM)) for 
each oligo interaction with SMAD1  and as controls, the binding of GST-SMAD1 to 
oligos containing known SMAD1 binding sequences (XVent) or known SRF binding 
sequences (Figure 2.6B, Table S2.2) (Henningfeld et al., 2000; Chang et al., 2001).  
SMAD1 bound oligo 8, covering bases -105 to -135, with the highest affinity 
(Kd=2.078 mM).  However, SMAD1 bound six additional oligos (2, 6, 9, 13, 16, 19) 
with affinities that are equal to or greater than twice that of XVent  (Kd=2.078 mM to 
Kd=3.758 mM) (Figure 2.6B, Table S2.2).  Results from these studies show that 
SMAD1 binds the Tbx20 cardiac regulatory element at 7 individual sites with an 
affinity at least twice that of the XVent control oligo (Kd= 7.829 mM), suggesting that 
the seven sites are high affinity SMAD1 binding sites (Figure 2.6C). Sequence 
analysis of the oligos bound by SMAD1 reveal two conserved, consensus SMAD 
binding sites with the sequences GTCT and CAGAC in oligos 16 and 8, respectively.  
We also observed that one region containing a putative binding site failed to bind 
SMAD1 protein in vitro.  From this, we propose the presence of non-traditional 
SMAD binding elements between bases -15 and -45 (oligo 2), -75 and -105 (oligo 6), 
-120 and -150 (oligo 8/9), -180 and -210 (oligo 13), and -270 and -300 (oligo 19). We 
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further note that SMAD1 is capable of binding non-canonical sites with affinities 
equal to that of canonical sites.  
 
The ability of SMAD1 protein to bind non-canonical sites within the Tbx20 
334bp cardiac regulatory element suggests the presence of a common SMAD1 motif 
within these oligos. Accordingly, sequence analysis by MEME software revealed a 
novel SMAD1 binding site with the sequence AGGA/CA/TG within oligos 19, 13, 9, 
6, and 2. (Figure 2.6D). Of the oligos containing the non-canonical SMAD site, 
SMAD1 bound oligo 6, containing the binding site AGGCAG, with the highest affinity 
(Figure 2.6B; Table S2.2). To determine if SMAD1 directly binds a portion of the 
Tbx20 cardiac element containing both canonical and non-canonical SMAD1 sites in 
vivo, we performed ChIP on stage 41 X. tropicalis tadpoles with a phospho-
SMAD1/5/8 antibody (Figure 2.6C). In parallel and as a positive control, we tested 
the occupancy of β-catenin on the Xnr6 locus in stage 9 X. laevis embryos, as Xnr6 
has been demonstrated by others to be a direct target of β-catenin by ChIP in 
Xenopus (Blythe et al., 2009).  A 6.8-fold enrichment above background of phospho-
SMAD1 was observed on the endogenous SMAD1 sites within the Tbx20 cardiac 
element (Figure 2.6E, Amplicon 1). We next tested the occupancy of endogenous 
phospho-SMAD1 on a single non-canonical SMAD1 site within the Tbx20 cardiac 
element (Figure 2.6C, Amplicon 2). Strikingly, phospho-SMAD1 was enriched 9.4-
fold above background on the non-canonical SMAD1 site, which is comparable to 
the enrichment of β-catenin we see at the Xnr6 locus (10.6-fold; Figure 2.6E). This 
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data is consistent with SMAD1 directly binding a novel non-canonical site within the 
Tbx20 cardiac element in vivo. 
 
Canonical SMAD sites alone are not sufficient for Tbx20 activation by SMAD1  
To determine which SMAD1 binding sites are critical for cardiac specific 
expression of Tbx20, we mutated the two consensus SMAD1 binding sites alone or 
in combination, in the context of the Tbx20(-2464)-EGFP or –luc reporter constructs 
(Figure 2.7A, B), and the Tbx20(-334)-EGFP or –luc constructs (Figure 2.7C, D). 
Results from these assays show that constructs lacking SMAD1 consensus sites are 
still SMAD1 responsive. Thus, these data strongly imply that SMAD1 
responsiveness is mediated by non-canonical SMAD1 binding sites. Finally, if we 
delete the 334bp minimal element in the context of the original Tbx20(-2464) cardiac 
reporter, both the response to SMAD1/4 in tissue culture assays and EGFP 
expression are greatly reduced (Figure 2.7E,F, data not shown).  Together, these 
data show that the 334bp region directly upstream of the Tbx20 start site is 
necessary and sufficient for cardiac expression of Tbx20 and that Tbx20 cardiac 
expression is dependent on SMAD1/4 activity.  
 
Xenopus Tbx20 reporter constructs are expressed in a cardiac-specific 
fashion in zebrafish  
 
As a further test if Tbx20 is a general target of the BMP/SMAD1 pathway we 
analyzed expression of Tbx20 in zebrafish mutant for the BMP receptor alk8. 
Consistent with our findings in Xenopus, we observe a significant reduction in Tbx20 
expression in zebrafish alk8 (lost-a-fin) mutants (Figure 2.8A,B).  Zygotic alk8 
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mutants are weakly dorsalized, exhibiting the effects of a mild disruption of BMP 
signaling (Bauer et al., 2001; Mintzer et al., 2001).  Correspondingly, Tbx20 
expression is diminished in the bilateral heart fields (Figure 2.8B).   
 
The observation that the BMP/SMAD1 pathway directly regulates the cardiac 
expression of Tbx20 through a set of non-canonical SMAD1 binding sites, and the 
observation that Tbx20 is downregulated in alk8 mutants, led us to question whether 
recognition of the canonical and non-canonical SMAD1 binding sites is specific to 
Xenopus or if these sites can serve as a general response to BMP/SMAD1 signaling 
in other vertebrates. To address these issues, we generated a Tbx20(-334)-EGFP 
fusion construct flanked by Tol2 transposase sites and injected this transgene 
together with Tol2 transposase RNA into zebrafish.  Injection of reporter constructs 
in this fashion yields relatively efficient, yet highly mosaic, transgene expression 
(Fisher et al., 2006).  The Tbx20(-334)-EGFP transgene was highly efficient at 
driving EGFP expression in the zebrafish heart (Figure 2.8C-E).  93% (92/99) of the 
injected embryos expressed the transgene, and 100% (92/92) of the expressing 
embryos displayed mosaic EGFP expression in the heart.  As with Xenopus, 
expression outside the heart was inconsistent and appeared as irreproducible 
ectopic expression of EGFP. In summary, our data demonstrate that the 334bp 
element from the Xenopus Tbx20 locus is sufficient for cardiac-specific in Xenopus 
and zebrafish. 
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DISCUSSION 
Studies of cardiac gene regulation have suggested that heart-specific 
transcription is regulated temporally and spatially via a set of distinct modular cis-
acting elements (Schwartz and Olson, 1999).  Here we report that SMAD signaling is 
required in vivo for expression of Tbx20 during cardiac chamber formation.  We have 
also identified a 334bp element in Xenopus that contains a series of seven high-
affinity SMAD1/4-binding sites that are necessary and sufficient for the evolutionarily 
conserved cardiac expression of Tbx20 in mouse and zebrafish. Complementary to 
this finding, we have identified additional sequences that attenuate the BMP/SMAD1 
response.  Collectively, our studies demonstrate a distinct temporal requirement for 
BMP signaling during heart development in which BMP signaling is required during 
the early phases of vertebrate heart development for the establishment of the 
cardiac lineage and a second, later role during cardiac chamber formation and 
maturation through the direct transcriptional regulation of Tbx20.  
 
Tbx20 cardiac expression requires canonical and non-canonical SMAD1 
binding sites 
 
Our data demonstrate a requirement for a set of high-affinity, canonical and 
non-canonical SMAD-binding sites in the regulation of Tbx20 expression.  Sequence 
analysis of regions within the 334bp Tbx20 cardiac element that were demonstrated 
to bind SMAD1 reveals two conserved consensus SMAD-binding sites containing 
the sequences GTCT and CAGAC, as well as a novel non-canonical SMAD binding 
motif containing the sequence AGGA/CA/TG. We observed that SMAD1 occupies a 
combination of these sites in vivo during cardiac maturation. We have demonstrated 
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that mutation of SMAD1/4 canonical binding sites, either singly or in combination, 
has little effect on the expression of Tbx20 either in vitro or in vivo, implying that it is 
the complement of canonical and non-canonical SMAD1-binding sites that is 
required for cardiac expression of Tbx20.  Further, our results suggest that the ability 
of SMAD1 to bind to DNA is not based on sequence alone.  This hypothesis is 
supported by our observation that a region of the Tbx20 minimal element containing 
a putative SMAD1/4-binding site failed to bind to SMAD1 in vitro.  Taken together, 
our data support a model in which Tbx20 expression is regulated during the later 
stages of heart development by BMP signaling.  In this model, the BMP pathway 
acts through a combinatorial set of unique SMAD-binding elements, the individual 
elements of which differ in their contributions to the response to growth factor 
signaling, and therefore, to transcriptional output.  
 
 Our finding that a complement of SMAD1/4-binding sites is required for Tbx20 
cardiac expression is broadly consistent with the results of studies on two other 
BMP-responsive genes, XVent and Nkx2.5.  Early mesodermal expression of XVent 
is dependent on five putative SMAD1/4-binding sites, while cardiac expression of 
Nkx2.5 is dependent on twelve individual SMAD1/4-binding sites (Henningfeld et al., 
2000; Liberatore et al., 2002; Lien et al., 2002). Similar to our findings, point 
mutations or deletions in multiple SMAD1/4-binding sites in the XVent promoter has 
no effect on SMAD responsiveness (Henningfeld et al., 2000).  However, regulation 
of cardiac-specific expression of Nkx2.5 appears to be unique in that cardiac tissue-
specific expression of Nkx2.5 is mediated by a direct interaction of a 
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SMAD1/SMAD4 complex and a member of the GATA transcription factor family 
(Liberatore et al., 2002; Caban et al., 2004).  Although we have identified a GATA 
consensus site within the minimal Tbx20 cardiac element, none of the Tbx20 
reporters respond to GATA4 (Fig. 3) and deletion of the GATA site has no effect on 
the cardiac-specific expression of Tbx20 (Fig. 7D).  Thus, tissue-specific expression 
of Tbx20, unlike that of Nkx2.5, appears to occur through a GATA-independent 
mechanism.  The activation of cardiac gene expression via BMP signaling has also 
been shown to be dependent on additional cardiac transcription factors.  For 
example, the myocardin-dependent expression of cardiac genes is synergistically 
activated by the direct interaction of SMAD1 with myocardin (Callis et al., 2005).  
However, data we obtained using a large panel of cardiac transcription factors 
demonstrate that, with the exception of SRF, none of these factors significantly 
induce Tbx20 expression in transient transcriptional assays.  While we cannot 
formally rule out a potential role of SRF in Tbx20 expression, mutation of the SRF-
binding site had no effect on the temporal or spatial expression of Tbx20 reporter 
constructs in vivo (data not shown). 
 
Cardiac-specific Tbx20 expression 
What, then, is the mechanism underlying the cardiac-specific expression of 
Tbx20?  We note that nuclear localization of SMAD1 during heart development is 
temporally regulated.  Based on this observation and the results of reporter 
analyses, we favor a model in which the complement of SMAD1/4-binding sites 
directs a pattern of broad temporal expression of Tbx20 in the embryo and this 
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temporal expression pattern is further spatially refined by restriction of expression to 
the developing cardiac tissue as a result of the action of as yet unidentified 
transcriptional repressors.  This idea is supported by our observations that 1), the 
response of Tbx20 reporters to SMAD1 and SMAD4 is enhanced by deletion of 
regions both outside and within the 334bp element; and 2), upon reduction of the 
334bp Tbx20 regulatory element to 81bp, reporter expression substantially 
increased in non-cardiac tissues in X. laevis transgenic animals.  These findings are 
consistent with studies that have demonstrated that the BMP arm of the SMAD 
signaling pathway is associated with the regulation of genes involved in early heart 
development, while the TGF-β/activin/nodal arm of the SMAD pathway appears to 
drive cardiac regulation of factors associated with fibrotic, apoptotic, and anti-
hypertrophic events related to progression to heart failure (reviewed in (Euler-Taimor 
and Heger, 2006)).  Further, it has been suggested that BMP signals act as long-
range diffusible morphogens originating from multiple locations in the embryo 
including the endoderm, ectoderm, or cardiac cells themselves (Schultheiss et al., 
1997; Schlange et al., 2000).  It is therefore interesting to speculate that the 
regulation of the novel 334bp Tbx20 cardiac element during late cardiogenesis is a 
result of a continued or second wave of BMP signaling from the underlying 
endoderm or from the myocardial cells, mediated by SMAD1/4.  
 
 Although the SMAD1/4-binding sites are critical for expression of Tbx20 
during cardiac chamber formation, the regulatory element described here does not 
activate endogenous expression of Tbx20 in other regions of the embryo.  Thus, our 
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minimal Tbx20 element does not comprise all of the information necessary for the 
complete expression of Tbx20 and elements regulating early cardiac and neural 
expression of Tbx20 remain to be identified.  Based on this observation and on the 
modular nature of the BMP/SMAD response elements described here, it appears 
that, as for regulation of Nkx2.5 expression, regulation of Tbx20 occurs in a modular 
manner.  Finally, taking into consideration 1), that the minimal element we have 
identified is required for expression of Tbx20 during cardiac chamber formation and 
2), established correlation between mutations in Tbx20 and human congenital heart 
disease, and 3), that not all human mutations that map to Tbx20 occur in the coding 
region of the gene (Kirk et al., 2007; Hammer et al., 2008; Liu et al., 2008; Qian et 
al., 2008), it will be interesting to determine if an association exists between 
mutations in the Tbx20 minimal element and congenital heart disease and/or cardiac 
hypertrophy.  
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Figure 2.1. A regulatory element 5’ to the Tbx20 genomic locus is sufficient to 
drive gene expression in the cement gland and heart.  (A) Schematic 
representation of the X. tropicalis Tbx20 genomic locus.  X. tropicalis Tbx20 consists 
of 8 exons spanning approximately 20 kB.  The Tbx20 transcriptional start site is 
located 287bp upstream of the transcriptional start site in exon 1.  A putative cardiac 
regulatory element is located at the 5’ end of the Tbx20 locus (dashed box).  (B) 
Schematic representation of the 2464bp region of the 5’ end of Tbx20 cloned in 
frame to the EGFP reporter to examine its regulatory capacity in X. laevis 
transgenics.  (C-F), As with endogenous Xenopus Tbx20 expression of the Tbx20 
EGFP reporter is expressed in the cement gland and heart of living X. laevis 
transgenic embryos.  (C), Ventral view of the anterior end of stage 46 sibling non-
transgenic (left) or transgenic (right) embryos.  (D), Fluorescent view of siblings in 
(C, E, and F), Magnified view of the EGFP expression driven by the Tbx20 
regulatory element in the cement gland (E) and heart (F) of the transgenic embryo in 
(D). 
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Figure 2.2.  A 334bp regulatory element recapitulates the endogenous 
expression of Tbx20 throughout the X. laevis heart.  A deletion series of the 5’ 
regulatory element was created to determine a reduced element sufficient to drive 
EGFP transgene expression.  (A), Schematic representation of the deletion series of 
Tbx20 elements fused to EGFP for X. laevis transgenesis.  (B, E, H), Ventral view of 
the anterior regions of living stage 46 (late tadpole) X. laevis embryos (left) and 
siblings transgenic for constructs shown in (A) (right) under white light.  (C, F, I) 
Embryos as viewed under fluorescent light.  Green autofluorescence in the gut can 
be noted in both control and transgenic embryos.  (D, G, I), Magnified views of the 
EGFP-expressing hearts of embryos in (C, F, and I) demonstrating that EGFP 
expression in the heart is maintained under the control of a Tbx20(-334) element.  
Transverse sections were cut through the embryos expressing Tbx20-EGFP shown 
in (B-J), and expression of the Tbx20(-2459)-EGFP (K, L), Tbx20(-1483)-EGFP (M, 
N), and Tbx20(-334)-EGFP (O, P) transgenes is demonstrated by antibody staining 
for EGFP.  Anterior (K, M, O) and posterior (L, N, P) sections show EGFP transgene 
expression throughout the heart.  TA – truncus arteriosis, OFT – outflow tract, CA – 
carotid arch, V – ventricle, T – trabeculae, EC – endocardial cushion, PA – 
pulmocutaneous arch, SA – systemic arch, LA – left atrium, RA – right atrium 
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Figure 2.3. XTbx20 5’ regulatory elements are activated by TGF-β/BMP 
signaling via SMAD1 and SMAD4 but not SMAD3.  (A,B), The Xenopus XTbx20 
5’ element is expressed in a cardiac-specific manner in E10.5 mouse embryos 
derived from a transgenic mouse founder expressing the XTbx20(-2464) fragment. 
(C,D), Magnified view of EGFP fluorescence in the heart of XTbx20(-2464)+/- mouse 
embryo. (E-G), Luciferase reporters controlled by three Tbx20 deletion elements 
were transfected into COS7 cells with a panel of cardiac factor expression plasmids.  
Both the Tbx20(-2464) (H,I) and Tbx20(-334) (K,L) reporters are activated by 
SMAD1 and SMAD4 in a dose-dependent manner when transfected with increasing 
amounts of SMAD expression plasmid.  (J), SMAD3 transfection does not induce the 
Tbx20(-2464) reporter, though the control SM22 reporter is dramatically induced.  
(M), Treatment of COS7 cells with increasing doses of a small molecule inhibitor of 
activin signaling SB431542 does not affect the activation of the Tbx20(-334) plasmid 
by SMAD4.  Values are the fold-increase in luciferase activity relative to that driven 
by the reporter alone.  Error bars represent the standard of fold induction for three 
trials. LV- left ventricle, RV- right ventricle, OFT- outflow tract. Scale bars: 1mm in 
(A-D). 
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Figure 2.4.  XTbx20 is expressed throughout the myocardium and 
endocardium of the X. laevis heart.  (A, B), Tbx20 is expressed in both the 
anterior and posterior regions of the X. laevis stage 46 heart.  Serial sections show 
that Tbx20 expression overlaps with that of the myocardial marker tropomyosin (C, 
D) and with phospho-SMAD1/5/8 expression in the endocardium (E, F) by 
immunohistochemistry.  (C-F), Anti-tropomyosin (Tm) staining is labeled in green, 
anti-pSMAD1/5/8 is labeled in red, and all nuclei are labeled with DAPI in blue.  TA-
truncus arteriosus, OFT-outflow tract, LA-left atrium, V-ventricle 
 
! 81!
Figure 2.5. SMAD1 activation is required for cardiac specific expression of 
Tbx20 in X. Laevis. (A-F), Transverse sections through the heart of stage 40 
anterior explants show loss of nuclear phospho-SMAD1/5/8 in the myocardium of 
dorsomorphin-treated explants (D-E, D’-E’) compared to DMSO-treated controls (A-
C, A’-C’) by immunohistochemistry. In the merged image, anti-phospho-SMAD1/5/8 
(pSMAD1/5/8) staining is labeled in red, anti-myosin heavy chain (MHC) is labeled in 
green, and all nuclei are labeled with DAPI in blue. (G-L), In situ hybridizations for 
Tbx20 performed on stage 40 anterior and cardiac explants show complete loss of 
Tbx20 expression in the heart (H, L) but not the hindbrain (J) of dorsomorphin-
treated anterior and cardiac explants compared to DMSO-treated controls (G, I, K). 
(M-P), Whole-mount antibody staining of stage 40 anterior explants show normal 
expression of the myocardial marker MHC in dorsomorphin-treated explants (N, P) 
compared to DMSO-treated controls (M, O). Dorso, dorsomorphin. Scale bars: 20 
µm in (A-F’); 1 mm in (G-P). 
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Figure 2.6.  SMAD1 binds to seven regions within the 334bp Tbx20 regulatory 
element in vitro and occupies a combination of canonical and non-canonical 
SMAD1 binding sites in vivo.  (A), Double stranded, 5’ carboxyfluorescein-labeled, 
30bp oligos designed for 2x coverage of the 334bp Tbx20 cardiac regulatory 
element for use in fluorescence polarization assays.  (B), Graphical representation of 
dissociation constants (Kd) for each oligo analyzed in fluorescence polarization 
studies. Bold type indicates oligos bound by SMAD1. (C), Schematic representation 
of the location of seven putative SMAD1 binding sites located within the 334bp 
cardiac regulatory element including the regions to be amplified by two separate sets 
of ChIP PCR primers. (D), Position weight matrix generated by MEME software from 
the sequence analysis of oligos 19, 13, 9, 6, and 2 reveals a novel non-canonical 
SMAD1 binding site within the 334bp cardiac regulatory element. (E), Phospho-
SMAD1 occupies a combination of canonical and non-canonical SMAD1 binding 
sites within the 334bp cardiac regulatory element. ChIP assay was performed on 
stage 41 X. tropicalis tadpoles with a phospho-SMAD1/5/8 antibody and precipitated 
DNA was probed with primers against either a combination of canonical and non-
canonical SMAD1 sites (Amplicon 1) or a single non-canonical SMAD1 site 
(Amplicon 2). For comparison, ChIP assay was performed on stage 9 X. laevis 
embryos with a β-catenin antibody, and precipitated DNA was probed with primers 
against Xnr6. Fold enrichment is the signal relative to background (no antibody 
control). 
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Figure 2.7.  SMAD1 activation is mediated through non-canonical SMAD1 
binding sites. Tbx20 reporter constructs with mutation of the two consensus SMAD 
1 binding sites alone or in combination, in the context of the Tbx20  (-2464)-EGFP or 
–luc reporter constructs (A, B), and the Tbx20(-334)-EGFP or –luc constructs (C, D), 
leads to a decrease but not loss of activation in response to SAMD1.  Deletion of the 
334bp regulatory element was from the 2464bp reporters Tbx20(-2464:-334)-luc and 
Tbx20(-2464:-334)-EGFP, led to a substantial decrease in reposen to SAMD1.  Fold 
induction reflects changes in induction relative to induction of the reporter alone, and 
error bars represent standard of three replicates.  
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Figure 2.8. The Xenopus Tbx20 334bp cardiac regulatory element is expressed 
in a cardiac-specific manner in zebrafish. (A,B), In situ hybridization depicts 
expression of Tbx20 in wild-type zebrafish embryos and alk8sk42 (Marques and 
Yelon, 2009) mutant siblings at the 10-somite stage; dorsal views, anterior to the 
top. Tbx20 expression is reduced in both the anterior lateral plate mesoderm, 
including the bilateral cardiac primordia, and the midline mesenchyme of zygotic 
alk8 mutants. (C-E), Lateral views of a live zebrafish embryo at 48 hpf, following 
injection with the XTbx20(-334) transgene.  Injected embryos express EGFP in the 
myocardium. 
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Figure S2.1. The Tbx20-EGFP reporter directs EGFP expression reproducibly 
in the heart and cement gland of transgenic siblings. (A,B), Ventral view of the 
anterior end of stage 46 non-transgenic (left) and transgenic siblings (right) 
generated from one batch of injections of the Tbx20(-2464)-EGFP reporter 
demonstrate consistent and reproducible EGFP expression within the heart and 
cement gland of transgenic embryos. Brightfield views of living embryos (A) and 
corresponding EGFP fluorescence (B) are shown. 
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Figure S2.2. Further deletion of the Tbx20(-334)-EGFP reporter leads to a 
decrease in activity in response to SMAD4 and an increase in non-specific 
Tbx20 expression. (A,B), Tbx20(-251)-luciferase reporter (A) and Tbx20(-81)-
luciferase reporter (B) and corresponding SMAD4 transcriptional assays. Fold 
induction reflects changes in induction relative to induction of the reporter alone, and 
error bars represent standard of three replicates. (C-F), Tbx20(-251)-EGFP (C, D) or 
Tbx20(-81)-EGFP (E, F) reporter constructs were introduced into X. laevis 
transgenic embryos.  Transgenic embryos are located at the right of each image, 
while non-transgenic siblings are at the left.  Brightfield views of living stage 46 
embryos (C,E) and EGFP expression of corresponding embryos (D,F) are shown. 
non-Tg, non-transgenic, Tg, transgenic 
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Figure S2.3.  SMAD1 inhibition during cardiac chamber differentiation does 
not affect expression of the cardiac markers tropomyosin and Tbx5. (A,B), In 
situ hybridization for Tbx5 on stage 40 DMSO (A) and dorsomorphin-treated (B) 
anterior explants show normal expression of Tbx5 in the heart and cardinal vein after 
SMAD1 inhibition. (C-F), Whole mount antibody staining for tropomyosin of a stage 
40 DMSO (C,E) or dorsomorphin-treated (D,F) anterior explant. Ventral view reveals 
no change in expression of tropomyosin in the heart after treatment with 
dorsomorphin. Dorso, dorsomorphin. Scale bars: 1 mm. 
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Table S2.1. ChIP Primer Sequences. 
ChIP Primer Primer Sequence 
Xnr6 Inner/Forward 5’- GGT AGA TGA AAG GCT GAC AGG TGT G -3’ 
Xnr6 Inner/Reverse 5’- GGC TGT TGA AAA CTG AAA TGA AGC -3’ 
SMAD1 sites/Forward 5’- TTT CTC TCG GAG CCC AGT GA -3’ 
SMAD1 sites/Reverse 5’- GCT GAT AAG TGT CTG GGA GG -3’ 
Non-canonical SMAD1 site/Forward 5’- ATA GGA TCT GTG TGG CCA TG-3’ 
Non-canonical SMAD1 site/Reverse 5’- CTG ACA GTG GCC AGG AGA TT-3’ 
 
 
Table S2.2. Dissociation constants (Kd), standard deviation and nucleotide 
sequence for each oligo analyzed in fluorescence polarization studies 
(*indicates oligos bound by SMAD1). 
OLIGO Kd (mM) Std. Dev. Oligo Sequence 
xVent 7.829 0.7465 AGAGAGAATGTTTAGCATAACAATAGC 
SRF site 13.59 0.6407 AGCTTCTTTACACAGGATGTCCATATTAGGACATCTGCGTCAGCAA 
Oligo 21 6.535 0.2181 CTATTTGATCAGCAAACGAGATGGATTACA 
Oligo 20 8.512 0.3635 ACGAGATGGATTACAGATGAGCATCCTTAG 
Oligo 19* 3.758 0.2244 GATGAGCATCCTTAGATTACTCTAAAAGCC 
Oligo 18 9.539 0.4817 ATTACTCCTAAAAGCCCCGCCCTTCTCTTAT 
Oligo 17 5.631 0.4146 CCGCCCTTCTCTTATGTCACGTGTGCTTTT 
Oligo 16* 2.848 0.08203 GTCACGTGTGCTTTTTTTTAGTAAGTCTTT 
Oligo 15 8.428 0.1427 TTTTAGTAAGTCTTTTTCTCTCGGAGCCCA 
Oligo 14 9.473 0.7696 TTCTCTCGGAGCCCAGTGAGAAAAAGAAGT 
Oligo 13* 3.56 0.19 GTGAGAAAAAGAAGTAGCTCGGCTGATCCT 
Oligo 12 9.128 1.409 AGCTCGGCTGATCCTATCTGGCCCTGCTCC 
Oligo 11 6.382 0.6181 ATCTGGCCCTGCTCCATCCCTGCTGCCCTT 
Oligo 10 5.97 0.598 ATCCCTGCTGCCCTTCATTCATTGCCTGTG 
Oligo 9* 2.836 0.3847 CATTCATTGCCTGTGCTCCAGCCGCCACCT 
Oligo 8* 2.078 0.2239 CTCCAGCCGCCACCTCCCAGACACTTATCA 
Oligo 7 5.566 0.4806 CCCAGACACTTATCAGCTGTATCAGGCAGA 
Oligo 6* 2.402 0.1846 GCTGTATCAGGCAGATGTGACGCTGCAGGG 
Oligo 5 7.201 0.5312 TGTGACGCTGCAGGGCTCCAATTGGCCAGG 
Oligo 4 8.436 0.3279 CTCCAATTGGCCAGGAGAGAGATAGGATCT 
Oligo 3 10.03 0.4913 AGAGAGATAGGATCTGTGTGGCCATGAAAT 
Oligo 2* 3.106 0.1021 GTGTGGCCATGAAATTAAGGAAGCAGAGGC 
Oligo 1 14.03 1.1 TAAGGAAGCAGAGGCTGAGAATGGGAACAG 
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Chapter 3 
 
The T-box transcription factor Tbx20 recruits a unique 
TLE-HDAC2-Tbx18 co-repressor complex 
 
Preface 
 This work is in review at the Journal of Proteome Research. The project was 
conceived by myself, Frank Conlon, and Ileana Cristea. The mass spectrometry 
analyses and data processing was done in collaboration with postdoctoral fellow 
Todd Greco and Ileanna Cristea. Graduate student Leslie Kennedy performed the 
Tbx18:Tbx20 co-immunoprecipitation. All other experiments were performed by 
myself. The manuscript was written by myself with contributions by Todd Greco; the 
manuscript was finalized by Frank Conlon and Ileanna Cristea. 
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ABSTRACT 
The cardiac transcription factor Tbx20 has a critical role in the proper morphogenetic 
development of the vertebrate heart and has been implicated in human congenital 
heart disease. Although it is established that Tbx20 exerts its function in the 
embryonic heart through positive and negative regulation of distinct gene programs, 
it is unclear how Tbx20 mediates proper transcriptional regulation of its target genes. 
Here, using a combinatorial directed proteomics/bioinformatics approach, we 
present the first characterization of Tbx20 transcriptional complexes. We have 
systematically investigated Tbx20 protein-protein interactions by integrating a 
targeted proteomic analysis with gene ontology classifications and functional protein 
networks. The resulting proteomic data set demonstrates that Tbx20 is associated 
with a transcription repression network composed of TLE/Groucho co-repressors, 
members of the Nucleosome Remodeling and Deacetylase (NuRD) complex, the 
chromatin remodeling ATPases RUVBL1-RUVBL2, and the T-box repressor Tbx18. 
We have extended these studies by establishing that the Tbx20 interaction with TLE 
co-repressors occurs via an eh1 binding motif, and demonstrated that this binding 
event is required for proper assembly of the repression network. Importantly, we 
went on to validate the TLE interaction in vivo, providing the first demonstration of 
endogenous Tbx20 interactions in embryonic heart tissue. Together, these studies 
led us to propose that Tbx20 associates with a unique TLE-dependent chromatin 
remodeling network to prevent inappropriate gene activation within the embryonic 
heart. 
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INTRODUCTION 
 The development and maturation of a functional heart is a complex process 
that involves distinct but overlapping phases of specification, proliferation, migration, 
differentiation, and morphogenesis. Disturbances in any of these processes can lead 
to a number of congenital heart defects. Currently, congenital heart defects affect 
nearly 1% of all newborns and are a significant cause of infant death (Reller et al., 
2008; van der Linde et al., 2011). Recent studies have demonstrated that human 
patients with dilated cardiomyopathy, atrial septal defects, or mitral valve disease 
carry mutations in the transcription factor Tbx20, while upregulation of Tbx20 gene 
expression has been reported in patients with tetralogy of Fallot (Kirk et al., 2007; 
Hammer et al., 2008; Liu et al., 2008; Qian et al., 2008). Tbx20 is a member of the 
T-box family of transcription factors, all of which share a well-conserved DNA 
binding domain known as the T-box and have diverse roles in embryonic 
development. Tbx20 has been identified in many organisms, including Drosophila, 
zebrafish, Xenopus, and mouse, and in all species examined Tbx20 transcripts are 
strongly expressed throughout the developing heart (Ahn et al., 2000; Griffin et al., 
2000; Meins et al., 2000; Iio et al., 2001; Brown et al., 2003; Conlon and Yutzey, 
2010; Kaltenbrun et al., 2011). Results from genetic analysis and protein depletion 
studies are consistent with a role for Tbx20 during the early stages of vertebrate 
heart development; hearts lacking Tbx20 show a progressive loss of 
cardiomyocytes, a failure of the heart to undergo looping and chamber formation, 
and defects in cardiomyocyte maturation (Brown et al., 2005; Cai et al., 2005; Singh 
et al., 2005; Stennard et al., 2005; Takeuchi et al., 2005). Collectively, these studies 
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suggest that the sequence, expression, and function of Tbx20 are evolutionarily 
conserved from flies to human. 
 
Similar to other T-box factors, Tbx20 is localized to the nucleus, binds DNA in 
a sequence-specific manner, and modulates transcription of downstream target 
genes (Stennard et al., 2003; Brown et al., 2005; Cai et al., 2005; Singh et al., 2005; 
Stennard et al., 2005; Takeuchi et al., 2005; Shen et al., 2011; Sakabe et al., 2012). 
Results from a number of studies have shown that Tbx20 can act to both promote 
and repress target gene expression in the heart; however, it is unclear how Tbx20 
initiates a transcriptional repressive program within the same cells in which it also 
acts as a potent transcriptional activator. It has been proposed that protein co-
factors may act to specify Tbx20 transcriptional activity (Sakabe et al., 2012). A 
model in which protein co-factors act as determinants of Tbx20 activity has several 
unresolved issues because few in vivo Tbx20 co-factors have been identified. 
Additionally, there is uncertainty about the precise mechanism by which binding of 
Tbx20 to DNA results in either activation or repression of a target gene. In vitro 
assays have been used to demonstrate interactions between Tbx20 and a suite of 
cardiac transcription factors that include Tbx5, Nkx2.5, Gata4, Gata5, and Islet1 
(Stennard et al., 2003; Brown et al., 2005), although none of these interactions have 
been shown to occur in vivo in the embryonic heart. Indeed, the presence of DNA-
binding motifs for Nkx2.5, Gata4, and Tbx5 in the promoter regions of Tbx20 target 
genes, in combination with evidence that these transcription factors act 
combinatorially to promote target gene expression suggest that cardiac transcription 
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factors are important co-factors for Tbx20 to activate gene expression in the 
developing heart (Stennard et al., 2003; Takeuchi et al., 2005; Sakabe et al., 2012). 
However, it is not well understood how Tbx20 functions as a transcriptional 
repressor as co-factors that may act as functional co-repressors have not been 
identified. Therefore, the precise mechanisms by which Tbx20 regulates distinct 
gene programs in the heart remains unclear. 
 
To begin to address these questions, we have undertaken, to our knowledge, 
the first proteomic study aimed at identifying Tbx20 protein interactions. Using 
affinity purification mass spectrometry (AP-MS) (Miteva et al., 2013), we have 
systematically isolated and characterized Tbx20-EGFP transcriptional complexes. 
With this approach, we have identified a unique Tbx20 transcription repression 
network that includes the Groucho-related proteins Transducin-like Enhancer of Split 
1 and 3 (TLE1/3), Metastasis-associated Protein 1 (MTA1), the histone-binding 
proteins RBBP4 and RBBP7, RUVB-like 1 and 2, Nucleolin, Nucleophosmin, Histone 
Deacetylase 2 (HDAC2), and the T-box repressor Tbx18. We provide evidence that 
Tbx20 recruits TLE1/3 through an evolutionarily conserved N-terminal engrailed 
homology 1 (eh1) binding motif and demonstrate that recruitment of a subset of this 
network requires binding of TLE3 to Tbx20. Finally, we find that TLE family members 
are expressed in mouse embryonic heart tissue, and that Tbx20 interacts with both 
TLE1 and TLE3 in vivo during heart development, representing the first endogenous 
Tbx20 interactions identified in embryonic heart tissue to date. We propose a model 
in which Tbx20 binds to TLE factors to assemble a chromatin remodeling and 
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deacetylase complex on target gene loci that may act to prevent inappropriate gene 
activation within the cardiac lineage. 
 
MATERIALS AND METHODS 
DNA constructs 
Mouse Tbx20a cDNA was fused to EGFP and cloned into the pMONO-neo-
mcs plasmid (Invitrogen) for expression in HEK293 cells. The Tbx20eh1mut-EGFP 
construct was generated by site-direct mutagenesis (Stratagene) of phenylalanine 
18 (F18L) and serine 19 (S19I) using the primers 5’-
CTCTCGAGCCAATGCCTTAATCATCGCCGCGCTTATGTC -3’ and  5’- 
GACATAAGCGCGGCGATGATTAAGGCATTGGCTCGAGAG -3’ according to 
manufacturer’s instructions. To generate the Tbx20-HA construct, mouse Tbx20a 
cDNA was fused to an HA epitope and cloned into pMONO-neo-mcs. The pCMV2-
TLE1-Flag construct was generously provided by Dr. Stefano Stifani (Buscarlet et 
al., 2009). The pCMX-TLE3 plasmid was kindly provided by Dr. Peter Tontonoz 
(Villanueva et al., 2011). Tbx18-Flag was generously provided by Dr. Chen-Leng Cai 
(Nie et al., 2010).  
 
Xenopus injections and animal cap isolation 
Xenopus laevis embryos were staged according to Nieuwkoop and Faber 
(Nieuwkoop, 1974) and injected with 1 ng Tbx20 or Tbx20-EGFP mRNA at the one-
cell stage using established protocols (Smith and Slack, 1983; Goetz et al., 2006). 
Animal caps were excised at stage 8-9 and cultured in 1X modified Barth’s saline 
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(MBS) until sibling embryos reached stage 13. Activin-treated caps were cultured in 
8 Units/mL Activin in 1X MBS.  
 
Isolation of Tbx20-EGFP protein complexes 
pMONO-Tbx20-EGFP or Tbx20eh1mut-EGFP plasmids were transfected into 
HEK293 cells using FuGENE (Roche Applied Science). Tbx20-EGFP complexes 
and GFP complexes were immunoaffinity purified from cells using in-house 
developed rabbit polyclonal anti-GFP antibodies conjugated to magnetic beads, as 
previously described (Cristea et al., 2005). Briefly, HEK293 cells expressing Tbx20-
EGFP or GFP alone were washed with cold PBS, harvested from the plate by 
scraping with a plastic spatula and pelleted at 1500 rpm for 10 min at 4°C. The cell 
pellet was resuspended in 100 µL/1 µg 20 mM HEPES, pH 7.4, containing 1.2% 
polyvinylpyrrolidone and protease inhibitors and snap frozen in liquid nitrogen. Cells 
were lysed by cryogenic grinding using a Retsch MM 301 Mixer Mill (10 cycles x 2.5 
min at 30 Hz) (Retsch, Newtown, PA) and the frozen cell powder was resuspended 
in optimized lysis buffer (5 mL/1 g cells) (20 mM K-HEPES pH 7.4, 0.1 M KOAc, 2 
mM MgCl2, 0.1% Tween-20, 1 µM ZnCl2, 1 µM CaCl2, 150 mM NaCl, 0.5% Triton X-
100 containing protease and phosphatase inhibitors). Cell lysates were 
homogenized using a Polytron (Kinematica) step (2 x 15 sec) and pelleted at 8000 
rpm at 4°C. Cleared lysates were rotated with 7 mg magnetic beads (M270 Epoxy 
Dynabeads, Invitrogen) coupled to anti-GFP antibodies for 1 hr at 4°C. The magnetic 
beads were then washed in lysis buffer (6 x 1 mL) (without protease and 
phosphatase inhibitors) and eluted from the beads in 40 µL 1x LDS Sample Buffer 
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(Invitrogen) at 70°C for 15 min. Eluted proteins were alkylated with 100 mM 
iodoacetamide for 1 hr at room temperature and subjected to mass spectrometry 
analysis. 
 
Mass spectrometry analysis of Tbx20-EGFP protein complexes 
Immunoisolates were analyzed by mass spectrometry as previously 
described (Tsai et al., 2012) with minor differences. Briefly, reduced and alkylated 
eluates were partially resolved by SDS-PAGE on 4-12% Bis-Tris NuPAGE gels 
(Invitrogen) and stained using SimplyBlue Coomassie stain (Invitrogen). Each lane 
was divided into 1 mm slices and binned into 8 wells of a 96-well plate. Gel slices 
were destained in 50 mM ammonium bicarbonate (ABC) containing 50% acetonitrile 
(ACN). Proteins were digested in-gel with 20 mL of 12.5 ng/mL trypsin in 50 mM 
ABC for 5 hrs at 37°C. Tryptic peptides were extracted in 0.5% formic acid for 4 hrs 
at room temperature, followed by 0.5% formic acid/50% ACN for 2 hrs at room 
temperature. The extracted peptides were concentrated by vacuum centrifugation to 
10 µL and either desalted online (trap column, Magic C18 AQ, 100 mm x 2.5cm) or 
offline using StageTips.  Desalted peptides (4 mL) were separated online by reverse 
phase C18 (Acclaim PepMap RSLC, 1.8 µm, 75 µm × 25 cm) over 90 min at 250 
nL/min using a Dionex Ultimate 300 nanoRSLC  and detected by an LTQ Orbitrap 
Velos or XL mass spectrometer (Thermofisher Scientific, San Jose, CA). 
 
The mass spectrometer was operated in data-dependent acquisition mode 
with dynamic exclusion enabled. A single acquisition cycle comprised a single full-
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scan mass spectrum (m/z = 350–1700) in the Orbitrap (r = 30,000 at m/z = 400), 
followed by collision-induced dissociation (CID) fragmentation in the linear ion trap of 
the top 10 (XL) or 20 (Velos) most intense precursor ions. FT full scan target value 
was 1E6 with a max. injection time of 300 ms. IT tandem MS target values were 5E3 
(XL) or 1E4 (Velos) with a maximum injection time of 100 ms. CID fragmentation was 
performed at an isolation width of 2.0 Th, normalized collision energy of 30, and 
activation time of 30 (XL) or 10 ms (Velos). 
 
Data processing and functional protein analyses 
MS/MS spectra were extracted from Thermo RAW files and searched by 
Proteome Discoverer/SEQUEST (version 1.3, Thermo Fisher Scientific) against the 
UniProt SwissProt protein sequence database (release 2010-11) containing forward 
and reverse entries (20,324 sequences) from human and the mouse Tbx20a 
sequence plus common contaminants. SEQUEST search parameters were as 
follows: full enzyme specificity with 2 missed cleavages, precursor and fragment 
tolerances, 10 ppm and 0.5 Da, fixed modification, carbamidomethylation of 
cysteine, and variable modifications, oxidized methionine and phosphorylation of 
STY.  SEQUEST peptide spectrum matches (MSF files) were loaded into Scaffold 
software (ver. 3.5.1, Proteome Software, Inc), subjected to an X! Tandem refinement 
search, and then analyzed by PeptideProphet and ProteinProphet algorithms to 
determine peptide and protein probabilities. The high mass accuracy option for 
probability scoring was enabled. The following peptide modifications were included 
in the X!Tandem refinement search: deamidation of NQ, and acetylation of K and 
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amino-terminus. Protein groups were assembled by Scaffold and filtered by a 
minimum of 2 unique peptides. Probability thresholds were empirically defined to 
achieve < 1% peptide and protein FDR as assessed by matches to the reverse 
database. Proteins descriptions, accession numbers, and their respective unique 
peptides and unweighted spectrum counts were exported to Excel for further 
analysis. 
 
Specific Tbx20 protein interactions were identified by spectral counting 
enrichment analysis (Tsai et al., 2012) comparing the Tbx20-EGFP versus EGFP 
alone conditions. The following criteria were applied to each individual replicate 
(N=3): 1) only proteins with > 5 spectrum counts were retained, 2) only those 
proteins that had a spectral count enrichment of > 2.5-fold versus GFP alone were 
retained, and 3) using NCBI GO annotations, proteins assigned a “nuclear” 
localization ontology term were retained (Table S3.1; see Table S3.2 for proteins 
excluded for not being associated with a nuclear localization ontology term). The 
proteins that fulfilled these criteria in all three replicates were imported into 
Cytoscape (Smoot et al., 2011) for classification into functional subgroups according 
to biological processes using the plugin ClueGO (Table S3.3) (Bindea et al., 2009). 
Proteins within GO term clusters were analyzed in STRING using protein accessions 
as input (Szklarczyk et al., 2011).  
 
Comparison of interaction protein abundance versus estimated average 
proteome abundance, defined here as an enrichment index, was used to identify 
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prominent interaction candidates from the GO-classified nuclear proteins (Tsai et al., 
2012). To calculate this enrichment index, first, a protein’s spectral counts was 
normalized within each biological replicate (N = 3) by the Tbx20 spectral count ratio 
of each individual replicate / average. Then, normalized spectral counts were 
converted to NSAF (Normalized Spectral Abundance Factor) values (Zybailov et al., 
2007) and further normalized by estimated proteome abundance from the human 
subset of the PAX (protein abundance across organisms) database (Wang et al., 
2012) (Table S3.4). Tbx20 spectral counts were excluded from this analysis. We 
have previously shown that calculating this enrichment index helps to point out 
protein complexes that are prominently associating with the bait (Tsai et al., 2012). 
In a separate spectral counting analysis for the eh1 motif mutant, protein interactions 
were normalized by the eh1mut/WT Tbx20 spectral count ratio. 
 
Analysis of Tbx20-EGFP and Tbx20eh1mut-EGFP protein complexes using mass 
spectrometry-based spectrum counting 
 
Tbx20-EGFP and Tbx20eh1mut-EGFP complexes were immunoisolated and 
analyzed by LC-MS/MS as described above. Peptide and protein identifications were 
filtered using the criteria described above, including the requirement of at least 5 
spectrum counts per protein identified for either wild-type or mutant isolations and 
the requirement that all proteins identified in the wild-type isolation be at least 2.5-
fold enriched over isolations from EGFP-expressing cells. To determine differences 
in interacting proteins between wild-type and mutant Tbx20 isolations, a spectrum 
counting approach was employed. Spectrum counts for each protein was normalized 
to the number of spectrum counts for wild-type Tbx20. The fold-change, relative to 
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wild-type Tbx20, in spectrum counts was used as a measure of the approximate 
relative abundance of interacting proteins, i.e., fold-change = normalized spectrum 
counts of the protein in eh1mut isolation/ spectrum counts of the protein in wild-type 
isolation). Interacting proteins with a fold change less than or equal to 0.5 between 
mutant and wild-type isolations were considered to be significantly reduced in 
mutant isolations (Table S3.5). 
 
Construction of a HEK293-HDAC2-EGFP stable cell line 
The HDAC2 ORF was amplified from an HDAC2 plasmid (gift from E. Seto, 
Moffitt Cancer Center), and inserted into the pLXSN-C-EGFP-FLAG vector to create 
the HDAC2-EGFP-flag fusion, as in (Greco et al., 2011). The PhoenixTM retrovirus 
expression system (Orbigen, San Diego, CA) was used to transduce HEK293 cells 
to express the HDAC2-EGFP-FLAG fusion according to the manufacturer’s 
instructions. The transduced cells were selected in 300 mg/L G418 (EMD, 
Gibbstown, NJ) and sorted by FACS (Vantage S.E. with TurboSort II, Becton 
Dickinson, Franklin Lakes, NJ) to obtain a stable cell line. The nuclear localization 
and deacetylation activity of the GFP-tagged HDAC2 were confirmed. 
 
Isolation of endogenous Tbx20 from mouse embryonic hearts 
Pregnant CD1 females were sacrificed on embryonic day 10.5 (E10.5) and 
the embryos removed. Embryonic hearts (n=25) were dissected from the embryos in 
cold PBS and snap-frozen in liquid nitrogen. Embryonic hearts were cryogenically 
lysed, and endogenous Tbx20 protein complexes were immunoaffinity purified as 
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described using 5 mg magnetic beads (M270 Epoxy Dynabeads, Invitrogen) 
conjugated to anti-Tbx20 antibodies (Santa Cruz Biotechnology). The isolated 
proteins were analyzed by Western blotting. 
 
Immunofluorescence and immunoblotting 
For immunofluorescence of HEK293 cells, cells were cultured in 8-well 
chamber slides pretreated with poly-D-lysine. For live imaging of EGFP 
fluorescence, cells were transfected with pMONO-Tbx20-EGFP. Forty-eight hours 
later, the cells were rinsed with 1X PBX and DAPI added (200 ng/mL in 1X PBS) for 
30 min. Cells were imaged by confocal microscopy on a Zeiss 710.  
 
Antibodies used for immunoblotting include mouse anti-GFP (JL8) (Clontech 
Living Colors Monoclonal), mouse anti-Flag (M2) (Sigma), goat anti-TLE1 (N-18) 
(Santa Cruz Biotechnology), rabbit anti-TLE3 (M-201) (Santa Cruz Biotechnology), 
mouse anti-GAPDH (Millipore), and goat anti-Tbx20 (Santa Cruz Biotechnology). 
 
RNA extraction and RT-PCR 
RNA was extracted using Trizol (Invitrogen) and purified on RNeasy columns 
(Qiagen). cDNA synthesis was performed from 0.5-1 µg of RNA using random 
primers and SuperScript II reverse transcriptase (Invitrogen). Expression levels were 
assessed using GoTaq Green Master Mix (Promega) and Taq polymerase on a 
GeneAmp PCR System (Applied Biosystems). PCR products were analyzed by 
2.5% agarose gel electrophoresis. 
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RESULTS 
Tbx20-EGFP is localized to the nucleus and transcriptionally active  
Identification of critical Tbx20 protein co-factors in a high throughput manner 
has been hampered by a lack of antibodies against Tbx20 that are suitable for 
directed proteomics analyses. Additionally, there are no cell lines that recapitulate 
endogenous Tbx20 expression and thus could provide sufficient material for large-
scale proteomics studies of Tbx20 protein complexes. Since the main goal of this set 
of studies was to determine the general transcriptional mechanisms by which Tbx20 
functions, we generated human embryonic kidney (HEK293) cells expressing Tbx20 
tagged at the C-terminus with EGFP (Figure 3.1A). HEK293 cells have been used as 
a cell culture model for studies on the transcriptional activity of Tbx20 (Brown et al., 
2005; Cai et al., 2005), indicating that this cell line contains the necessary cohort of 
transcriptional co-factors required for Tbx20-mediated transcriptional regulation. In 
agreement with its known role in transcription, Tbx20-EGFP localizes strongly to the 
nucleus when expressed in HEK293 cells, as shown by live GFP fluorescence 
microscopy (Figure 3.1B).  
 
To confirm that the EGFP-tagged Tbx20 is transcriptionally active, we made 
use of a Xenopus animal cap assay. A recent study demonstrated that animal caps, 
which consist of naïve pluripotent cells, when excised from embryos injected with 
Tbx20 mRNA express the early mesoderm marker Xbra, but not the skeletal muscle 
marker Myf5, indicating that Tbx20 can induce cell fate changes in the early embryo 
(Stennard et al., 2003). To assess whether EGFP-tagged Tbx20 has the same ability 
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to induce gene expression changes as untagged Tbx20, we injected Tbx20 and 
Tbx20-EGFP mRNA into one-cell stage Xenopus laevis embryos. By stage 8, 
Tbx20-EGFP protein is localized throughout the animal pole of the embryo, as 
shown by live GFP fluorescence microscopy (Figure 3.1C). At stage 9, animal caps 
were excised from Tbx20, Tbx20-EGFP, and uninjected embryos and cultured until 
sibling whole embryos reached stage 13. After extraction of RNA, we assessed the 
expression of the early mesodermal markers chordin and Xbra, and as a negative 
control, Myf5, by RT-PCR and compared levels of induction to expression of these 
genes within whole embryos, untreated caps, and, as a positive control, caps treated 
with the mesoderm-inducing factor Activin. Both EGFP-tagged Tbx20 and untagged 
Tbx20 induce chordin expression to the same degree as Activin (Figure 3.1D). 
Further, Tbx20 and Tbx20-EGFP induce moderate levels of Xbra compared to 
Activin-induced caps; however, there was no induction of the muscle marker Myf5 by 
either version of Tbx20 or by Activin treatment. Untreated caps did not express any 
of the tissue-specific markers tested. These data indicate that EGFP-tagged Tbx20 
is transcriptionally active and retains the ability to modulate downstream gene 
expression. 
 
Directed proteomics of Tbx20-EGFP interactions reveals association with a 
unique transcription repression network 
  
To systematically identify Tbx20-associated proteins, we performed 
immunoaffinity purifications of Tbx20-EGFP complexes from HEK293 cells using a 
high affinity in-house developed antibody against GFP (Cristea et al., 2005). In 
parallel, as controls, we performed immunoaffinity purifications from cells expressing 
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EGFP alone (Tables S3.1, S3.2). Immunopurified proteins were partially resolved by 
SDS-PAGE, digested in-gel with trypsin, and analyzed by nLC-tandem MS (MS/MS) 
on an LTQ Orbitrap XL or an LTQ Orbitrap Velos. Three independent biological 
replicates were performed (Tables S3.1, S3.2); two of these immunopurifications 
were performed in the presence of DNase to eliminate interactions mediated by 
binding of factors on adjacent DNA sequences. Raw MS/MS spectra from each 
experiment were analyzed by SEQUEST database searches (Proteome Discoverer) 
and loaded into Scaffold for further analysis. Protein identifications from all three 
replicates were filtered using stringent confidence parameters (see Materials and 
Methods). A spectrum counting approach was employed to assess enrichment of 
protein interactions with Tbx20-EGFP relative to EGFP alone. First, proteins were 
required to be reproducibly present at an abundance of at least 5 spectrum counts. 
From these proteins, interactions that were deemed non-specific were excluded, 
which were defined as proteins showing less than 2.5-fold spectrum count 
enrichment over proteins that interact with EGFP alone. Further, given the nuclear 
localization of Tbx20-EGFP, proteins lacking a nuclear gene ontology term were 
excluded as likely non-specific associations occurring during whole-cell lysis (Table 
S3.2). 
 
To assess the Tbx20 nuclear interactome as a whole, we classified the 
proteins passing our spectrum count and fold enrichment criteria into functional 
subgroups by Cytoscape, using the ClueGO plugin (Bindea et al., 2009; Smoot et 
al., 2011). Specifically, proteins were assigned into gene ontology (GO) term 
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clusters according to biological function ontologies. When we examined Tbx20 
nuclear interactions, the most prominent biological function category contained 53 
proteins related to RNA processing (Figure 3.2A and Table S3.3). This is expected, 
as it is well established that DNA template that is being actively transcribed is often 
closely associated with RNA processing machinery and suggests that a portion of 
Tbx20 binding is closely associated with active transcription. Nuclear interactions 
also included 13 proteins involved in nucleosome assembly (i.e., chromatin 
remodeling, DNA conformation change), 16 proteins assigned to DNA 
repair/synthesis, and 10 proteins assigned to nuclear transport (Figure 3.2A and 
Table S3.3). Collectively, these putative Tbx20 interactions represent different 
complexes and functions of Tbx20 throughout the nucleus. Given the lack of 
knowledge regarding the molecular mechanisms of Tbx20-mediated transcriptional 
regulation, we reasoned that the specific protein functions represented within the 
chromatin modification/remodeling category could provide new insight on the 
potential roles of Tbx20 in gene regulation.   
 
In total, 114 proteins with annotated nuclear localization passed our spectrum 
count and fold enrichment criteria, 97% of which occur in all three biological 
replicates, while the remainder passed our stringent specificity criteria in at least two 
of the three experiments (Table S3.1). Given that chromatin remodeling and 
transcription repression complexes are often large multi-protein complexes, we 
speculated that the specific proteins represented within the ‘chromatin remodeling’ 
category were likely to be interconnected. To test this hypothesis, we analyzed the 5 
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proteins within this functional cluster (Table 3.1 and Table S3.3) using STRING, a 
knowledge database of known and predicted protein-protein interactions (Szklarczyk 
et al., 2011), with the aim of generating a predictive Tbx20 interaction network. 
Surprisingly, all 5 of these proteins form a highly interconnected network containing 
chromatin remodeling and deacetylase functions and include the chromatin-
remodeling ATPase RUVBL1, the nucleolar protein Nucleophosmin (NPM1), and 
core components of the Nucleosome Remodeling and Deacetylase (NuRD) complex 
(RBBP4, RBBP7, and HDAC2)—a major ATP-dependent chromatin remodeling 
complex with important roles in transcription and chromatin assembly (reviewed in 
(Bowen et al., 2004)). In addition, NCL, RUVBL2, and MTA1, which were also found 
to interact with Tbx20, were integrated into this network based upon their known or 
predicted functional association with components of the chromatin remodeling 
network (Table 3.1 and Figure 3.2B, grey lines) (Li et al., 1996; Xue et al., 1998; 
Ikura et al., 2000; Sardiu et al., 2008). 
 
As this is the first demonstration that Tbx20 is associated with chromatin 
remodeling proteins, it was unclear how Tbx20 might be functionally linked to this 
chromatin modification network. There is evidence that MTA family proteins interact 
directly with transcription factors at target gene loci (Roche et al., 2008); however, 
different transcription factors have been shown to bind to different regions of 
individual subunits of the NuRD complex (Fujita et al., 2004; Li et al., 2009). To 
attempt to identify the functional link between Tbx20 and the chromatin remodeling 
network, we first returned to our list of nuclear-enriched proteins to search for 
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additional components of a chromatin modification network that may have been 
excluded in our original analysis due to incomplete GO annotation. Surprisingly, this 
search uncovered the presence of the transcriptional co-repressors Transducin-like 
Enhancer of split 1 and 3 (TLE1 and TLE3) and the T-box transcriptional repressor 
Tbx18 (Figure 3.2B and Table 3.1). TLE family members are orthologs of the 
Drosophila Groucho protein and have been previously demonstrated to bind directly 
to T-box factors, including Tbx18 and Tbx15, through an engrailed homology 1 (eh1) 
binding motif and achieve transcriptional repression by recruiting histone 
deacetylases (Chen et al., 1999; Farin et al., 2007).  
 
To examine if Gro/TLE factors could serve as proximal interacting partners, 
linking Tbx20 to chromatin remodeling complexes, we examined the relative 
enrichment level of proteins within the interaction network. As previously described 
(Tsai et al., 2012; Miteva et al., 2013), we estimated the relative enrichment of 
proteins within the immunoisolates by normalizing their relative protein abundances 
(NSAF values) (Zybailov et al., 2007) to their proteome abundances from the PAX 
database (pax-db.org) (Table S3.4). This relative enrichment analysis was 
performed for the 114 proteins with enrichment in Tbx20 immunoisolations and 
"nuclear" GO subcellular localization (see Table S3.3). Respective enrichment index 
values were then expressed on the Gro/TLE-chromatin remodeling network. We 
hypothesized that proteins within the interaction network having greater enrichment 
indices would represent more proximal and perhaps essential Tbx20 interactions. 
Indeed, TLE1/3 and Tbx18 comprise a group of the most highly enriched 
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components of the interaction network (Figure 3.2B). This supports a critical role for 
these proteins in regulating Tbx20 function, suggesting they may be directly linked to 
Tbx20.  
 
Tbx20 forms protein complexes with TLE1/3, Tbx18, and HDAC2  
The T-box proteins Tbx15 and Tbx18 have been reported to bind directly to 
TLE3 via N-terminal eh1 binding motifs (Farin et al., 2007), indicating that the eh1 
motif may represent a common motif used by T-box transcription factors to bind 
Gro/TLE family members. To determine whether Tbx20 directly recruits Groucho co-
repressors via an eh1 binding motif, we next investigated the interaction between 
Tbx20 and TLE1/3. Tbx20 contains an N-terminal eh1 binding motif that is fully 
conserved in all vertebrate orthologs of Tbx20 (Figure 3.3A).  To confirm an 
interaction between Tbx20 and TLE1/3 and determine whether these interactions 
require the eh1 motif, we generated a Tbx20eh1mut-EGFP expression construct in 
which the eh1 motif has been ablated by site-directed mutation of phenylalanine 18 
and serine 19 to an isoleucine and a leucine, respectively (Tbx20F18I; S19L-EGFP). 
Reciprocal immunoisolations of TLE1 and TLE3 complexes were performed in the 
presence of wildtype Tbx20-EGFP or Tbx20eh1mut-EGFP. Mutation of the eh1 motif 
significantly reduced the ability of Tbx20-EGFP to co-immunoprecipitate with either 
TLE1 or TLE3, suggesting that Tbx20 binds TLE1/3 directly through this motif 
(Figure 3.3B,C). 
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The finding that Tbx20 interacts with both a Gro/TLE complex and the 
Groucho dependent repressor Tbx18 (Farin et al., 2007) indicates that Tbx20 and 
Tbx18 may heterodimerize to regulate a common set of targets in a Groucho 
dependent manner. To further investigate the interaction between Tbx20 and Tbx18, 
we transfected HEK293 cells with Tbx18-Flag alone or in the presence of Tbx20-
EGFP. Immunopurification with an anti-Flag antibody and western blot analysis 
revealed efficient co-isolation of Tbx20 (Figure 3.3D). Collectively, these data imply 
a role for a Tbx20-Tbx18 repressor complex during vertebrate development.  
 
To investigate the link between the Tbx20-TLE1/3 complex and HDAC2, we 
generated an HEK293 cell line stably expressing HDAC2 tagged at the C-terminus 
with EGFP. To confirm an interaction between Tbx20 and HDAC2, we performed 
reciprocal isolations of HDAC2-EGFP in the presence or absence of Tbx20-HA. 
Tbx20 was successfully co-isolated with HDAC2-EGFP (Figure 3.3E). As a number 
of studies indicate that binding to Groucho co-factors results in recruitment of 
deacetylase machinery (Chen et al., 1999), we also performed isolations of HDAC2-
EGFP in the presence of over-expressed TLE3 and Tbx20. Interestingly, excess 
TLE3 results in a substantial increase in the amount of Tbx20 associated with 
HDAC2, suggesting that TLE3 stabilizes and likely bridges an interaction between 
Tbx20 and HDAC2 (Figure 3.3E). We also noticed that HDAC2-EGFP co-isolated 
with a higher amount of TLE3 in the absence of Tbx20-HA. Therefore, an alternative 
explanation is that Tbx20 competes or interferes with TLE3 binding to HDAC2, 
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possibly forming intermediate interactions with both HDAC2 and TLE3-containing 
complexes. 
 
Quantitative mass spectrometry reveals that Tbx20 recruits a Groucho-
dependent repressive complex  
 
To distinguish between these possibilities and to assess precisely which 
components of the chromatin modification network that we identified (see Figure 
3.2B) are recruited by the Tbx20-TLE3 interaction, we used label-free quantitative 
mass spectrometry to quantify differences between Tbx20-EGFP and Tbx20eh1mut-
EGFP protein complexes.  To do this, we expressed Tbx20-EGFP and Tbx20eh1mut-
EGFP in HEK293 cells and performed parallel isolations of EGFP-tagged Tbx20 
complexes. Changes in the relative abundance of interacting chromatin remodeling 
factors between wild-type and mutant Tbx20 complexes were assessed using a 
spectrum counting approach (see Materials and Methods). To correct for the total 
amount of isolated Tbx20 complexes between conditions, we normalized the 
spectrum counts for associated proteins in mutant Tbx20 complexes by wild-type 
Tbx20-EGFP spectrum counts. Consistent with our previous result, we did not 
identify any TLE1 or TLE3 in the Tbx20eh1mut mutant isolation. Further, we did not 
observe any Tbx18 in Tbx20eh1mut mutant complexes, and association with HDAC2 
and RBBP4 was significantly reduced compared to wild-type, suggesting that Tbx20 
interacts with these components in a Groucho-dependent manner (Figure 3.4A,B 
and Table S3.5). These data suggest that TLE co-repressors play a central role in 
the formation of a Tbx20 transcriptional repressive complex by recruiting the co-
repressor Tbx18 and core components of the NuRD complex including HDAC2. 
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Additionally, these results confirm that using a targeted proteomics approach, we 
can efficiently isolate and identify specific Tbx20 interactions that may help define 
the mechanisms involved in Tbx20-mediated gene regulation. 
 
Endogenous Tbx20 interacts with TLE factors in mouse embryonic hearts 
Our proteomic analysis suggests that Tbx20 is linked to a transcriptional 
repressive complex via direct interaction with a TLE family member. To assess the 
endogenous Tbx20 association with TLE family members in vivo at the time in 
embryogenesis at which Tbx20 has been shown to function, we first examined the 
expression of all of the TLE family members in mouse embryonic day 10.5 (E10.5) 
heart tissue by RT-PCR. At this stage of development, Tbx20 is uniformly expressed 
throughout the four-chambered embryonic heart (Kraus et al., 2001) where it is 
required for proper transcriptional regulation of cardiac!chamber-specific genes (Cai 
et al., 2005; Singh et al., 2005; Stennard et al., 2005; Takeuchi et al., 2005). All of 
the TLE family members are highly expressed at this time, with the exception of 
TLE2, which is expressed at relatively low levels (Figure 3.5A).  
 
Importantly, we were able to detect an interaction between endogenous 
Tbx20 and both TLE1 and TLE3 in the embryonic heart, indicating that Tbx20 binds 
both TLE factors in vivo during heart development (Figure 3.5B). This finding 
represents the first demonstration of endogenous Tbx20 protein-protein interactions 
from an embryonic heart. These data further validate our proteomic approach and 
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demonstrate for the first time that Tbx20 assembles a TLE repressor complex in the 
embryonic heart at the time at which Tbx20 functions in cardiac development. 
 
DISCUSSION 
Despite the critical role of Tbx20 in cardiac development, the precise 
mechanisms by which Tbx20 regulates distinct gene programs in the heart are not 
understood. Studies in mouse knockout models of Tbx20 indicate that Tbx20 is 
required for proper patterning and morphogenesis of working myocardium (Cai et al., 
2005; Singh et al., 2005; Stennard et al., 2005; Takeuchi et al., 2005). Thus, 
activating and repressive activity of Tbx20 on target genes underlies the primary 
cardiomyocyte lineage split into specialized chamber and non-chamber myocardium. 
To identify and characterize the determinants of Tbx20 transcriptional activity in the 
heart, it is essential to identify Tbx20 interacting proteins. Our study constitutes the 
first comprehensive analysis of Tbx20 protein interactions. Using an unbiased 
proteomics/bioinformatics approach, we identified a unique transcriptional repression 
network that includes Groucho co-repressors, components of the NuRD complex, 
and a RUVBL1-RUVBL2 chromatin remodeling complex. Collectively, our data are 
consistent with a model in which Tbx20 recruits a Groucho co-repressor complex 
with histone deacetylase activity to target genes, rendering the chromatin 
inaccessible for activation.  
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Tbx20 interacts with a Gro/TLE repressor complex 
The Tbx20 homolog Midline was recently demonstrated to bind Groucho 
directly in an eh1-dependent manner in Drosophila whole embryos, and this 
interaction was required for proper transcriptional repression of the wingless gene 
during segmentation of the ectoderm (Formaz-Preston et al., 2012). Our studies 
confirm and expand upon this work by demonstrating that 1) vertebrate Tbx20 
interacts with Groucho homologs, 2) vertebrate Tbx20 interacts with at least two 
members of the Groucho-related TLE family, TLE1 and TLE3, in human cells and in 
the mouse embryonic heart through the eh1 motif, and 2) Tbx20-TLE interactions 
directly result in the recruitment of components of the chromatin-remodeling NuRD 
complex including HDAC2. These data suggest that recruitment of Gro/TLE co-
repressor complexes and subsequent deacetylation of target loci represent an 
evolutionarily conserved mechanism by which Tbx20 functions and thus, one mode 
by which Tbx20 promotes inactive chromatin states during development. A thorough 
expression analysis of TLE factors in the developing heart has not been published; 
although, it has been reported that TLE1 and TLE3 transcripts were not detectable in 
the mouse embryonic heart by in situ hybridization (Santisteban et al., 2010). Our 
data, however, suggests that most members of the mouse TLE family are expressed 
in the heart at stage E10.5 of embryogenesis. Further, TLE1 and TLE3 proteins co-
isolate with endogenous Tbx20 at E10.5. The availability of other TLE factors in the 
heart, and our results showing that Tbx20 interacts with both TLE1 and TLE3, 
suggests that Tbx20 may interact with multiple members of this family to 
cooperatively regulate genes in different regions of the heart. As such, it will be 
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interesting to determine whether individual TLE family members have distinct 
temporal and spatial expression patterns in the forming heart or whether they can 
act redundantly on Tbx20 target genes. 
 
Our directed proteomic analysis of Tbx20 complexes combined with a label-
free spectrum counting approach indicates that binding of TLE factors by Tbx20 
results in the recruitment of additional members of a unique co-repressor complex, 
including core components of the NuRD complex HDAC2 and RBBP4, and Tbx18. 
Interestingly, interactions with the remainder of the repression network were 
unaffected by the eh1 mutation, suggesting that they are recruited independently of 
the eh1 binding motif and TLE recruitment. These results suggest two possibilities. 
First, assembly of the entire transcription repression complex could occur in two 
independent steps, whereby an intact TLE co-repressor complex is recruited via the 
eh1 binding motif, while the remainder of the complex is recruited independently via 
other binding motifs within Tbx20. Interestingly, RUVBL2 (also called Reptin) was 
demonstrated to co-occupy the Hesx1 promoter with TLEs and HDAC1 to silence 
Hesx1 expression during mouse pituitary development (Olson et al., 2006), 
indicating that this protein, although still present within Tbx20eh1 mutant complexes, 
may be part of an intact TLE co-repressor complex.  
 
The second possibility is that Tbx20 is a component of both a TLE co-
repressor complex that include the proteins TLE1/3, Tbx18, HDAC2, and RBBP4, 
and also part of a broader chromatin remodeling protein interaction network that 
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includes RBBP7, MTA1, RUVBL1, RUVBL2, NCL, NPM1. The precise composition 
of Tbx20 transcriptional complexes likely varies spatially and temporally during 
development such that incorporation of unique subunits might impart functional 
specialization of the complex within specific tissue types and at defined 
developmental windows. In support of this notion, RUVBL1/2 (synonyms: 
Reptin/Pontin) complexes have been shown to have a role in the transcriptional 
regulation of cardiomyocyte proliferation but only after progenitors have assembled 
into a linear heart tube in zebrafish embryos(Rottbauer et al., 2002). Tbx20 has a 
well-documented role in cardiomyocyte proliferation(Cai et al., 2005) and seems to 
exert opposite effects on cell proliferation in embryonic versus fetal 
cardiomyocytes(Chakraborty and Yutzey, 2012). Therefore, it is tempting to 
speculate that association of Tbx20 with a RUVBL1/2 complex in fetal 
cardiomyocytes underlies this switch in the activity of Tbx20 transcriptional 
complexes. The temporal and tissue-specific regulation of Tbx20 protein complexes 
will be a subject of future investigation. 
 
Transcriptional repression by Tbx20 and Tbx18 
An unexpected finding of these studies is that Tbx20 interacts with the tissue-
specific transcription factor Tbx18. In the developing heart, Tbx18 expression 
overlaps with that of Tbx20 in a subset of cardiomyocytes within the interventricular 
septum and a portion of the left ventricle at a stage when the heart is undergoing 
chamber specialization and expansion, processes that are both dependent on 
proper Tbx20 function (Christoffels et al., 2009; Conlon and Yutzey, 2010; 
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Kaltenbrun et al., 2011; Zeng et al., 2011). Thus, interaction with Tbx18 in this 
subset of cardiomyocytes provides one potential mechanism through which Tbx20 
may function to regulate regionally distinct gene programs in the heart. Tbx18 is also 
expressed in the epicardium, an epithelial monolayer that covers the myocardium 
and is a critical source of signals and cells for the underlying myocardium (Kraus et 
al., 2001). Recently, a microarray analysis of isolated epicardial cells revealed Tbx20 
as an epicardium-enriched transcription factor (Huang et al., 2012), opening the 
possibility for a Tbx18-Tbx20 transcriptional complex within the epicardium. Tbx18 
also plays a prominent role in formation of the myocardial sinus horns that make up 
the venous pole of the heart; however, it is not clear whether Tbx20 is co-expressed 
with Tbx18 within this tissue (Christoffels et al., 2006). Collectively, these studies 
imply a role for a Tbx20-Tbx18 repressor complex during cardiovascular 
development and further, demonstrates that our targeted proteomic analysis of 
Tbx20 complexes results in the identification of tissue-specific interactions likely to 
be important in the context of the developing embryo. 
 
Tbx18 has also been shown to interact with TLE3 via an eh1 binding motif 
within the N-terminus of the protein (Farin et al., 2007). In this study, transcriptional 
assays demonstrated that Tbx18 can repress activation of the Nppa/ANF promoter 
by the cardiac transcription factors Gata4, Nkx2.5, and Tbx5. This finding was 
interpreted as Tbx18 abrogation of Nppa/ANF expression through competition with 
Tbx5, a second T-box protein, for T-box binding sites (TBEs) within the Nppa/ANF 
promoter. Similarly, Tbx18 is predicted to repress Tbx6-mediated activation of the 
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Notch ligand Delta-like 1 (Dll1) in anterior somites through competition with Tbx6 
(Farin et al., 2007). Collectively, these data imply a model in which Tbx18 competes 
with other T-box activators for occupancy of TBEs and subsequently achieves 
repression by recruiting a TLE co-repressor complex to the target gene. In contrast, 
our data strongly implies a mechanism by which Tbx20 and Tbx18 are 
simultaneously bound to TLE3 at their respective eh1 motifs, and that binding of 
Tbx20 to TLE3 is a critical event preceding its interaction with Tbx18. Therefore, it 
appears that Tbx18 and Tbx20 may be acting cooperatively as repressors on a 
common set of target genes. Our lab has previously reported that Tbx20 also 
interacts physically with Tbx5 (Brown et al., 2005), suggesting that 
heterodimerization with other T-box factors may represent an important mechanism 
by which Tbx20 regulates gene expression in the embryo. This model is consistent 
with a recent study demonstrating that cardiogenic transcription factors act on 
enhancers in a cooperative manner (Junion et al., 2012). In this “transcription factor 
collective” model, occupancy of one or more of the transcription factors on a target 
locus initiates the recruitment of the remainder of the transcription factors via 
protein-protein interactions (as opposed to a specific arrangement of sequence 
motifs within the target promoter).  
 
In summary, the goal of our study was to expand upon the current knowledge 
of the Tbx20 transcriptional network. By combining immunoaffinity purification with 
targeted proteomics and functional network analysis, we have identified a Tbx20 
transcription repression network with chromatin remodeling and deacetylase 
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functions. We also identified Tbx18 as a Tbx20 interaction, raising the question of 
whether Tbx20 transcriptional repression relies on cooperative activity of Tbx20 and 
other cardiac transcription factors, similar to what has been shown for Tbx20 
transcriptional activation in the presence of the activators Gata4, Nkx2.5, and Tbx5 
(Stennard et al., 2003; Takeuchi et al., 2005). Future studies will aim to delineate the 
biological role of these repressive interactions, particularly as they relate to 
regulation of the cardiogenic program.  
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Figure 3.1. Tbx20-EGFP is nuclear-localized and transcriptionally active. (A) 
Schematic of EGFP-tagged (green) Tbx20 expression construct, showing the N-
terminal (white), T-box (black), transactivation (blue), and repression (brown) 
domains. A putative Tbx5 protein-protein interaction (PPI) domain lies within the N-
terminus and T-box. Numbers denote amino acid residues. (B) Tbx20-EGFP is 
localized to the nucleus in HEK293 cells, as confirmed by live GFP fluorescence and 
colocalization with DAPI. (C) Tbx20-EGFP mRNA was injected at the 1-cell stage 
into Xenopus embryos. Expression of Tbx20-EGFP in the animal pole of stage 9 
Xenopus embryos was confirmed by live GFP fluorescence. (D) RT-PCR analysis of 
the mesodermal genes chordin and Xbra and the skeletal muscle gene Myf5 in 
stage 13 whole embryos, stage-matched untreated animal caps, Activin-treated 
animal caps, Tbx20-injected animal caps, and Tbx20-EGFP-injected animal caps. 
The housekeeping gene Gapdh was used as a loading control for all RT-PCR 
reactions. 
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Figure 3.2. Directed proteomics of Tbx20-EGFP protein complexes reveals 
association of Tbx20 with an HDAC-containing chromatin remodeling and 
Groucho transcriptional protein network. (A) GO enrichment analysis of Tbx20 
interactions using ClueGO clustering according to biological function ontologies. (B) 
The Cytoscape network was assembled from automated retrieval and manual 
curation of protein functional associations using STRING analysis (grey lines) and 
literature curation (solid black lines), respectively.  Potential interactions/functional 
associations with Tbx20 are indicated by black dashed lines. Nodes are labeled with 
respective gene symbols and enrichment index values (see Materials and Methods) 
are represented by node size and blue color intensity. 
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Figure 3.3. Tbx20 interacts with TLE1/3, HDAC2, and Tbx18. (A) Protein 
sequence alignment of an N-terminal eh1 binding motif in Tbx20 demonstrating 
complete conservation of the eh1 motif across all vertebrate homologs of Tbx20. h, 
human; m, mouse; x, Xenopus; z, zebrafish. (B) Reciprocal immunoisolations of 
TLE1-Flag (FL) complexes from HEK293 cells expressing either Tbx20-EGFP or 
Tbx20eh1mut -EGFP. (C) Reciprocal immunoisolations of TLE3 complexes from 
HEK293 cells expressing either Tbx20-EGFP or Tbx20eh1mut-EGFP. (D) Reciprocal 
immunoisolations of Tbx18-Flag (FL) complexes from HEK293 cells expressing 
Tbx18-Flag in the presence or absence of Tbx20-EGFP. (E) Reciprocal 
immunoisolations of HDAC2-GFP from HEK293 cells expressing Tbx20-HA and/or 
TLE3. 
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Figure 3.4. Tbx20 assembles a Groucho-Tbx20 repression complex via the eh1 
binding motif. Wild-type Tbx20-EGFP and Tbx20eh1mut-EGFP were immunoaffinity 
purified from HEK293 cells with associated proteins and analyzed by mass 
spectrometry. Fold changes in spectrum counts for each interaction illustrated in (A) 
is shown for the isolated Tbx20eh1mut mutant versus wild-type Tbx20. (B) The relative 
size of the circles indicates increased or decreased relative abundance of each 
interaction as determined by the fold-change in spectrum counts for mutant versus 
wild-type Tbx20 isolations. !!!!!!!!!!!!!!!
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Figure 3.5. Endogenous Tbx20 interacts with TLE1/3 in mouse embryonic 
hearts. (A) RT-PCR analysis of TLE family members and cardiac-specific markers 
Nkx2.5 and Tbx20 in E10.5 heart tissue. All samples derived from embryonic hearts 
dissected at E10.5. (B) 25 hearts were dissected, and endogenous Tbx20 
complexes were isolated with an antibody against Tbx20, analyzed by SDS-PAGE, 
and immunoblotted with antibodies against TLE1 and TLE3. In parallel and as a 
control, a mock immunoprecipitation was performed in the absence of Tbx20 
antibody. !
! ! !
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Table 3.1. Tbx20-associated proteins identified by LC-MS/MS. Numbers 
represent an average across three experimental replicates. 
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Table S3.1. Nuclear-enriched DNA-independent Tbx20 interactions from three 
independent immunoisolations. Tbx20 associations that occur in the presence of 
DNase, are nuclear-enriched, and meet specificity criteria (see Materials and 
Methods) in three independent immunoisolations. 
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Table S3.2. Proteins excluded from nuclear-enriched DNA-independent Tbx20 
interactions identified in three independent isolations. Tbx20 associations that 
pass specificity criteria (see Materials and Methods), but are lost in the presence of 
DNase and/or do not have a known nuclear localization. 
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Table S3.2. - Continued 
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Table S3.2. - Continued 
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Table S3.2. - Continued 
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Table S3.2. - Continued 
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Table S3.2. - Continued 
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Table S3.2. - Continued 
 
 
 
 
 
 
 
! 148!
Table S3.3. GO analysis of nuclear-enriched interactions by biological 
functions. 
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Table S3.4. Enrichment analysis of nuclear-enriched Tbx20 associations.  
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Table S3.5. Label-free quantitative mass spectrometric analyses of nuclear-
enriched Tbx20- and Tbx20eh1mut-associated proteins. 
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Table S3.5. - Continued 
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Chapter 4 
A novel method to detect cardiac-specific Tbx20 protein-
protein interactions reveals association with a broad 
chromatin-remodeling network  
 
ABSTRACT 
 Previous work demonstrated that Tbx20 associates with a transcription 
repression network in human cells (Chapter 3). To extend these studies and 
investigate the cardiac-specific components of Tbx20 transcription complexes, we 
have developed a novel approach to isolate endogenous Tbx20 protein complexes 
from mouse ESC-derived cardiomyocytes. Specifically, we have developed an 
Avitag-tagged Tbx20 knock-in cell line that allows for a high throughput mass 
spectrometry approach to identify cardiac-specific Tbx20 protein interactions. Here, 
we demonstrate the feasibility of this approach by presenting evidence of efficient 
Tbx20 isolation from ESC-derived cardiac progenitors. We go on to show that Tbx20 
co-isolates with known binding partners, Gata4 and TLE3, in these cells. In addition, 
we observed association with a broad network of chromatin-remodeling proteins, 
including components of the NuRD, SWI/SNF, and INO80 complexes. These studies 
represent the first comprehensive analysis of Tbx20 protein complexes from cardiac 
cells and greatly enhance our understanding of the Tbx20 transcription network 
during heart development. 
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INTRODUCTION 
 Transition from a pluripotent cell into a functional cardiomyocyte requires the 
activity of a number of critical cardiogenic transcription factors. Tbx20 interacts with 
a suite of other transcription factors within the developing heart to drive cardiac gene 
expression (Stennard et al., 2003; Takeuchi et al., 2005), and a number of studies 
also demonstrate a role for Tbx20 in transcriptional repression during cardiac 
development (Cai et al., 2005; Singh et al., 2005; Sakabe et al., 2012). Therefore, 
the activities of Tbx20 appear to be context dependent and ultimately controlled by 
co-activators and co-repressors. We have previously observed that Tbx20 interacts 
with a network of co-repressors in human cells including members of the NuRD and 
INO80 chromatin remodeling complexes (Chapter 3), implying that Tbx20 may 
interact with chromatin remodelers to regulate gene expression in the developing 
heart. However, it is unclear which components of this network may represent 
cardiac-specific interactions. Additionally, protein-protein interactions that occur in a 
tissue-specific and/or temporal manner during cardiomyocyte development were 
likely to be excluded from our previous analysis due to the difficulties in isolating 
endogenous Tbx20 from its native cell type. 
 
 Therefore, to gain insight into the Tbx20 cardiac transcription network and to 
understand how Tbx20 acts as a repressor within the context of the developing 
heart, we sought to identify Tbx20 interaction partners from ESC-derived cardiac 
progenitor cells. To allow us to isolate endogenous Tbx20, we generated mouse 
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ESCs in which the Avitag (Schatz, 1993) is inserted into the endogenous Tbx20 
locus and that stably express the E. coli. biotin ligase BirA. Subsequent directed 
differentiation of Tbx20Avi; BirA ESCs into cardiomyocytes allows for BirA-mediated 
biotinylation of the Avitag at the time and place where Tbx20 is endogenously 
expressed over the course of cardiomyocyte differentiation. Tbx20 protein 
complexes were then isolated using a streptavidin purification approach (de Boer et 
al., 2003) and subjected to mass spectrometry analysis to identify interaction 
partners. Utilizing the biotin/avidin system for protein purification has a number of 
crucial benefits for this set of studies. First, it completely obviates the need for a 
high-affinity antibody, which for many transcription factors including Tbx20 simply do 
not exist. Second, the interaction of biotin with avidin is one of the highest affinity 
interactions known in nature (Savage et al., 1992). Finally, BirA specifically 
conjugates biotin to the 15 amino acid Avitag sequence (Cronan and Reed, 2000; 
Cull and Schatz, 2000), a synthetic sequence that is not reproduced in any 
mammalian genome allowing for highly specific tagging and subsequent isolation of 
the target protein. 
 
 In this study, we demonstrate that using the biotin/avidin system in 
combination with directed cardiac differentiation of mouse ESCs we are able to 
efficiently isolate endogenous Tbx20 protein from cardiac progenitor cells. Using this 
system we are able to detect an interaction with the cardiac transcription factor 
Gata4, a known binding partner of Tbx20 that is specifically expressed in the 
developing heart. We also detect an association with TLE3, an interaction we have 
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previously shown to take place in the mouse embryonic heart and in human cells 
(Chapter 3). In addition, we identified a number of chromatin-associated proteins not 
yet shown to interact with Tbx20, including several proteins in the INO80, SWI/SNF, 
and NuRD chromatin remodeling complexes. Collectively, these studies provide the 
first demonstrate that Tbx20 associates with a broad chromatin remodeling network 
to modify gene expression in cardiac progenitor cells. 
 
MATERIALS AND METHODS 
DNA Constructs 
The pLenti-BirA plasmid was obtained from Addgene (Addgene plasmid 
29649; principal investigator Eric Campeau) and modified to contain a 
polyadenylation signal for expression in mammalian cells. In collaboration with the 
UNC gene therapy core facility, the pLenti-BirA plasmid was packaged and purified 
into a concentrated lentivirus. 
 
Generation of Tbx20Avi; BirA cell line and differentiation 
To generate a targeting construct to introduce the Avitag into the mouse 
Tbx20 locus, the Avitag sequence followed by a loxP-flanked neo cassette was 
inserted into the stop codon of exon 8 of a Tbx20a genomic fragment derived from a 
129 Sv genomic BAC library. The targeting construct was linearized and 
electroporated into ES cells of E14TG2a.4 origin. Targeted ES cells were placed 
under 250 µg/mL G418 selection for 7-10 days to test for neomycin resistance. 
G418-resistant ES cell clones (n=384) were screened for homologous recombination 
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in the Tbx20 locus by southern blot analysis (Southern, 1975). Three ES cell clones 
were correctly targeted, and one of these clones was subsequently used to derive 
the Tbx20Avi/+; BirA cell line. Briefly, Tbx20Avi/+ ES cells were grown to approximately 
40% confluence, then transduced with 5 MOI Lenti-BirA for 8 hrs. Twenty-four hours 
following transduction, cells were placed under 200 µg/mL hygromycin selection for 
4-5 days. Hygro-resistant Tbx20Avi/+  cells were subsequently used for cardiomyocyte 
differentiations. 
 
 Tbx20Avi/+; BirA ES cells were maintained on gelatin-coated dishes in a 
feeder-free culture system and differentiated according to the Keller protocol 
(Kattman et al., 2011). ES cells were differentiated in serum-free (SF) media as 
described previously (Gadue et al., 2006). Briefly, ES cells were trypsinized and 
cultured at 75,000 cells/mL on uncoated petri dishes in SF medium without 
additional growth factors for 48 hrs. Two-day-old aggregated embryoid bodies (EBs) 
were dissociated and the cells reaggregated for 48 hrs in SF medium containing 5 
ng/mL human Activin A, 0.1 ng/mL human BMP4, and 5 ng/mL human VEGF (all 
growth factors purchased from R&D Systems).  Four-day-old EBs were dissociated 
and 2 x 106 cells were seeded into individual gelatin-coated wells of a 6-well dish in 
StemPro-34 SF medium (Invitrogen) supplemented with 2 mM L-glutamine, 1 mM 
ascorbic acid, 5 ng/mL human VEGF, 20 ng/mL human bFGF, and 50 ng/mL human 
FGF10 (R&D Systems). Cardiomyocyte monolayers were maintained in this media 
for 4-5 additional days with cells typically beginning to beat 2 days after seeding onto 
gelatin (total of 7-8 days of differentiation). 
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Immunofluorescence and immunoblotting 
For immunofluorescence of cardiomyocytes, four-day-old ES cell-derived 
embryoid bodies were dissociated and seeded into 8-well chamber slides precoated 
with 0.1% gelatin. Induced cardiomyocytes were fixed on day 7 of differentiation in 
4% paraformaldehyde for 20 min at room temperature, washed 3 times in 1X PBS, 
permeabilized in 0.1% Triton X-100 in 1X PBS for 10 min, and blocked in 10% fetal 
bovine serum (FBS) in 1X PBS containing 0.1% Tween 20 for 30 min. Anti-myosin 
heavy chain (Abcam) was applied overnight, followed by 3 washes in 1X PBS, and 
incubation with goat anti-mouse Alexa 546 (Invitrogen) for 1 hr. Cells were incubated 
in DAPI (200 ng/mL in ethanol) for 30 min and visualized by confocal microscopy on 
a Zeiss 710. Antibodies used for immunoblotting include mouse anti-GAPDH 
(Millipore) and chick anti-BirA (Abcam). 
 
RNA extraction and RT-PCR 
RNA was extracted using Trizol (Invitrogen) and purified on RNeasy columns 
(Qiagen). cDNA synthesis was performed from 0.5-1 µg of RNA using random 
primers and SuperScript II reverse transcriptase (Invitrogen). Expression levels were 
assessed using GoTaq Green Master Mix (Promega) and Taq polymerase on a 
GeneAmp PCR System (Applied Biosystems). PCR products were analyzed by 
2.5% agarose gel electrophoresis. 
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Isolation of Tbx20-Avitag complexes from cardiac progenitor cells 
Day 4 Tbx20Avi; BirA EBs and, as a control, Day 4 Tbx20Avi EBs were 
collected and washed with cold PBS. The EBs were pelleted at 1500 rpm for 10 min 
at 4°C. The cell pellet was resuspended in 100 µL/1 µg 20 mM HEPES, pH 7.4, 
containing 1.2% polyvinylpyrrolidone and protease inhibitors and snap frozen in 
liquid nitrogen. Cells were lysed by cryogenic grinding using a Retsch MM 301 Mixer 
Mill (10 cycles x 2.5 min at 30 Hz) (Retsch, Newtown, PA) and the frozen cell 
powder was resuspended in optimized lysis buffer (5 mL/1 g cells) (20 mM K-
HEPES pH 7.4, 0.1 M KOAc, 2 mM MgCl2, 0.1% Tween-20, 1 µM ZnCl2, 1 µM 
CaCl2, 200 mM NaCl, 0.5% Triton X-100 containing protease and phosphatase 
inhibitors) followed by a 10 min rotation at 4° to improve extraction. Cell lysates were 
homogenized using a Polytron (Kinematica) step (2 x 15 sec), followed by DNase 
treatment (10 U/mL lysate) for 30 min at room temperature. DNase-treated lysates 
were pelleted at 3000 rpm at 4°C. Cleared lysates were rotated with 6 mg magnetic 
beads coupled to streptavidin (M270 Streptavidin Dynabeads, Invitrogen) for 4 hrs at 
4°C. The magnetic beads were then washed in lysis buffer (6 x 1 mL) (without 
protease and phosphatase inhibitors) and eluted from the beads in 80 mM sodium 
acetate, 95% formamide, pH 9.0 at 95°C for 15 min. LDS Sample Buffer (Invitrogen) 
and reducing agent (Invitrogen) (final 1X concentration of both) were added to 
eluates and eluted proteins were alkylated with 100 mM iodoacetamide for 1 hr at 
room temperature and subjected to mass spectrometry analysis. 
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Mass spectrometry analysis of Tbx20 protein complexes 
Immunoisolates were analyzed by mass spectrometry as previously 
described (Chapter 3). 
 
RESULTS 
Generation of a Tbx20Avitag knock-in mouse ESC line 
 To allow for immunoaffinity purification of endogenous Tbx20 protein 
complexes, we introduced a short synthetic sequence known as the Avitag into the 
endogenous Tbx20 locus through homologous recombination in mouse ESCs. The 
Avitag was introduced into the carboxy terminus of the Tbx20a isoform (Figure 4.1A) 
and a Tbx20Avi/+ ESC clone was obtained (Figure 4.1B). Tbx20 protein tagged with 
the Avitag can be biotinylated through recognition of the Avitag sequence by the E. 
coli biotin ligase BirA, allowing for immobilization of Tbx20 immunocomplexes on 
streptavidin-coupled beads. To accomplish this, we generated a lentivirus that 
ubiquitously expresses BirA under the control of the PGK promoter. We then 
transduced Tbx20Avi/+ ESCs with the BirA lentivirus and placed the cells under 
hygromycin selection to eliminate any cells that did not integrate the BirA construct 
(Figure 4.2A). To obtain cardiac progenitor cells expressing tagged Tbx20 and BirA, 
we differentiated hygromycin-resistant Tbx20Avi/+ cells using a serum-free 
differentiation method developed by Kattman et al. that reproducibly generates 
cultures containing >60% cardiomyocytes (Kattman et al., 2011) (Figure 4.2A). 
Hygromycin-resistant Tbx20Avi/+ cells stably express BirA through Day 4 of the 
differentiation protocol (Figure 4.2B). 
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 Molecular analysis of Tbx20Avi/+; BirA cell populations at each day of 
differentiation revealed gene expression patterns consistent with normal cardiac 
development (Figure 4.2C). Expression of Mesp1, which is closely associated with 
specification of cardiac mesoderm (Bondue et al., 2011), peaks at day 3 of 
differentiation and is quickly downregulated. Markers of cardiac progenitors including 
Gata4/5 (Kelley et al., 1993; Laverriere et al., 1994), Tbx5 (Horb and Thomsen, 
1999), Nkx2.5 (Bodmer et al., 1990), and Isl1 (Cai et al., 2003) are expressed 
starting at day 3 and continue to be expressed for the duration of the culture. 
Terminal differentiation of cardiomyocytes is marked by the onset of expression of 
cardiac Troponin T (cTnT) (Toyota and Shimada, 1981) at day 5, indicating efficient 
development of a cardiogenic population of cells. Further, rapid downregulation of 
the beta isoform of actin (β-actin) (Garrels and Gibson, 1976), which is expressed in 
non-muscle or non-contractile cells, coincides with the upregulation in cTnT 
expression, indicating a transition into terminally differentiated cardiomyocytes at this 
stage. Tbx20-Avitag transcripts recapitulate endogenous Tbx20a expression and are 
at the highest levels in cardiac progenitors at day 4 and in differentiated 
cardiomyocytes at day 7. This is consistent with a role for Tbx20 in early cardiac 
development and in the later stages of cardiomyocyte morphogenesis and 
specialization (Kraus et al., 2001; Brown et al., 2005; Cai et al., 2005; Singh et al., 
2005; Stennard et al., 2005; Takeuchi et al., 2005). Additionally, Tbx20Avi/+; BirA cells 
routinely immunostain positive for the cardiomyocyte muscle protein Myosin Heavy 
Chain (MHC) and contract by day 6 of differentiation (Figure 4.2D and data not 
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shown). Collectively, these results demonstrate a novel approach to isolating Tbx20 
protein-protein interactions and will be a powerful tool for studying the tissue-specific 
functions of Tbx20 in the context of cardiomyocyte development. 
 
The Avitag-BirA system successfully isolates known Tbx20 protein-protein 
interactions  
 
 To determine if the Avitag-BirA system can be used to isolate endogenous 
Tbx20 from cardiac progenitor cells and to identify cardiac-specific factors that 
associate with Tbx20, we isolated Tbx20 complexes from Day 4 Tbx20Avi; BirA EBs. 
As a negative control, we performed streptavidin purifications on Tbx20Avi EBs. In the 
absence of BirA, Tbx20 is not biotinylated or able to bind streptavidin; therefore, this 
serves as a control for the specificity of the Tbx20 isolation and allows us to identify 
(and subsequently exclude from our analyses) endogenously biotinylated proteins 
that non-specifically bind the beads. Immunocomplexes from Tbx20Avi; BirA EBs 
(Avi-BirA) and Tbx20Avi EBs (Avi) were sequenced by mass spectrometry. Using this 
technique, Tbx20 was successfully isolated from Avi-BirA EBs (Figure 4.3A, B and 
Table 4.1). In addition, we identified the factors Gata4 and TLE3, proteins previously 
shown to complex with Tbx20 in the context of heart development ((Stennard et al., 
2003) and Chapter 3), as Tbx20-associated proteins in ESC-derived cardiac 
progenitors (Table 4.1). Interestingly, we never detect a Tbx20-TLE3 association in 
Day 7 ESC-derived cardiomyocytes, indicating that there is a temporal requirement 
for this interaction specifically within cardiac progenitors that have not yet undergone 
terminal differentiation (data not shown). 
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Tbx20 interacts with a chromatin remodeling network in cardiac progenitors 
 We have previously demonstrated that Tbx20 interacts with chromatin 
remodeling proteins in human cells (Chapter 3). Therefore, to characterize the 
composition of the cardiac-specific Tbx20 chromatin remodeling network, we looked 
for components of chromatin remodeling complexes with known roles in cardiac 
development (see Introduction). This preliminary search revealed association of 
Tbx20 with a number of chromatin remodeling proteins. This network includes 
several proteins within the INO80 complex (Ruvbl1, Ruvbl2, Actl6a), the NuRD 
complex (Rbbp4/RbAp48, Rbbp7/RbAp46, Hdac1, Gatad2a/p66α, Gatad2b/p66β), 
and the SWI/SNF complex (Smarcc1/BAF155, Smarcd1/BAF60A, Actl6a/BAF53) 
(Table 4.1). We previously identified interactions with the INO80 complex and 
members of the NuRD complex (see Chapter 3); this data provides further evidence 
of those interactions and implies that association with chromatin remodelers is 
critical for Tbx20-mediated regulation of cardiac differentiation.  
 
DISCUSSION 
We have previously characterized the Tbx20 transcriptional proteome in 
human cells and found that Tbx20 interacts with a number of chromatin remodelers. 
To expand upon this work and to begin to characterize the cardiac-specific 
components of the Tbx20 transcription network, we have developed a novel 
approach to isolate endogenous Tbx20 protein complexes from mouse ESC-derived 
cardiomyocytes. This system allows for highly effective immunoaffinity purification of 
Tbx20 complexes at various stages of cardiomyocyte differentiation, providing us 
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with the ability to compare the Tbx20 transcription network at different stages of 
cardiomyocyte development. As evidence that the Avitag-BirA approach is a 
sensitive and reliable method to detect Tbx20 protein-protein interactions, we 
detected two known cardiac-specific Tbx20 associations. The first, Gata4, is a 
cardiac transcription factor that has been demonstrated to directly interact with 
Tbx20 in vitro, and to synergize with Tbx20 to activate cardiac gene expression 
(Stennard et al., 2003; Takeuchi et al., 2005); however, the present study represents 
the first demonstration of a physical interaction between Gata4 and Tbx20 in cardiac 
cells. The second, TLE3, we have previously demonstrated to interact with Tbx20 in 
HEK 293 cells and in mouse embryonic hearts (Chapter 3). In this study, we 
identified a Tbx20-TLE3 interaction in cells that have not yet transitioned to 
terminally differentiated cardiomyocytes. Further, we never detect this interaction in 
Day 7 ESC-derived cardiomyocytes (data not shown) indicating that there is a 
temporal requirement for a Tbx20-TLE co-repressor complex in cardiac progenitors. 
Further investigation will be needed to examine the precise role this complex plays 
in cardiac differentiation. 
 
Using the Avitag-BirA technology, we provide the first demonstration of a 
cardiac-specific Tbx20 chromatin remodeling network. Our mass spectrometry 
analysis indicates that Tbx20 interacts with a number of different chromatin 
remodeling complexes in cardiac progenitors. This network includes the INO80 
complex components Ruvbl1 and Ruvbl2, both of which we detected in our previous 
proteomic analyses and which have documented roles in cardiac growth in zebrafish 
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(Chapter 3 and (Rottbauer et al., 2002). Tbx20 is required for proliferation in the 
developing heart (Cai et al., 2005; Shelton and Yutzey, 2007; Chakraborty and 
Yutzey, 2012); therefore, it will be interesting to determine if the function of Tbx20 in 
maintaining proper proliferation is dependent upon interaction with the INO80 
complex in the developing heart. 
 
Our previous proteomic studies identified components of the NuRD complex 
in complex with Tbx20. Our preliminary studies in cardiac progenitor cells provide 
independent confirmation of this data, and expand upon those studies by 
demonstrating interaction with additional components of the NuRD complex. The 
cardiac Tbx20-NuRD complex includes the MBD-binding proteins Gatad2a/p66α and 
Gatad2b/p66β, the histone-binding proteins Rbbp4 and Rbbp7, and Hdac1. 
Interestingly, in human cells we found Tbx20 associated with Hdac2; however, in 
cardiac cells, Tbx20 is associated with Hdac1. This could be due to functional 
redundancy between Hdac1 and Hdac2, as myocardium deletion of both genes, but 
not of each gene individually, results in defects in myocardial growth and 
morphogenesis (Montgomery et al., 2007). Additionally, Hdac1 and Hdac2 
redundantly regulate a number of gene targets in the heart and have both been 
shown to occupy the Tnni2 promoter in neonatal rat cardiomyocytes, indicating that 
Hdac1 and -2 regulate a common set of genes in the heart (Montgomery et al., 
2007).  
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We also observed the core catalytic subunit of NuRD, Chd4/Mi-2β, and MTA2 
in the Avitag-BirA isolation; however, these interactions were not enriched over the 
Avitag isolations (data not shown). As the analysis presented here represents a 
single Tbx20 immunoisolation, additional independent immunoisolations are needed 
to determine if Chd4 and MTA2 are bona fide Tbx20 associations. Interestingly, we 
do not observe MBD subunits in either the human (Chapter 3) or cardiac Tbx20-
NuRD complexes we have identified. As MBD proteins are implicated in targeting 
the NuRD complex to genomic locations through their association with methylated 
DNA, it is likely that targeting of the Tbx20-NuRD complex relies solely on Tbx20 
binding to target promoters and subsequent recruitment of the NuRD complex. 
Collectively, these data present the first evidence that Tbx20 associates with the 
NuRD complex in cardiac cells, implying that Tbx20 is involved in chromatin 
remodeling and histone deacetylation of target genes. 
 
Tbx20 also interacts with members of the SWI/SNF remodeling complex in 
cardiac progenitor cells. The specific SWI/SNF subunits we identified, BAF155, 
BAF60a, and BAF53, represent components that are common to both SWI/SNF 
ATP-dependent chromatin remodeling complexes PBAF and BAF. BAF complexes 
have a well-documented role in chromatin activation through interaction with cardiac 
transcription factors on cardiac promoters (Lickert et al., 2004; Takeuchi et al., 
2011); SWI/SNF complexes also function to transcriptionally repress genes in the 
heart through recruitment of HDACs (Hang et al., 2010). Tbx20 interacts genetically 
with Brg1 (Takeuchi et al., 2011), a component of BAF complexes, during cardiac 
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development; however, a physical interaction between Tbx20 and SWI/SNF 
components was not demonstrated prior to this study. Further studies will aim to 
delineate the precise role a Tbx20-BAF complex plays in regulating Tbx20 target 
genes in the developing heart. 
 
In conclusion, we have demonstrated that Tbx20 interacts with a broad 
network of chromatin remodeling proteins in cardiac progenitor cells (Figure 4.4), 
interactions that are predicted to result in both transcriptional activation and 
repression of gene expression. This work implicates Tbx20 as an important dual 
transcriptional activator and repressor in the developing myocardium. These results 
further underscore the complexity of the Tbx20 transcription network, and suggest 
that disease-causing mutations in Tbx20 may lead to disruption of interaction 
networks critical for proper Tbx20-mediated transcriptional regulation. 
 
ACKNOWLEDGMENTS 
 I would like to thank Leslie Kennedy for her assistance in the identification of 
a Tbx20Avi ESC recombinant by southern blot. Additionally, I would like to thank an 
undergraduate student, Evan Farina, for his assistance with the RT-PCR analysis of 
the ESC-derived cardiomyocytes. Finally, all proteomic analyses were performed in 
collaboration with Ileana Cristea’s group at Princeton University. Postdoctoral fellow 
Todd Greco in the Cristea lab in particular was critical to the success of the mass 
spectrometry analyses. 
 
! 175!
Figure 4.1. Generation of Tbx20Avitag allele. (A) The Avitag targeting construct was 
introduced into the stop codon of exon 8 and contains two arms of Tbx20 homology, 
the Avitag sequence, and a PGK-Neomycin cassette flanked by loxP sites for 
positive selection of targeted ES cell clones. HindIII restriction sites are indicated 
and were used to screen by southern blot for recombinants. (B) Southern blot 
showing successful integration of the Avitag into one allele of the Tbx20 locus. 
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Figure 4.2. Directed cardiac differentiation of Tbx20Avi; BirA ESCs recapitulates 
normal cardiogenesis. (A) Experimental design for generating Tbx20Avi; BirA 
cardiomyocytes. Tbx20Avi/+ ES cells were transduced with a BirA lentivirus and 
placed under selection to remove cells that failed to integrate the BirA construct. 
Tbx20Avi/+; BirA ES cells were induced to form embryoid bodies (EBs) and were 
cultured in conditions to generate induced cardiomyocytes (iCMs) by day 5 of 
differentiation. (B) Western blot showing stable levels of BirA protein after BirA 
transduction and 4 days of differentiation. (C) RT-PCR analysis of genes that 
sequentially mark non-contractile or non-muscle cells (yellow), specified cardiac 
mesoderm (red), cardiac progenitors (green), and differentiated cardiomyocytes 
(blue) across stages of cardiac differentiation of ESCs. Note that expression levels 
of Tbx20-Avitag recapitulate that of untagged Tbx20a. All samples are derived from 
cells taken at indicated stage of differentiation. Rps29 was used as a loading control 
for RT-PCR reactions. (D) Induced cardiomyocytes stain positive for MHC, as shown 
by immunoflourescence of day 7 cardiomyocytes with anti-MHC antibody and DAPI 
co-stain. 
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Figure 4.3. Endogenous Tbx20 is isolated from Tbx20Avi; BirA cardiac 
progenitor cells. (A) Endogenous Tbx20 was immunoprecipitated from Day 4 
Tbx20Avi; BirA  or Tbx20Avi EBs on streptavidin-conjugated beads and analyzed by 
western blot analysis with a streptavidin-HRP conjugate. (B) Identification of Tbx20 
peptide by LC-MS/MS analysis. 
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Figure 4.4. Model of the cardiac Tbx20 chromatin remodeling network. The 
chromatin remodeling interaction network was assembled from automated retrieval 
of protein functional associations using STRING analysis. Black lines represent 
evidence of physical binding. Blue lines represent interactions inferred by functional 
associations. Nodes are labeled with respective gene symbols. 
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Table 4.1. Tbx20 interacting proteins in cardiac progenitor cells (N=1). 
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Chapter 5 
Discussion and Future Directions 
 
 The formation of the 4-chambered vertebrate heart arises from a series of 
complex processes during embryonic development that includes the specification 
and differentiation of the different cardiac cell types within the heart, proliferation, 
and morphological movements of the early heart fields (Harvey, 2002; Buckingham 
et al., 2005; Evans et al., 2010). These processes are directed through the activity of 
a number of critical cardiogenic transcription factors that act combinatorially to 
promote proper heart growth and specialization (Sepulveda et al., 1998; Morin et al., 
2000; Hiroi et al., 2001; Stennard et al., 2003; Vincentz et al., 2008; Junion et al., 
2012). One of these factors, Tbx20, is critical for heart development; however, there 
are huge deficiencies in our understanding of how Tbx20 activity is regulated during 
cardiogenesis. This dissertation comprises a set of studies that investigates the 
Tbx20 transcription network. Tbx20 cardiac expression during chamber maturation 
in the embryo is directly regulated by BMP signaling. In an effort to identify the 
mechanisms by which Tbx20 regulates downstream gene targets during heart 
development, we employed two proteomic screens to characterize the composition 
of Tbx20 transcription complexes. From these screens, we observed that Tbx20 
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recruits multiple transcriptional co-repressors and chromatin remodeling complexes, 
thus laying the foundation for a much expanded Tbx20 transcription network that 
encompasses multiple mechanisms of activation and repression. 
 
Tbx20 cardiac expression is regulated by BMP signaling 
 In Chapter 2, we identify a Xenopus Tbx20 cardiac enhancer that acts 
downstream of BMP signaling in the embryonic heart. Interestingly, this enhancer is 
critical for the maintenance of Tbx20 expression in the heart at a time when the 
cardiac chambers are undergoing specialization and expansion, processes that are 
arrested in the absence of Tbx20 function (Cai et al., 2005; Singh et al., 2005). This 
finding implicates the BMP pathway as a critical source of signaling for proper 
chamber maturation, and furthermore, suggests that the initiation of Tbx20 
expression in cardiac progenitor cells occurs independently of the BMP-responsive 
cardiac enhancer we identified. Consistent with this set of studies, Zhang et al. 
(Zhang et al., 2011) observed that Tbx20 is a downstream target of BMP10 during 
ventricular wall development and maturation in the mouse. Additionally, the 
investigators observed that the effect of BMP10 overexpression on Tbx20 
expression was limited to ventricular cardiomyocytes; Tbx20 expression in the atria 
and atrioventricular cushions was unaffected by changes in BMP10 levels in the 
heart. An earlier report in chicken embryo explants demonstrated that Tbx20 
expression in the endocardial cushions is up-regulated by BMP2 (Shelton and 
Yutzey, 2007). Collectively, these studies suggest that signaling through the BMP 
arm of the TGFα superfamily represents a key signaling pathway in the regulation of 
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Tbx20 expression in the heart. The precise tissue and temporal specificity of Tbx20 
expression may be regulated by the differential expression of various BMP ligands 
within the developing heart and their ability to bind distinct Tbx20 regulatory 
elements. As such, it will be interesting to identify the endogenous ligand, perhaps a 
BMP ligand, that lies upstream of Tbx20 activation within cardiac progenitor cells. 
 
A role for Groucho/TLE in cardiac development 
 Chapter 3 details the identification of a Tbx20 transcription repression 
network in HEK 293 cells that includes an intact TLE-HDAC co-repressor complex. 
Tbx20 binds TLE1/3 through an N-terminal eh1 binding motif; binding of Tbx20 to 
TLE results in recruitment of HDAC2 to the protein complex. We additionally verified 
that Tbx20 forms a complex with TLE factors in vivo in the developing heart, and in 
ESC-derived cardiac progenitors. These studies imply that Groucho/TLE factors 
have a role in transcriptional repression in the embryonic heart by interacting with 
Tbx20. The eh1 binding motif has been identified in a number of other T-box factors 
(Copley, 2005), some of which have important roles in cardiovascular development 
including Tbx2, Tbx3, and Tbx18 (Harrelson et al., 2004; Hoogaars et al., 2004; 
Christoffels et al., 2006). Therefore, Tbx20-mediated recruitment of a TLE co-
repressor complex may represent a more global mechanism of repression utilized by 
T-box factors during heart development. 
 
 The Drosophila Groucho gene was originally named for the bunches of 
bristles above the eyes that result from a viable mutation within the Enhancer of split 
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complex, a chromosomal region that gives rise to 13 separate transcripts including 
members of the bHLH family of transcription factors (also known as Hairy-related 
proteins) (Lindsley and Grell, 1968; Knust et al., 1992). Hairy-related proteins play 
critical roles during neurogenesis by repressing target genes when bound to 
Groucho (Paroush et al., 1994; Fisher et al., 1996). Groucho was subsequently 
demonstrated to act as a transcriptional co-repressor when bound to other subsets 
of DNA binding factors including Runt domain proteins Engrailed and Dorsal 
(Dubnicoff et al., 1997; Jimenez et al., 1997). Therefore, Groucho proteins are 
recruited to target promoters by binding to sequence specific transcription factors. 
 
The four vertebrate homologues of Drosophila Gro are termed transducin-like 
enhancer of split (TLE) 1-4 due to homology with the β subunit of transducin, a 
heterotrimeric G protein (Stifani et al., 1992). A fifth member of the TLE family 
encodes the closely related Amino Enhancer of split (Aes) (Miyasaka et al., 1993). 
Aes is highly similar to the amino terminal domains of other TLE proteins but lacks 
the C-terminal WD-40 repeats that mediate interaction with DNA-binding proteins 
(Miyasaka et al., 1993). Aes does harbor the Q-domain, a multimerization motif that 
facilitates interactions with other Groucho members (Miyasaka et al., 1993; Pinto 
and Lobe, 1996; Chen and Courey, 2000). Aes proteins can antagonize TLE-
mediated repression in a dominant negative manner by binding to Gro/TLE through 
the Q domain (Muhr et al., 2001; Swingler et al., 2004). Binding of Aes proteins to 
Gro/TLE also blunts repressive function of Gro proteins, as Aes does not interact 
with HDACs (Brantjes et al., 2001). TLE1-4 are expressed broadly throughout 
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mouse development; however, individual TLE proteins are expressed in 
combinatorial as well as complementary patterns during cell differentiation 
suggesting non-redundant functions (Stifani et al., 1992; Yao et al., 1998; 
Gasperowicz and Otto, 2005). Further studies support this and demonstrate that 
TLE proteins having distinct functions during development, TLE1 is involved in 
myogenesis, hematopoiesis, neurogenesis, and eye development (Imai et al., 1998; 
Yao et al., 2000; Gao et al., 2001; Zhu et al., 2002; Swingler et al., 2004); TLE2 in 
osteogenesis (Thirunavukkarasu et al., 1998); TLE3 in placental and adipose 
development (Nakayama et al., 1997; Villanueva et al., 2011); and TLE4 in B cell 
development and left-right asymmetry (Eberhard et al., 2000; Linderson et al., 2004; 
Bajoghli et al., 2007).  
 
Of the TLE family members, TLE4 in the only TLE protein previously linked to 
heart development (Bajoghli et al., 2005; Bajoghli et al., 2007). Misexpression of Aes 
to block Groucho co-repressor function in medaka embryos results in an alteration in 
heart tube orientation (Bajoghli et al., 2005; Bajoghli et al., 2007). Interestingly, TLE4 
misexpression also leads to cardiac laterality defects (Bajoghli et al., 2007). Nkx2.5 
is expressed normally in these embryos, indicating that heart looping defects are not 
secondary to a disruption in cardiac specification. Aes- and TLE4- injected embryos 
also display displacements of other visceral organs in including the spleen, 
gallbladder and gut indicating a general disruption of embryonic left-right patterning 
rather than a cardiac-specific defect (Bajoghli et al., 2007). Indeed, the first visible 
symmetry break in the embryo occurs when the symmetrical heart tube undergoes a 
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rightward looping (Mercola, 1999). In the medaka fish, TLE4 appears to affect left-
right patterning of the embryo by both regulating Brachyury expression within the 
dorsal forerunner cells that give rise to Kupffer’s vesicle and by regulating the 
asymmetric activities of the Nodal and Lefty genes later in embryogenesis (Bajoghli 
et al., 2007). A cell autonomous role for Groucho proteins within cardiac cells of the 
developing heart has not yet been established. 
 
 Evidence suggests that Gro/TLE proteins mediate transcriptional repression 
through a number of mechanisms. It has long been known that both Drosophila and 
mammalian Gro/TLE proteins interact with class I histone deacetylases (Chen et al., 
1999; Brantjes et al., 2001). Additional studies in Drosophila demonstrate that 
histone deacetylase activity is required for efficient repression by Gro, and mutations 
in Gro and Rpd3 have synergistic effects on embryonic development (Chen et al., 
1999). Further, inhibition of histone deacetylase activity by trichostatin A (TSA) 
treatment results in a loss of Gro-mediated transcriptional repression by the 
homeodomain protein NK-3 (Choi et al., 1999). A recent study demonstrates that 
Gro colocalizes with Rpd3 on a target gene, and this colocalization is associated 
with deacetylation of lysines in the histone tails of H3 and H4 (Winkler et al., 2010). 
A decrease in acetylation levels leads to increased nucleosome density and 
therefore transcriptional repression (Winkler et al., 2010). Interestingly, in all of these 
studies, histone deacetylase inhibition, either by TSA treatment or RNAi knockdown 
of Rpd3 in Drosophila cells, does not result in a complete loss of Gro-mediated 
repression indicating that Gro may utilize histone deacetylase-independent 
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mechanisms of silencing (Chen et al., 1999; Choi et al., 1999; Winkler et al., 2010). 
Further, Rpd3 mutants display relatively mild defects in embryogenesis, again 
suggesting that Gro proteins do not function solely through recruitment of histone 
deacetylases (Mannervik and Levine, 1999). 
 
One line of evidence indicates that Groucho proteins oligomerize along areas 
of the genome to promote a silent chromatin structure (Chen et al., 1998; Sekiya and 
Zaret, 2007; Martinez and Arnosti, 2008; Winkler et al., 2010). A role for Groucho 
oligomerization was first implicated by the observation that native Gro forms a 
tetramer in solution; point mutations that block tetramerization of Gro also block 
repression by Gro in cultured Drosophila cells (Chen et al., 1998). Recent studies 
have shown that Gro contacts a large region of chromatin consisting of several 
kilobases suggesting that Gro oligomers may modify chromatin over extensive 
regions (Sekiya and Zaret, 2007; Martinez and Arnosti, 2008). Further, the formation 
of higher order Gro/TLE oligomers that blanket a genomic region seems to result in 
a condensation of the chromatin, which functions to impair activator recruitment 
(Sekiya and Zaret, 2007). Collectively, these studies support a model of Groucho 
repression in which 1) Groucho/TLE is recruited to a target gene through interaction 
with a sequence-specific transcription factor, 2) Gro/TLE recruits a histone 
deacetylase complex, which deacetylates local histone tails leading to a more closed 
chromatin configuration, and 3) Gro/TLE simultaneously recruits additional Gro/TLE 
subunits to form higher order Gro complexes across the genomic region, resulting in 
further condensing the chromatin and blocking activator access to the template. 
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T-box factors are critical drivers of distinct subprograms during cardiac 
development (Bruneau et al., 2001; Harrelson et al., 2004; Brown et al., 2005; 
Christoffels et al., 2006; Mesbah et al., 2008; Wiese et al., 2009; Scambler, 2010); 
however, there are still large gaps in our understanding of the precise mechanisms 
by which T-box proteins mediate transcriptional activation or repression. In 
particular, very little is known about how T-box factors act as repressors due to a 
lack of knowledge regarding T-box protein associations with known co-repressors 
and a dearth of direct transcriptional targets. Our studies have identified a role for a 
Groucho/TLE-Hdac complex in Tbx20-mediated transcriptional repression. 
Repression by the T-box factor Tbx18 also relies on binding to Groucho proteins 
(Farin et al., 2007). Interestingly, we identified Tbx18 as part of a TLE-recruited 
repression complex. The biological relevance of a Tbx20-Tbx18 repressor complex 
is unclear due to limited regions of coexpression; however, this finding testifies to the 
potential of T-box factors to form Groucho repression complexes. Heterodimerization 
with other T-box factors may serve to increase target site specificity.  
 
The T-box factors Tbx2 and Tbx3 act as transcriptional repressors and 
contain a highly conserved eh1 domain (Lingbeek et al., 2002; Copley, 2005; Yarosh 
et al., 2008), implying the potential to form Groucho repression complexes. 
Additionally, Tbx3 interacts with Hdac1, 2, 3, and 5 in primary breast cancer cells, 
and Tbx3 repressive function in these cells requires HDAC activity (Yarosh et al., 
2008). Class I Hdacs have a well-established role in heart development and function 
indicating that histone deacetylation is crucial for proper transcriptional control of 
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heart development (Montgomery et al., 2007; Montgomery et al., 2008; Trivedi et al., 
2008; Trivedi et al., 2010). These studies strongly imply that formation of TLE-HDAC 
complexes may represent a significant repression mechanism for T-box factors in 
the developing heart. Additional studies are needed to examine the roles of 
individual TLE family members in heart development to determine if there is 
functional redundancy among TLE proteins in the heart, or if there are distinct 
requirements for individual TLEs within specific cardiac regions. 
 
Tbx20 is part of a broad chromatin remodeling network in the heart 
 Our studies demonstrate for the first time that Tbx20 interacts with 
components of multiple chromatin remodeling complexes in cardiac cells. The 
chromatin remodeling network includes the INO80 complex, NuRD complex, and the 
SWI/SNF complex. As previously described, the INO80 complex has been 
implicated in heart development in one report, which showed that it is required for 
the regulation of cardiac growth in zebrafish (Rottbauer et al., 2002). This is first 
report of an interaction between a cardiac transcription factor and components of the 
INO80, providing a plausible mechanism for targeting INO80 activity in the 
developing heart. The similarity in the proliferation phenotypes resulting from Tbx20 
gain-of-function mutations and the activating mutation in Reptin (Ruvbl2) suggest 
that a Tbx20-INO80 complex regulates embryonic cardiomyocyte proliferation in the 
forming heart (Rottbauer et al., 2002; Chakraborty and Yutzey, 2012). 
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SWI/SNF complexes have a well-established role in heart development 
(Lickert et al., 2004; Wang et al., 2004; Stankunas et al., 2008; Takeuchi and 
Bruneau, 2009; Hang et al., 2010; Takeuchi et al., 2011). SWI/SNF complexes are 
thought to potentiate transcription factor activation of cardiac genes through 
nucleosome mobilization that permits the binding of factors to DNA template. A 
genetic interaction between Tbx20 and BAF complex member Brg1 has previously 
been demonstrated (Takeuchi et al., 2011); however, this is the first demonstration 
of a physical interaction between Tbx20 and members of the SWI/SNF. Other 
cardiac transcription factors including Tbx5, Nkx2.5, and Gata4 have been shown to 
physically interact with Brg1 (Takeuchi et al., 2011). Interestingly, we also identified 
Gata4 as a Tbx20-associated protein in ESC-derived cardiac progenitors, providing 
further evidence of protein complexes that contain a complement of cardiac 
transcription factors and SWI/SNF components. These studies provide further 
support for a model of heart-specific chromatin activation through interactions of 
cardiac transcription factors with BAF complexes. 
 
An exciting and novel finding of this work was the demonstration of a Tbx20-
NuRD association in human cells and ESC-derived cardiac progenitors. The NuRD 
complex is associated with histone deacetylase activity and functions as a 
transcriptional repressor (Xue et al., 1998). The defining components of the NuRD 
complex, as determined by multiple independent purifications, include an Mi-2 
chromatin remodeling subunit, an Mbd3 subunit, and an Mta subunit (Tong et al., 
1998; Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998). Mta subunits (Mta1, 
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2, or 3) are mutually exclusive and contribute to functional diversity of the NuRD 
complex (Yao and Yang, 2003; Fujita et al., 2004). Mbd3 protein, although highly 
homologous to the mCpG-binding protein Mbd2, does not appear to bind mCpG 
directly indicating that another factor is required for localization of the NuRD complex 
to DNA template (Saito and Ishikawa, 2002). NuRD also contains a core histone 
deacetylase complex that traditionally includes Hdac1, Hdac2, Rbbp4 (RbAp46), and 
Rbbp7 (RbAp48) (Tong et al., 1998; Wade et al., 1998; Xue et al., 1998; Zhang et 
al., 1998). The chromatin remodeling activity of Mi-2 may allow the deacetylases 
access to the histone tails. The Gatad2a (p66α) and Gatad2b (p66β) proteins are 
also associated with NuRD. We have demonstrated that Tbx20 interacts with many 
components of the mammalian NuRD complex in ESC-derived cardiac progenitor 
cells.  
 
The role of the NuRD complex in embryonic development has been assessed 
by looking at the requirement for NuRD components during early development. 
Drosophila Mi-2 is critical for HOX gene repression during embryo patterning (Kehle 
et al., 1998). A requirement for NuRD in early cell fate decisions was demonstrated 
by the observation that ablation of Mbd3 in the mouse is embryonic lethal at E5.5 
(Hendrich et al., 2001). Subsequent studies demonstrate a requirement for Mbd3 for 
proper differentiation of ES cells to a variety of cell fates, indicating that the NuRD 
complex creates an epigenetic state in ES cells that allows for commitment to certain 
lineages (Kaji et al., 2006). Gatad2a null mice live substantially longer than the Mbd3 
null mice but die at around E10.5 with a range of developmental defects that 
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includes a severe delay in development (Marino and Nusse, 2007). The early 
requirement for the NuRD complex in embryonic development has prevented the 
identification of a role for the NuRD complex specifically within the developing heart. 
As such, it would be interesting to investigate the phenotypes that arise from 
conditional deletion of NuRD components specifically within the heart. Nonetheless, 
we have demonstrated that Tbx20 recruits the NuRD complex in ESC-derived 
cardiac progenitor cells implicating the NuRD complex in transcriptional control of 
cardiac differentiation and/or proliferation.  
 
Taken together, these studies implicate Tbx20 as a critical dual activator and 
repressor of target gene expression during heart development and demonstrate that 
Tbx20 interacts with a number of repressor and chromatin remodeling complexes to 
ensure proper transcriptional regulation of target genes. Additionally, our data 
indicate that proper control of Tbx20 target gene expression occurs through 
selective association with distinct transcription complexes. It will be of great interest 
to determine the relationship between individual Tbx20 target genes and the unique 
transcription complexes we have identified. 
 
Future Directions 
  It is clear from a number of studies that Tbx20 acts to direct multiple critical 
processes throughout cardiogenesis, including fetal cardiomyocyte proliferation, 
cardiac chamber maturation, and adult cardiomyocyte function (Brown et al., 2005; 
Cai et al., 2005; Shen et al., 2011; Chakraborty and Yutzey, 2012). We speculate 
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then that Tbx20 transcriptional activity is mediated through temporal interactions with 
unique transcription complexes during cardiomyocyte development. Our studies 
have thus far established association of Tbx20 with a number of repression and 
chromatin remodeling complexes, one of which- a TLE repressor complex- is 
assembled in cardiac progenitor cells and not differentiated cardiomyocytes, 
providing one example of a Tbx20 transcription complex that is temporally regulated 
during cardiomyocyte differentiation. It will be interesting to define the temporal core 
components of the other Tbx20 transcription complexes we have identified over the 
course of cardiomyocyte differentiation and to investigate the requirements for those 
interactions during distinct developmental windows. Together, these investigations 
will define the components of Tbx20 transcription complexes more fully during 
cardiac development and delineate the effects of assembling distinct transcription 
complexes on Tbx20 function in cardiomyocytes. 
 
 In addition to defining the role of various Tbx20 transcription complexes in 
heart development, it will be critical to link the activity of these complexes to Tbx20 
target gene expression in the embryo. Very few direct targets of Tbx20 in the 
embryo have been identified, and this hinders our understanding of the precise gene 
programs regulated by Tbx20 during heart development. The identification of Tbx20 
target genes has been hampered by a lack of ChIP-grade antibodies against Tbx20. 
However, we have presented the generation of a novel mouse ESC line that has 
been genetically modified to have a Tbx20 allele tagged with the Avitag. This cell 
line, in addition to being highly amenable to systems based proteomics approaches, 
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will also allow us to perform chromatin immunoprecipitation followed by high 
throughput sequencing of Tbx20-DNA complexes over the course of cardiomyocyte 
differentiation. To complement this work, it would be interesting to determine the 
overlap between Tbx20 target genes and the target sites of distinct transcription 
complexes known to associate with Tbx20. Taken together, these studies will allow 
us to generate a genomic-proteomic profile of Tbx20 during cardiomyocyte 
differentiation. 
 
 The T-box family of transcription factors is an evolutionary ancient family of 
proteins that have expanded from the founding T-box member, Brachyury (Naiche et 
al., 2005). The expansion of the T-box family coincided with the divergence of T-box 
factor functions such that T-box genes now regulate multiple developmental 
processes in a wide range of tissues and organs.  Early approaches to understand 
how T-box genes function demonstrated that most T-box proteins act as 
transcriptional activators (Kispert et al., 1995; Conlon et al., 1996; Zhang and King, 
1996); however, recent work by our laboratory and others have since confirmed that 
T-box proteins function as both activators and repressors (Lingbeek et al., 2002; Cai 
et al., 2005; Singh et al., 2005; Stennard et al., 2005; Farin et al., 2007). Studies on 
the function of T-box proteins during development are consistent with a general role 
for the T-box family in cell specification and differentiation (Naiche et al., 2005). The 
mechanisms by which these closely related genes exert different effects during 
embryogenesis is not well understood; however, the unique function of each T-box 
factor is likely dictated by the stage of development, the tissue-restricted gene 
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expression of each factor, and the specific target genes of each factor. The common 
evolutionary history of T-box genes and their similar functions during embryogenesis 
suggests that T-box factors likely employ similar mechanisms of gene regulation. 
Therefore, the Tbx20 chromatin remodeling network we have identified may 
represent a core interaction network that is crucial to the function of all T-box factors. 
Future investigations will seek to reveal the proteomic profiles of other T-box factors 
to determine if the findings outlined here represent a global T-box interaction 
network. Additionally, it will be interesting to determine if chromatin remodeling is an 
evolutionarily conserved mechanism of T-box gene regulation by examining T-box 
protein interactions in invertebrates like Drosophila and Caenorhabditis elegans, 
which have 8 and 20 T-box members, respectively (Pflugfelder et al., 1992; Kispert 
et al., 1994; Agulnik et al., 1995; Plageman and Yutzey, 2005). 
 
In conclusion, these studies have provided important insight into the 
mechanisms by which Tbx20 acts to regulate transcription within the vertebrate 
heart. In addition, it represents the first unbiased assessment of Tbx20 protein-
protein interactions, which has contributed greatly to our understanding of the Tbx20 
transcription network. Many of our findings, most notably that of a Tbx20-TLE-HDAC 
repressor complex, likely represent global mechanisms of transcriptional regulation 
used by other cardiac transcription factors, particularly other cardiac T-box factors. 
Our current understanding of the precise components of the gene programs 
regulated by cardiac transcription factors is limited due to a paucity of information 
regarding the direct embryonic gene targets of cardiac transcription factors; 
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however, it is likely that many cardiac transcription factors regulate common sets of 
genes. ANF is an example of a cardiac gene that is regulated by many individual 
cardiac transcription factors (Durocher et al., 1996; Lee et al., 1998; Morin et al., 
2000; Small and Krieg, 2003; Plageman and Yutzey, 2004). As such, it is likely that 
cardiac transcription factors employ many of the same protein complexes to regulate 
downstream transcription. For instance, multiple T-box factors employ a TLE 
repressor complex (Farin et al., 2007), and several cardiac transcription factors are 
known to interact with the SWI/SNF complex (Takeuchi et al., 2011). Therefore, the 
Tbx20 protein-protein interactions we have identified here likely represent 
complexes that are critical for the activity of a number of transcription factors in the 
heart on diverse sets of target genes. However, it is important to note that mutation 
or misregulation of one cardiac transcription is sufficient to lead to congenital heart 
disease indicating that each factor also has a unique requirement during heart 
development. Therefore, it will be critical to repeat the studies outlined in this thesis 
for all members of the cardiac transcription factor collective to gain a comprehensive 
understanding of the players involved in embryonic heart patterning and congenital 
heart disease. Finally, Tbx20 has recently been shown to contribute to heart function 
and disease in adults (Shen et al., 2011) indicating that our findings are likely to 
extend to the role of Tbx20 in regulating genetic programs postnatally and in the 
adult heart.  
 
Most importantly, the identification of novel determinants of Tbx20 activity 
through the comprehensive proteomics studies outlined in this thesis will yield 
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additional candidate genes associated with human congenital heart disease and 
lead to a greater understanding of how Tbx20 contributes to congenital heart 
disease. As previously mentioned, future studies seeking to identify the embryonic 
gene targets and the protein interactome for each individual cardiac transcription 
factor will lead to an even more comprehensive list of potential risk factors for 
congenital heart disease. Why is this so critical, and how will these findings improve 
our treatment of congenital heart defects in human patients? Currently, congenital 
heart malformations are treated primarily through surgical repair of the malformed 
region. As such, early detection of these malformations in the newborn is critical to 
avoid mortality, morbidity, and handicap. Despite this, heart disease goes 
unrecognized in newborn babies in more than half of those with congenital cardiac 
malformations due to the fact that many infants with heart defects are asymptomatic 
at birth (Richmond and Wren, 2001). Some of the most dangerous diagnoses, such 
as left ventricular outflow tract obstructions, become symptomatic only once they are 
established on a rapidly deteriorating course that can lead to death in mere hours 
(Abu-Harb et al., 1994). In the age of genomics, it is now possible to detect genetic 
risk factors early in pregnancy, well before physical signs of disease arise, leading to 
a more detailed assessment of fetal heart health. Therefore, the challenge presented 
to us is, in many ways, a problem of numbers. We simply do not know many of the 
players involved in the transcriptional control of heart patterning. My thesis work 
seeks to address this deficiency and has revealed previously unknown components 
of the cardiac transcription network that are likely to be important in heart 
development, function, and disease. In the future, the identification of additional risk 
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factors for congenital heart disease must be one of critical importance for both a 
better understanding of the biology of heart development, as well as for the 
improvement in our ability to detect disruptions in this process. 
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Xenopus: An emerging model for studying congenital 
heart disease 
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ABSTRACT 
Congenital heart defects affect nearly 1% of all newborns and are a significant cause 
of infant death. Clinical studies have identified a number of congenital heart 
syndromes associated with mutations in genes that are involved in the complex 
process of cardiogenesis. The African clawed frog, Xenopus, has been instrumental 
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in studies of vertebrate heart development and provides a valuable tool to 
investigate the molecular mechanisms underlying human congenital heart diseases. 
In this review, we discuss the methodologies that make Xenopus an ideal model 
system to investigate heart development and disease. We also outline congenital 
heart conditions linked to cardiac genes that have been well-studied in Xenopus and 
describe some emerging technologies that will further aid in the study of these 
complex syndromes.   
 
INTRODUCTION 
Xenopus as a Model System for Human Congenital Heart Disease  
It is becoming increasingly clear that many forms of human disease are 
associated with defects in genes required for early steps in embryonic development. 
The African clawed frog, Xenopus shares surprising similarities with humans both 
genetically and anatomically. Thus, the molecular and cellular pathways through 
which these genes function can be elucidated using Xenopus to model vertebrate 
heart development and disease. Xenopus has numerous advantages as a model 
system in which to identify and characterize cellular and developmental processes. 
Unlike the mouse, the Xenopus embryo develops externally, and its early patterning 
and morphogenesis have been extensively studied. The Xenopus embryo is 
relatively large and is amenable to surgical manipulations, allowing defined regions 
to be excised and cultured in simple salt solutions in which the developmental and 
downstream transcriptional effects of exogenous growth factors can be determined. 
These classical approaches are complemented by molecular techniques that allow 
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the overexpression or knockdown of specific gene products in the early embryo 
(Harvey and Melton, 1988; Heasman et al., 2000). In addition, transgenesis 
techniques are well established and technologies are continually being optimized 
(Chesneau et al., 2008). Moreover, recent sequence annotation and assembly of the 
Xenopus tropicalis genome has demonstrated that it has long regions in which 
genes exhibit remarkably similar synteny relationships to those found in the human 
genome (Showell and Conlon, 2007; Hellsten et al., 2010). Specifically, regarding 
human congenital heart disease (CHD), Xenopus has unique advantages for 
studying cardiovascular development (Warkman and Krieg, 2006; Bartlett and 
Weeks, 2008; Evans et al., 2010). First, early Xenopus development can proceed in 
the absence of a functional circulation system, allowing defects to be extensively 
analyzed in living embryos. Second, Xenopus has a pulmonary system and a two-
chambered atrium. Third, Xenopus has a well-established fate map that is not 
confounded by extensive cell mixing (Dale and Slack, 1987; Moody, 1987). Only 
three hours after fertilization, it is possible to identify the blastomeres that will give 
rise to the adult heart. Collectively, this unique set of attributes places Xenopus as 
an ideal model system for studying congenital heart defects and in this review we 
will describe the experimental tools available to researchers, together with the 
existing Xenopus models of human CHDs (Table A1.1). 
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METHODS FOR STUDYING HEART DEVELOPMENT AND DISEASE IN 
XENOPUS 
 
Protein Depletion and Overexpression 
The advent of effective antisense techniques has enabled researchers to 
associate developmental processes with the genes that control them. The most 
extensively used of these techniques are the use of morpholino oligonucleotides (MOs), 
which inhibit the function of specific genes by preventing translation or splicing of 
messenger RNA (mRNA). This technique has resulted in the publication of many 
studies of heart development in Xenopus that have advanced our understanding of this 
process in vertebrates (Brown et al., 2005; Garriock et al., 2005a; Small et al., 2005; 
Zhang et al., 2005; Inui et al., 2006; Kumano et al., 2006; Brown et al., 2007; Hilton et 
al., 2007; Bartlett and Weeks, 2008; Christine and Conlon, 2008; Movassagh and 
Philpott, 2008; Nagao et al., 2008). MO antisense oligonucleotides are neutrally 
charged synthetic nucleic acid analogs that are stable, soluble, and bind to RNA with 
high affinity (Heasman et al., 2000; Moulton, 2007). In addition, they are resistant to 
nuclease degradation and have limited interaction with proteins (Summerton, 2007; 
Eisen and Smith, 2008; Bill et al., 2009). MOs are designed to reduce gene function in 
two ways. First, the MO can be designed to target sequences in the 5′ untranslated 
region close to the translation initiation codon of the gene to sterically block the 
attachment of the ribosomal machinery and inhibit protein translation (Heasman et al., 
2000). Alternatively, MOs can be designed to target the splice junctions in the pre-
mRNA strand, resulting in the incorporation of intron-encoded amino acids and, in many 
cases, early termination of translation via premature stop codons or by a shift in the 
reading frame of the subsequent sequence (Morcos, 2007).  
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Strategies other than MOs have been employed to inhibit gene function. These 
include antisense RNA injection (Harland and Weintraub, 1985; Melton, 1985; Dagle 
and Weeks, 2001), RNA interference in which the RNA is targeted for degradation by 
the binding of small inhibitory RNA molecules and recruitment of the RNA-induced 
silencing complex (Zhou and others, 2002; Summerton, 2007), DNA with chemically 
modified phosphate linkages that employs cellular RNase H to cleave the target RNA 
strand (Summerton, 2007), and peptide nucleic acid nucleotides which sterically block 
RNA translation in a similar way to MOs (Harland and Weintraub, 1985; Melton, 1985; 
Dagle and Weeks, 2001; Zhou et al., 2002; Summerton, 2007). However, due to few 
off-target effects, their binding success and their commercial availability, MOs have 
become a favored tool for studying gene function in vertebrate models (Knudsen and 
Nielsen, 1996; Summerton, 2007).  
 
Protein overexpression can be as valuable a technique as protein depletion to 
determine the role of a particular gene in development. The microinjection of capped 
mRNA into the Xenopus embryo has commonly been used to study heart development 
in the context of globally increased function of the protein under investigation, the 
effects of lateral- and lineage-specific overexpression, and to study isoform-specific 
phenotypes (Campione et al., 1999; Kitaguchi et al., 2000; Stennard et al., 2003; Goetz 
et al., 2006). Overexpression of truncated or mutated proteins can also be utilized to 
reproduce and investigate phenotypes caused by mutations identified in human patients 
with CHD (Ataliotis et al., 2005; Bartlett et al., 2007). Furthermore, protein function can 
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be manipulated in a spatio-temporal manner by injecting hormone-inducible constructs 
with timed dexamethasone application (Kitaguchi et al., 2000; Afouda et al., 2008). 
 
Xenopus Explants for Cardiogenic Assays 
The Xenopus embryo is particularly amenable to tissue explant assays due to 
its unique ability to heal after microsurgery. In addition, Xenopus embryonic tissue 
can survive in the absence of added nutrients (due to the yolk contained in 
embryonic cells) allowing culture of tissue explants in a simple saline solution. The 
first use of Xenopus explants in a cardiogenic assay was performed by Horst Grunz 
in 1992 (Grunz, 1992) who demonstrated that the isolated blastopore lip, fated to 
give rise to notochord and somites but not the heart, gives rise to differentiated 
cardiac tissue when cultured in the presence of the growth factor-blocking 
compound suramin. This demonstrated the importance of growth factor signaling in 
negatively regulating the induction of cardiac cell fate in the dorsal marginal zone 
(DMZ), which restricts cardiac cell fate to two bilateral groups of cells in the 
dorsoanterior mesoderm of the gastrula. Similar experiments by Schneider and 
Mercola have shown that Wnt signaling can antagonize cardiac specification in DMZ 
explants. When an arc of dorsal marginal zone mesoderm containing the heart 
progenitors is excised from the equatorial region of the gastrula and cultured in 
isolation it gives rise to differentiated, beating cardiac tissue. However, 
overexpression of wnt3A and wnt8 in these DMZ explants by injection of plasmid 
DNA into dorsal blastomeres results in a downregulation of cardiac marker 
expression, suggesting that inhibition of endogenous Wnt signaling might be 
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required for proper heart induction (Schneider and Mercola, 2001). Indeed, when the 
Wnt inhibitors dickkopf1 or crescent are expressed ectopically in non-cardiogenic 
ventral marginal zone (VMZ) explants, cardiac terminal differentiation can be 
induced. This results in the striking observation of beating cardiac tissue within the 
cultured explants (Schneider and Mercola, 2001). A role has also been identified for 
wnt11, encoding a non-canonical Wnt antagonist, in the induction of heart formation 
by the observation that it is sufficient to induce expression of cardiac markers and 
differentiation of contractile cardiac tissue in VMZ explants (Pandur et al., 2002). As 
WNT11 both inhibits β-catenin through the canonical pathway and activates JNKAs 
WNT11 also inhibits β-catenin through the canonical pathway, Pandur et al. injected 
mRNA encoding a dominant negative LEF-1 and observed that disruption of β-
catenin signaling alone fails to induce a contractile phenotype in VMZ explants. s. 
This result indicates that heart induction may require both 1) low levels of Wnt/β-
catenin activity and, 2) activation of non-canonical Wnt/JNK signaling through 
WNT11 activation of the non-canonical Wnt signaling cascade through WNT11 is 
required for cardiac differentiation in this assay (Pandur et al., 2002). Alternately, it 
could reflect activity differences between TCF and LEF factors in β-catenin inhibition 
as another group demonstrated that injection of a dominant negative TCF3 was 
indeed sufficient to induce cardiogenesis in Xenopus animal caps.  
 
    Explants have also been used to investigate factors required for induction of 
cardiogenesis via a loss-of-function approach. For example, MO knockdown of hex 
(a transcription factor induced by antagonists of the canonical Wnt pathway) in DMZ 
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explants resulted in loss of cardiac markers, indicating that heart induction by Wnt 
antagonists relies upon activation of hex (Foley and Mercola, 2005).  
 
    The Xenopus animal cap also serves as a useful tissue for cardiogenic 
assays and can be used to examine the ability of various molecules to affect cardiac 
gene expression and differentiation. The animal cap consists of prospective 
ectoderm at the animal pole of a blastula embryo and is fated to become epidermal 
and neural tissues. Because the ectodermal cells of the animal pole are pluripotent, 
they can be induced to give rise to alternate cell lineages, including mesodermal 
derivatives such as the heart. Logan and Mohun demonstrated that cardiac muscle 
is induced in animal caps treated with high concentrations of the mesoderm-inducing 
factor activin (Logan and Mohun, 1993). A more recent protocol involving the 
dissociation and reaggregation of animal caps in the presence of activin results in 
beating animal cap explants that can form ectopic hearts in Xenopus adults following 
transplantation into the hosts at embryonic stages (Ariizumi et al., 2003). As with 
DMZ and VMZ explants, animal caps have been used to advance our understanding 
of the role of WNT signaling during cardiogenesis. Activin-induced expression of 
GATA factors in animal caps is abolished upon injection of an inducible form of β-
catenin, suggesting that Wnt signaling may act to repress gata gene expression to 
restrict cardiogenesis (Afouda et al., 2008). In addition, inhibition of gata4 and gata6 
by MO injection in animal cap explants results in decreased wnt11 expression, 
whereas injection of inducible versions of Gata4 and Gata6 results in upregulation of 
wnt11 expression, placing GATA factors in a regulatory pathway that links canonical 
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and non-canonical Wnt signaling during cardiogenesis (Pandur et al., 2002; Afouda 
et al., 2008). 
 
Finally, prospective cardiac tissue itself can be explanted from the embryo 
and used for cardiogenic assays in the absence of the rest of the embryo. This 
technique is particularly useful when it is necessary to bypass an early embryonic 
requirement for a gene to assess its later role in the developing heart. In short, 
tissue posterior to the cement gland including the heart field can be excised starting 
at stage 22 when the cardiac precursor populations form a ridge of tissue on top of 
underlying endoderm. In isolation, these explants will go on to form beating hearts in 
culture (Raffin et al., 2000; Langdon et al., 2007). Using this assay, a recent study 
identified a role for SHP-2, a protein tyrosine phosphatase that is disrupted in human 
CHD, in the maintenance of cardiac progenitors (Langdon et al., 2007). 
 
Xenopus Transgenesis 
The development of transgenesis in Xenopus has allowed investigators to 
introduce heritable genetic modifications into the frog genome, propelling Xenopus 
forward as both a genetic and developmental model. Transgenic procedures in 
Xenopus have primarily been used for promoter/enhancer analyses and for 
expressing transgenes in a tissue-specific manner with defined promoters. Early 
experiments involving microinjection of circular or linear DNA demonstrated that 
integration into the genome occurred in a significant number of injected embryos 
(Rusconi and Schaffner, 1981; Etkin and Roberts, 1983; Andres et al., 1984; Bendig 
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and Williams, 1984; Etkin et al., 1984). The first characterization of transgenic frogs 
produced by this method showed that the resulting animals were mosaic and that 
the copy number was highly variable, even within cells from the same animal (Etkin 
and Pearman, 1987). It was not until the development of the Restriction Enzyme 
Mediated Integration (REMI) strategy that the problem of mosaicism was overcome 
(Kroll and Amaya, 1996b). Using this method, sperm nuclei are incubated with 
linearized DNA and a restriction enzyme along with egg extracts which promote 
DNA decondensation. The modified sperm nuclei are then injected into unfertilized 
eggs, where the foreign DNA is believed to integrate randomly into the genomic 
DNA during the DNA repair process prior to the first cell division (Amaya and Kroll, 
1999; Smith et al., 2006). 
 
Other methods of transgenesis that utilize different core insertion techniques 
have been used with varying success. Transposable elements such as Sleeping 
Beauty or the Tol2 transposon have been used as an alternative to REMI to facilitate 
transgene integration in Xenopus (Kawakami et al., 2000; Kawakami et al., 2004; 
Parinov et al., 2004; Choo et al., 2006; Hamlet et al., 2006; Sinzelle et al., 2006; 
Yergeau and Mead, 2007; Yergeau et al., 2009). The more commonly used 
transposon Tol2 is an active and autonomous transposable element that can 
integrate into one or multiple sites in the genome and has been used successfully in 
zebrafish for insertional mutagenesis, although this method of transgenesis in 
Xenopus has not been as efficient as expected. Other groups have optimized the 
use of integrase-mediated transgenesis utilizing the bacteriophage ΦC31 and the 
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more frequently used I-SceI meganuclease (Allen and Weeks, 2005; Allen and 
Weeks, 2009). The I-SceI meganuclease, originally isolated from Saccharomyces 
cerevisiae, is used to digest transgene DNA containing I-SceI 18-bp recognition sites 
and this reaction mixture is injected into unfertilized eggs where it integrates 
randomly into the host genome. Copy number of integrated transgenes is relatively 
low, ranging from one to four, compared to the REMI method which typically results 
in the integration of transgene concatemers (two to six copies) at four to eight sites 
in the genome (Kroll and Amaya, 1996a). (Jacquier and Dujon, 1985; Ogino et al., 
2006; Pan et al., 2006). 
 
The developmental regulation of several cardiac genes has been 
characterized with Xenopus transgenesis, leading to a clearer picture of the complex 
gene regulatory networks that guide heart development. This commonly involves in 
vivo analysis of cis-regulatory regions that drive cardiac expression in the heart and 
is accomplished by inserting the promoter of interest upstream of a reporter 
transgene, such as green fluorescent protein (GFP), to follow transgene expression 
in the live embryo. This approach has been used to identify cardiac-specific 
regulatory elements for atrial natriuretic factor (anf), cardiac α-Actin, myosin Light 
Chain 2 (mlc2), myosin light chain 1v (mlc1v), nkx2-5, alpha myosin heavy chain (α-
mhc), and tbx20 (Sparrow et al., 2000; Latinkić et al., 2002; Small and Krieg, 2003; 
Latinkić  et al., 2004; Garriock et al., 2005b; Smith et al., 2005; Mandel et al., 2010). 
Additional studies examining the mechanisms of regulating these cardiac elements 
have revealed much about the signaling pathways that act on cardiac genes during 
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development. Importantly, many of these regulatory elements are evolutionarily 
conserved as they are sufficient for cardiac-specific expression in other vertebrates 
including mice.     
 
One of the benefits of transgenesis is the ability to tightly control the spatial 
and temporal expression of a transgene during development with tissue-specific 
promoters. Several cardiac promoters that drive expression throughout the 
developing heart have been used with great success to misexpress a gene of 
interest specifically in the heart-forming region. Using transgenic embryos 
expressing bmp4 under the control of the mlc2 promoter, Breckenridge et al. 
demonstrated that ectopic expression throughout the developing heart results in 
randomization of the direction of cardiac looping, indicating that asymmetric BMP4 
signaling is required for proper cardiac looping (Breckenridge et al., 2001). 
 
CONGENITAL HEART DISEASE 
Atrial Septal Defects: Nkx2.5 and Gata4 
Atrial Septal Defects (ASD) are relatively common and account for 10% of all 
human congenital heart defects (Hoffman and Kaplan, 2002). ASD refers to a failure 
of the atrial septum to fully separate the right and left atrial chambers after birth and 
is often accompanied by other forms of CHD including cardiac conduction system 
abnormalities. The cardiac transcription factor Nkx2.5 is mutated in a number of 
patients with non-syndromic ASD, suggesting a critical function for this gene in the 
septogenesis process (Schott et al., 1998; Benson et al., 1999).  
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Nkx2.5 encodes a homeodomain protein that is highly conserved from 
Drosophila to human. Nkx2.5 is expressed early in development, and in combination 
with other cardiac transcription factors, helps define the cardiogenic field in which it 
plays an essential role in the specification of cardiac progenitors from the 
cardiogenic mesoderm. Cardiac expression of Nkx2.5 persists into adulthood, 
however, a complete understanding of the role NKX2.5 plays during the later stages 
of heart formation has been complicated by the fact that targeted disruption of 
murine Nkx2.5 results in embryonic lethality at E9-E10, prior to heart looping (Lyons, 
1995). Interestingly, a recent study in Xenopus demonstrated that injection of two 
truncated forms of Xenopus laevis NKX2.5, corresponding to two human NKX2.5 
point mutations identified in patients with cardiac defects including ASD and 
atrioventricular conduction delays, results in atrial septal and conduction system 
defects (Schott et al., 1998; Bartlett et al., 2007). Significantly, this study focused on 
the effects of injecting mutant forms of nkx2.5on internal changes to the hearts of 
stage 46 embryos when the Xenopus heart is fully looped with chambers, septae, 
valves, and a functional conduction system (Bartlett et al., 2007). The results 
suggest that early expression of mutant nkx2.5 in the frog can lead to a late 
phenotype that includes cardiac defects consistent with those seen in human 
disease.  
 
NKX2.5 has also been shown to physically interact with the cardiac zinc finger 
transcription factor GATA4, an additional gene mutated in in patients with ASD 
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(Durocher et al., 1997; Lee et al., 1998; Sepulveda et al., 1998; Pehlivan et al., 
1999; Garg et al., 2003). The NKX2.5-GATA4 interaction synergistically activates 
cardiac promoters during the cardiogenic program, suggesting that deficiencies in 
either member of this transcriptional complex can result in ASDs (Durocher et al., 
1997; Lee et al., 1998; Sepulveda et al., 1998). Studies utilizing the embryonic 
carcinoma P19 cell line have shown Gata4 to be essential for cardiac differentiation. 
However, Gata4 null mice can generate differentiated cardiac myocytes that express 
contractile proteins but are deficient in ventral morphogenesis, resulting in a failure 
of cardiomyocytes to form a linear heart tube at the ventral midline (cardia bifida) 
(Grepin et al., 1995; Grepin et al., 1997; Kuo et al., 1997; Molkentin et al., 1997). 
Recent studies in Xenopus complement the mouse work and demonstrate with MOs 
that gata4 is dispensable for cardiac specification but essential for proper heart 
morphogenesis downstream of the induction of the myocardium (Haworth et al., 
2008). Interestingly, when GATA4, GATA5, and GATA6 are all depleted from 
Xenopus embryos, myosin heavy chain expression is completely lost from most 
morphant embryos, suggesting that there is GATA factor redundancy in the 
regulation of myocardial differentiation, providing a possible explanation for the 
persistent presence of differentiated cardiomyocytes in Gata4-/- mice (Peterkin et al., 
2007). 
 
DiGeorge Syndrome: Tbx1 
DiGeorge syndrome (DGS) is a congenital disorder that has many 
overlapping characteristics with velo-cardio-facial syndrome and conotruncal 
anomaly face syndrome due to shared deletions within chromosome band 22q11.2 
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(Yamagishi and Srivastava, 2003; Baldini, 2004). For this reason, these syndromes 
are collectively known as 22q11 deletion syndrome (del22q11DS). Approximately 
80% of neonates displaying del22q11DS have congenital heart defects that include 
Tetralogy of Fallot, persistent truncus arterious, and cardio-facial abnormalities 
(Epstein, 2001; Yamagishi and Srivastava, 2003; Baldini, 2004; Di Felice and 
Zummo, 2009; Momma, 2010; Starr, 2010).  
 
DGS is one of the most prevalent chromosomal microdeletion genetic 
disorders. The region of chromosome 22q11.2 that is deleted in DGS encompasses 
1.5 to 3 Mb and includes 24-30 genes (Epstein, 2001; Yamagishi and Srivastava, 
2003; Baldini, 2004). A heterozygous mouse genetic model in which the orthologous 
chromosomal region affected in DGS is deleted displays similar phenotypes as 
those in human patients (Lindsay et al., 1999; Lindsay and Baldini, 2001). The 
deleted region frequently includes the locus encoding the T-box transcription factor 
Tbx1. In a genetic analysis screen, five patients were identified who exhibited DGS 
phenotypes and had Tbx1 mutations but not chromosomal microdeletions, 
suggesting that Tbx1 may be contributing to the DGS phenotype in these individuals 
(Yagi et al., 2003). DGS abnormalities have been correlated with disrupted 
pharyngeal and neural crest patterning during development. Subsequently, Tbx1 
was shown to be expressed in the pharyngeal arches, and mouse genetic models 
have demonstrated that Tbx1 haplo-insufficiency disrupts the development of the 
fourth pharyngeal arch arteries, possibly in conjunction with FGF8 signaling 
(Chapman et al., 1996; Lindsay et al., 2001b; Merscher et al., 2001; Kochilas et al., 
 226 
2002; Sauka-Spengler et al., 2002; Vitelli et al., 2002; Kochilas et al., 2003; Baldini, 
2004; Ataliotis et al., 2005; Showell et al., 2006). In addition, Tbx1 plays a role in 
growth and septation of the outflow tract (OFT). Conditionally ablating Tbx1 in the 
Nkx2.5 domain of the secondary heart field results in mild pharyngeal defects and a 
severe defect in aorto-pulmonary septation of the OFT that is associated with neural 
crest migration defects and reduced proliferation of cells in the secondary heart field 
(Waldo et al., 2001; Xu et al., 2004). FGF signaling may be involved in the latter 
event as there is a reduction in Fgf10 expression in the secondary heart field in 
Tbx1-null mice. Further, Fgf10 is a direct transcriptional target of Tbx1 in vitro 
(Waldo et al., 2001; Xu et al., 2004). Interestingly, the defect in OFT septation 
suggests a dose-dependent role for Tbx1 because this phenotype can be partially 
rescued upon reestablishing Tbx1 expression (Jerome and Papaioannou, 2001; 
Lindsay et al., 2001a; Xu et al., 2004).  
 
Tbx1 has been identified in many vertebrates including Xenopus laevis and 
Xenopus tropicalis. In these model systems, the expression domains of tbx1 
replicate those seen in other vertebrates, namely the pharyngeal arches, otic 
vesicle, and mesenchyme surrounding the OFT (Chapman et al., 1996; Sauka-
Spengler et al., 2002; Kochilas et al., 2003; Ataliotis et al., 2005; Showell et al., 
2006). A dominant interfering mutant of tbx1 injected into Xenopus embryos results 
in very similar phenotypes to those of mice deficient in Tbx1, including pharyngeal 
defects, unlooped heart, pericardial edema, and a reduction in anterior structures. 
These defects can be rescued by co-injecting wild-type tbx1 mRNA. To lineage trace 
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the fate of TBX1-deficient cells, Ataliotis et al. co-injected β-galactosidase mRNA 
and the dominant interfering mutant tbx1 mRNA into Xenopus embryos and 
identified a requirement for TBX1 in cells that contribute to pharyngeal mesoderm 
(Ataliotis et al., 2005). Additionally, recent advances in Xenopus transgenesis have 
enabled researchers to analyze cardiac and craniofacial phenotypes in embryos with 
reduced functions of specific genes, effectively generating models of CHD such as 
DGS. Using the active promoter of mlc1v to drive GFP, craniofacial and cardiac 
muscle formation was followed in Xenopus embryos injected with the dominant 
interfering mutant of tbx1, enabling real-time visualization of cardiac structural 
defects in developing embryos (Smith et al., 2005). 
Holt-Oram Syndrome: Tbx5 
Holt-Oram Syndrome (HOS), also known as heart-hand syndrome, is a 
congenital autosomal dominant disorder that primarily affects the heart and upper 
limbs (Holt and Oram, 1960). HOS is the most common heart-hand syndrome, 
affecting nearly 1 in 100,000 total births (Basson et al., 1994). Approximately 75% of 
patients with HOS experience cardiac defects, most commonly ASD, ventricular 
septal defects (VSD), and/or defects in the cardiac conduction system (Basson et 
al., 1994; Benson et al., 1996; Newbury-Ecob et al., 1996; Cross et al., 2000; 
McDermott et al., 2005). Atypical phenotypes have also been discovered and 
characterized, and phenotypic expression is variable even within families (Newbury-
Ecob et al., 1996; Sletten and Pierpont, 1996; Brassington et al., 2003; Lehner et al., 
2003; McDermott et al., 2005; Garavelli et al., 2008). HOS is often caused by 
mutations in the coding region of the T-box transcription factor Tbx5 on chromosome 
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12q.24.1 (Basson et al., 1997; Li et al., 1997; Basson et al., 1999). More than 70% 
of patients with HOS have a mutation in the Tbx5 coding exons, and 85% of these 
mutations are de novo (McDermott et al., 2005). Most HOS mutations are predicted 
to result in haploinsufficiency of Tbx5 (Li et al., 1997; Basson et al., 1999).   
 
Mice lacking Tbx5 do not survive past E10.5 due to arrested cardiac 
development caused by impaired cardiac differentiation (Bruneau et al., 2001). 
Heterozygous Tbx5del/+ mice display subtle defects in the paw and wrist, enlarged 
hearts with ASD, cardiac conduction defects, and a variety of additional complex 
cardiac defects reminiscent of patients with HOS. The expression of several cardiac 
genes is reduced in mice lacking Tbx5. Two of these genes, ANF and Cx40, are also 
reduced in mice expressing 50% of the normal TBX5 levels (Moskowitz et al., 2004). 
Similar heart and limb defects are observed in the orthologous Tbx5 zebrafish 
mutant heartstrings, suggesting that both the expression domain and protein 
function of Tbx5 are conserved among vertebrates (Garrity et al., 2002). In Xenopus, 
tbx5 is first expressed in the migrating heart primordia and eye anlage of the late 
neurula embryo. Its expression is maintained in the primitive heart tube, although its 
expression becomes more graded after looping of the heart, with higher expression 
in the ventricle than the atria (Horb and Thomsen, 1999; Showell et al., 2006). 
Consistent with work in other organisms, Tbx5 was demonstrated to be critical for 
proper heart morphogenesis in Xenopus (Horb and Thomsen, 1999; Brown et al., 
2005). Overexpression of a dominant negative hormone-inducible form of TBX5 
blocks heart tube formation, whereas knockdown of tbx5 expression by MO results 
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in reduced cardiac cell number and an unlooped heart tube (Horb and Thomsen, 
1999; Brown et al., 2005). The decrease in cardiac cell number in the tbx5 morphant 
embryos was demonstrated to result from a proliferation defect caused by a delay or 
arrest in the G1/S phase of the cell cycle, implicating a role for TBX5 in cardiac cell 
cycle control (Goetz et al., 2006). These results from Xenopus as well as those from 
human studies (Hatcher et al., 2001), suggest that HOS defects may in part arise 
from a decrease in cell cycle progression and cardiac cell proliferation in Tbx5-
expressing regions. In addition, work in a number of model systems has 
demonstrated a conserved role for Tbx5 in the regulation of cardiac-specific gene 
expression (Liberatore et al., 2000; Bruneau et al., 2001; Hatcher et al., 2001; Hiroi 
et al., 2001; Garrity et al., 2002; Plageman and Yutzey, 2004; Brown et al., 2005). !
Spectrum of Congenital Heart Defects: Tbx20 
Tbx20 is a member of the T-box family of transcription factors and is one of 
the first genes to be expressed in the cardiac lineage along with Nkx2.5, Gata4, and 
Tbx5. In all species examined, expression of Tbx20 is maintained throughout the 
primary heart field, in both myocardium and endocardium, as development proceeds 
and persists in the adult heart. Kirk et al. were the first group to identify mutations in 
human Tbx20 in patients with familial CHD (Kirk et al., 2007). The two mutations 
identified are both in the T-box DNA binding domain and segregate with a spectrum 
of cardiac pathologies including ASD, VSD, valve disease, pulmonary hypertension, 
and cardiomyopathy. Loss-of-function mutations were the first to be identified. 
However, several other groups have since identified new Tbx20 mutations with both 
loss- and gain-of-function that are associated with CHD (Posch et al.; Liu et al., 
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2008; Qian et al., 2008). In addition, upregulation of Tbx20 expression has been 
noted in patients with Tetralogy of Fallot (Hammer et al., 2008). The wide range of 
defects associated with mutant or misregulated Tbx20 may be the result of the 
expression of Tbx20 in both myocardium and endocardium, where endocardial 
cushions give rise to valves and the interventricular septum.  
 
Although the early expression of Tbx20 in cardiogenic mesoderm suggests a 
role in the specification, migration, and/or differentiation of cardiac progenitors, a 
requirement for TBX20 is not evident until the early stages of heart morphogenesis, 
as shown by studies in fish and frogs (Szeto et al., 2002; Brown et al., 2005). Upon 
MO knockdown of Tbx20 in zebrafish and Xenopus embryos, morphant embryos 
display unlooped heart tubes and pericardial edema, but express markers of cardiac 
specification and differentiation, indicating an essential role for TBX20 in cardiac 
morphogenesis. In addition, TBX20-depleted Xenopus hearts have reduced 
cardiomyocyte cell numbers and fail to properly form chambers (Brown et al., 2005). 
Likewise, mice lacking Tbx20 undergo normal cardiac specification and 
differentiation, but development is arrested in the primary linear heart tube stage, 
and chamber differentiation is not initiated (Cai et al., 2005; Singh et al., 2005; 
Stennard et al., 2005; Takeuchi et al., 2005). There also appears to be a proliferation 
defect in Tbx20 null hearts that is thought to be mediated by a loss of repression of 
Tbx2, thereby allowing aberrant repression of the cell cycle gene N-Myc in chamber 
myocardium (Cai et al., 2005; Singh et al., 2005). The misregulation of Tbx2 in 
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Tbx20 mutant hearts may partially explain the loss of cardiomyocytes seen in 
Xenopus and mouse Tbx20 mutants. 
 
The frequent occurrence of cardiac defects resulting from perturbations in the 
complex regulatory network guiding the cardiomyogenic program highlights the 
importance of understanding the interactions that occur between members of this 
network. Xenopus embryos co-injected with MOs against tbx20 and tbx5 display a 
more severe cardiac phenotype than single mutants, indicating that TBX20 and 
TBX5 cooperate to regulate cardiac morphogenesis (Brown et al., 2005). TBX20 
physically interacts with the cardiac transcription factors NKX2.5, GATA4, GATA5, 
and TBX5 and, in transcription assays, TBX20 synergistically activates cardiac 
promoters in the presence of NKX2.5, GATA4, and ISLET1 (Stennard et al., 2003; 
Brown et al., 2005; Takeuchi et al., 2005). Surprisingly, in transient transcription 
assays, the shorter TBX20b isoform, which is terminated shortly after the T-box 
domain, is more effective at activating reporter gene expression than the longer 
TBX20a that is the predominant isoform expressed in the heart during development 
(Stennard et al., 2003). To determine which TBX20 isoform promotes changes in 
morphogenesis and gene expression in vivo, Tbx20a and Tbx20b mRNAs were 
injected into Xenopus embryos . Overexpression of Tbx20a, but not Tbx20b, results 
in multiple developmental defects, including shortening of the anterior/posterior axis 
and secondary axis formation (Stennard and others, 2003). Tbx20 mRNAs were also 
injected into explanted Xenopus animal pole caps resulting in an upregulation of the 
early mesoderm marker Xbra and the cardiac marker Nkx2.5 in the Tbx20a-injected, 
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but not Tbx20b-injected, caps (Stennard and others, 2003). These studies suggest 
that the C-terminal domain of TBX20a is essential for TBX20 activity in the embryo 
and highlight the utility of Xenopus embryo assays for investigating the biological 
relevance of in vitro findings.  !
Noonan Syndrome: Shp-2 
Noonan syndrome is one of the most common forms of CHD. The disorder 
leads to several cardiac developmental abnormalities including ASD, VSD, 
pulmonary stenosis, and hypertrophic cardiomyopathy (Noonan, 1968; Noonan, 
1994). Noonan syndrome was shown to be associated with mis-sense mutations in 
SHP-2 in approximately half of affected individuals (Tartaglia et al., 2001; Kosaki et 
al., 2002; Maheshwari et al., 2002; Tartaglia et al., 2002). Shp-2 mis-sense 
mutations are associated with a gain-of-function and are thought to result in 
prolonged downstream activation of several growth factors including epidermal 
growth factors (EGFs), fibroblast growth factors (FGFs), and platelet-derived growth 
factor (Feng et al., 1994; Van Vactor et al., 1998; Feng, 1999; Qu, 2000; Zhang et 
al., 2000; Tartaglia et al., 2001). Interestingly, patients with acute myelogenous 
leukemia (AML), acute lymphoblastic leukemia (ALL), and juvenile myelomonocytic 
leukemia (JMML) carry a second, mostly mutually exclusive, somatically introduced 
subset of mis-sense mutations in Shp-2, strongly suggesting a genotype-phenotype 
relationship between Shp-2 mis-sense mutations and disease (Musante et al., 2003; 
Tartaglia et al., 2003; Bentires-Alj et al., 2004; Loh et al., 2004; Kratz et al., 2005). 
However, the cellular and biochemical basis for the role of SHP-2 in Noonan 
syndrome, AML, ALL, and JMML is unknown.  
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Shp-2 is a widely expressed non-receptor tyrosine phosphatase comprised of 
two tandemly arranged SH2 domains and a protein tyrosine phosphatase (PTP) 
domain. Shp-2, also known as Sh-Ptp2, Ptpn11, Ptp1d, and Ptp2c, is the vertebrate 
homologue of the Drosophila gene corkscrew (csw). The sequence, expression 
pattern, and function of Shp-2 are highly conserved throughout evolution. For 
example, Xenopus and human orthologues display 94% sequence identity, and as in 
fly and mouse, Xenopus shp-2 is believed to be ubiquitously expressed (Tang et al., 
1995; Langdon et al., 2007). Moreover, several animal models have suggested a 
critical role for Shp-2 in vertebrate development. For example, mice expressing an 
internal deletion of the amino-terminal (N-SH2) domain of Shp-2 die at late 
gastrulation and display several mesodermal abnormalities including heart and 
vascular defects (Saxton et al., 1997; Saxton and Pawson, 1999; Yang et al., 2006). 
In addition Shp-2 mutant cells derived from homozygous mutant embryos show that 
Shp-2 is required for full and sustained activation of the MAPK pathway in response 
to FGF, thus demonstrating that SHP-2 functions downstream of the FGF/MAPK 
pathway in vivo (Saxton et al., 1997; Saxton and Pawson, 1999). Consistent with 
these findings, studies in Xenopus have shown that a dominant negative form of 
Xenopus Shp-2 can completely block mesoderm formation in response to both 
MAPK and FGF (Tang et al., 1995). Furthermore, in vitro and tissue culture studies 
have shown that csw/Shp-2 interacts directly with the FGF inhibitor SPROUTY, 
leading to SPROUTY phosphorylation and inactivation (Hanafusa et al., 2004; Jarvis 
et al., 2006). 
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In the mouse and chick, SHP-2 is required in the EGF pathway for formation 
of cardiac valves. However, because approximately one-third of patients with 
Noonan-associated heart defects appear to undergo normal valvulogenesis (Chen et 
al., 2000; Krenz et al., 2005), it remains unclear if SHP-2 is required downstream of 
other receptor tyrosine kinase receptors for other aspects of heart development. To 
address whether SHP-2 functions in cardiac pathways in addition to EGF and 
valvulogenesis and to bypass the early embryonic requirements for SHP-2, Langdon 
et al. (2007) used a Xenopus cardiac explant assay and chemical SHP-2 inhibitors 
to demonstrate that SHP-2 is required for the survival of actively proliferating cardiac 
progenitor populations but not those that have exited the cell cycle. It was further 
demonstrated that SHP-2 is directly phosphorylated on specific residues in vivo in 
response to FGF signaling, that SHP-2 co-immunoprecipitates with the FGF receptor 
adaptor, and that a constitutively active Noonan-associated Shp-2 mutation can 
rescue cardiac defects induced by FGF inhibition. Collectively, these studies imply 
that SHP-2 functions in the FGF/MAPK pathway to maintain survival of proliferating 
populations of cardiac progenitor cells. However, it remains to be determined why 
mis-sense mutations in Shp-2 lead to a tissue-specific effect in animals and humans. 
 
Heterotaxy and Cardiac Looping Defects: Zic3 
Heterotaxy (situs ambiguus) is a spectrum disorder in which the position of 
thoracic and abdominal organs is abnormal. Heterotaxy malformations are thought 
to arise from defective left-right patterning during embryonic development.  
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Establishing laterality in the embryo is a complex process involving a 
multitude of spatio-temporal signaling events (Mercola, 1999; Boorman and Shimeld, 
2002). Initially, cells in the left-right coordinator (posterior notochord in mammals, 
gastrocoel roof plate in Xenopus, and Kupffer’s vesicle in zebrafish) adjacent to the 
organizing node develop specialized motile cilia that generate a leftward fluid flow 
and an asymmetrical morphogen gradient (Tabin and Vogan, 2003; Blum et al., 
2009; Sutherland and Ware, 2009). The subsequent lateralized expression of nodal, 
a member of the transforming growth factor β (TGFβ) family, is then thought to be 
involved in specifying left-right asymmetry via the notch signaling pathway (Krebs et 
al., 2003; Raya et al., 2003). Pitx2, a paired homeobox transcription factor, also 
plays a crucial role in organ symmetry, particularly in heart looping, downstream of 
nodal signaling (Ryan et al., 1998).  
 
One of the first major morphological symmetry-breaking events in vertebrates 
occurs when the relatively symmetrical heart tube undergoes a rightward (dextral) 
bend, after which a complex process of looping and septation results in the mature 
multi-chambered heart (Mercola, 1999; Manner, 2000; Boorman and Shimeld, 2002; 
Manner, 2009). Cardiac looping defects are commonly observed in cases of 
heterotaxy, and these defects account for approximately 3% of all CHDs. Other 
common heart phenotypes seen in heterotaxic patients include ASD, VSD, 
transposition of the great arteries, double outlet right ventricle, single ventricle, and 
aortic arch defects (Bowers et al., 1996; Lin et al., 2000; Belmont et al., 2004; 
Sutherland and Ware, 2009). Numerous cases of familial clustering of heterotaxy 
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have been identified, suggesting autosomal inheritance of the disorder. However, X-
linked inheritance has also been shown, involving mutations in the conserved zinc-
finger transcription factor gene, Zic3 (Gebbia et al., 1997; Ware et al., 2004). Heart 
defects and altered nodal expression are observed in Zic3 mutant mice (Purandare 
et al., 2002). In Xenopus embryos, zic3 is expressed in the mesoderm of the 
gastrulating embryo in a left-right (L-R) symmetrical fashion, however, unilateral 
right-sided overexpression of zic3 is sufficient to disturb the L-R axis, resulting in 
abnormal heart and gut looping and affecting the lateral expression of pitx2 and 
nodal related 1 (XnrI) (Kitaguchi and others, 2000). Xenopus zic3 is therefore 
considered to have a conserved early role in transducing signals from the left-right 
organizer and establishing asymmetry (Kitaguchi et al., 2000; Kitaguchi et al., 2002).  
 
The amphibian model system has historically been used to study left-right 
patterning since the early 1900s by Spemann and colleagues. Subsequently, the 
Xenopus model was established, and has proven ideally suited to study the role of 
left-right laterality, using well-accepted techniques such as lineage tracing and fate 
mapping, in the process of heart development (Gormley and Nascone-Yoder, 2003; 
Blum et al., 2009). One of the first events in Xenopus embryonic development is 
cleavage at the one-cell stage to form two blastomeres, the descendents of which 
will contribute almost exclusively to either the left or the right side of the embryo. 
This feature enables researchers to independently alter signaling events or gene 
expression unilaterally to determine their effect on asymmetry and to conduct left-
right lineage tracing experiments, particularly of the heart region (Branford et al., 
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2000; Kitaguchi et al., 2000; Kitaguchi et al., 2002; Dagle et al., 2003; Chen et al., 
2004; Ramsdell et al., 2006; Toyoizumi et al., 2006; Jahr et al., 2008). Recent work 
in Xenopus has demonstrated that cell lineages in the heart display a high degree of 
asymmetry, and that defects in left-right patterning alter cardiomyocyte allocation 
and differentiation in the heart, leading to cardiac malformations (Chen et al., 2004; 
Ramsdell et al., 2006). The Xenopus model is therefore an optimal organism to 
study the fate of cardiac cell populations and to determine how specific genes such 
as Zic3 may be involved in establishing laterality in the heart and their roles in 
heterotaxic phenotypes.  !
Axenfeld-Reiger Syndrome: Pitx2 and FoxC1 
Axenfeld-Rieger syndrome (ARS) is a complex autosomal dominant disorder 
primarily characterized by anomalies of the anterior segment of the eye, face, teeth, 
and umbilical stump.  Congenital heart defects, including ASD, pseudotruncus 
arteriosus, and mitral valve and intraventricular septal defects have also been 
reported in a number of patients with ARS (Cunningham et al., 1998; Mammi et al., 
1998; Davies et al., 1999; Bekir and Gungor, 2000; Baruch and Erickson, 2001; 
Grosso et al., 2002; Maclean et al., 2005; Calcagni et al., 2006; Aysenur Pac et al., 
2008; Weisschuh et al., 2008; Antevil et al., 2009; Akkus and Argin, 2010).  Linkage 
analyses have identified four different loci in humans, 4q25, 6p25, 13q14, and 
16q24, each of which has been independently associated with ARS. Further 
analyses of 4q25 and 6p25 in patients with ARS have uncovered mutations in two 
genes, Pitx2 and Foxc1, respectively (Amendt et al., 2000; Hjalt and Semina, 2005; 
Maclean et al., 2005). 
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Pitx2 is a highly conserved homeodomain transcription factor that is 
expressed asymmetrically in the left lateral plate mesoderm in chick, zebrafish, 
Xenopus, and mouse embryos (Ryan et al., 1998; Campione et al., 1999). At heart-
forming stages, pitx2 expression continues to be restricted to the left half of the heart 
tube in Xenopus embryos. In mouse, Pitx2 is expressed in the left side of the heart 
tube and in the left ventricle, OFT, and atrium during heart looping (Ryan et al., 
1998). The defects observed in Pitx2 null and hypomorphic mice, such as altered 
looping of the heart, absence of atrial septation, and dysmorphic ventricular 
septation, recapitulate the defects observed in human ARS patients with Pitx2 
dysfunction (Gage et al., 1999; Lin et al., 1999; Lu et al., 1999).  
 
The use of Xenopus has been instrumental in understanding the dual role of 
Pitx2 in heart development, firstly in directing the looping of the heart tube and 
secondly in controlling the morphogenesis of the cardiac chambers. Misexpression 
of pitx2 by injection of its mRNA on the right side of the Xenopus embryo results in a 
reversal of heart looping, showing the conserved role of pitx2 in directing this event. 
The restricted expression of pitx2 is likely to be downstream of the TGFβ signaling 
family, as bilateral injections of mRNA encoding nodal or activin results in bilateral 
expression of the gene (Campione et al., 1999). Further, injection of a dominant 
negative form of the activin type II receptor into Xenopus embryos alters pitx2 
expression levels and subsequent heart looping. These findings are supported by 
similar experiments in chick (Ryan et al., 1998). Of the three isoforms of Pitx2 
present during development, experiments in Xenopus, zebrafish, and mouse 
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demonstrate that Pitx2c is the isoform that is specifically expressed in heart (Essner 
et al., 2000; Schweickert et al., 2000). The injection of modified antisense 
oligonucleotides that mediate degradation of pitx2c mRNA in Xenopus embryos 
results in cardiac defects that are very similar to phenotypes observed in Pitx2 
mutant mice, including abnormal atrial septation, extracellular matrix restriction, 
abnormal positioning of the atrial and ventricular chambers, and restriction of 
ventricular development. These tadpoles also exhibit dramatic straightening of the 
OFT, followed by a rightward migration (Dagle et al., 2003). This study demonstrates 
the conservation of pitx2 function in Xenopus cardiac development and its 
relationship to ARS. It has recently been shown that Pitx2 patterns the second heart 
field and is required to specify the left versus right atrium (Liu et al., 2002; Ai et al., 
2006; Galli et al., 2008). It will be interesting to determine if Xenopus can be 
exploited as a useful model for testing the effects of various ARS-derived mutations 
on Pitx2 function during second heart field development and for further identifying 
the mechanisms by which Pitx2 functions.  
 
Foxc1 is a member of the forkhead family of transcription factors and is 
expressed in endothelial and mesenchymal cells of the developing heart as well as 
in endocardial cushions derived from cardiac neural crest cells (Iida et al., 1997; 
Winnier et al., 1999; Kume et al., 2001; Seo et al., 2006). Foxc1 transcripts have 
also been detected in the second heart field and in the proepicardium (Seo and 
Kume, 2006). In the newly formed heart, Foxc1 is expressed in the atrial septum, the 
venous, aortic and pulmonary valves, and the mitral and tricuspid valves (Swiderski 
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et al., 1999).  Consistent with its widespread expression in the heart, FOXC1 plays a 
critical role in heart valve formation and atrial septation as suggested by the cardiac 
defects noted in mice mutant for Foxc1. Specifically, Foxc1 homozygous mutants 
display interruption or coarctation of the aortic arch, VSD, and pulmonary and aortic 
valve dysplasia (Winnier et al., 1999). Mice lacking both Foxc1 and the closely 
related Fox transcription factor Foxc2 have even more severe cardiac abnormalities 
consisting of hypoplasia or lack of the OFT and right ventricle as well as the inflow 
tract, and dysplasia of the OFT and atrioventricular cushions. These mice also have 
an abnormally formed epicardium, reduced cell proliferation, and increased 
apoptosis of neural crest cells (Winnier et al., 1999; Kume et al., 2001; Seo and 
Kume, 2006).  
 
Foxc1 has been identified in Xenopus and is present in cardiac lineages 
(Koster et al., 1998; Gessert and Kuhl, 2009). Depletion of foxc1 during early 
Xenopus development results in downregulation of adhesion molecules involved in 
mesoderm development and increased apoptosis, correlating with the phenotypes 
observed in the mouse mutants (Cha et al., 2007). It remains to be determined if 
reduction of FOXC1 levels in Xenopus has similar effects on cardiac morphology to 
those observed in mouse knockouts and patients with ARS.  However, the early 
phenotypes of FOXC1 depletion during Xenopus development provide a model in 
which to investigate the phenotypic changes that result from Foxc1 disruption. !!!
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CHARGE Syndrome: Chd7 
CHARGE syndrome (Coloboma, Heart defects, choanal Atresia, Retarded 
growth and development, Genital abnormalities, and Ear anomalies) is a complex 
disease associated with a number of cardiac abnormalities including Tetralogy of 
Fallot, atrioventricular canal defects, and aortic arch anomalies (Davenport et al., 
1986). The majority of individuals with CHARGE syndrome have mutations in the 
coding region of chromodomain helicase DNA binding protein 7 (Chd7) (Vissers et 
al., 2004; Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al., 2006; Delahaye 
et al., 2007; Wincent et al., 2008; Kaliakatsos et al., 2010; Wessels et al., 2010).  
 
Chd7 expression has been characterized in the chick and mouse, where it 
has been found to be expressed mainly in the neural ectoderm and branchial arches 
(Bosman et al., 2005; Aramaki et al., 2007; Hurd et al., 2007). Mutant Chd7 mice 
display defects in neural stem cell proliferation, olfaction, and some cardiac defects, 
including formation of the interventricular septum (Bosman et al., 2005; Adams et al., 
2007; Hurd et al., 2007; Layman et al., 2009). It has been proposed that the multiple 
phenotypes in CHARGE syndrome are caused by defects in neural crest cell (NCC) 
migration (Siebert et al., 1985). Recently, Chd7 was found to be expressed in 
Xenopus NCCs as well as in human NC-like cells. MO knockdown of chd7 in 
Xenopus perturbs the migration of NCCs to the pharyngeal arches. This phenotype 
is partially rescued by injecting human Chd7 mRNA, suggesting that the molecular 
function of CHD7 is well-conserved. In addition, overexpression of human Chd7 with 
a substitution of a conserved lysine residue in its ATPase domain results in a 
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dominant-negative effect (Bajpai et al., 2010). This dominant negative effect 
recapitulates the major features of CHARGE syndrome described above, including 
abnormal positioning of the truncus arteriosus and OFT. Analysis of markers 
associated with NCCs reveal that chd7 is not required for the induction or survival of 
NCCs, but for their specification. The expression of sox9, twist, and slug, genes that 
mark multipotent, migrating NCCs, is severely perturbed in chd7 downregulated 
embryos (Sauka-Spengler and Bronner-Fraser, 2008; Bajpai et al., 2010). These 
studies in Xenopus have provided a powerful in vivo model in which to study the role 
of NCCs in heart development and the CHDs that result from improper NCC 
migration and specification. More recently, the chromatin remodeling factors CHD8 
and BRG1 have been shown to physically interact with CHD7 (Bajpai et al., 2010; 
Batsukh et al., 2010) and Brg1 was demonstrated to play a role in regulating cardiac 
growth and differentiation (Hang et al., 2010). The roles of Chd8 and Brg1 in a 
Xenopus model of CHARGE syndrome could aid in the understanding of this 
complex syndrome. !
FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES IN XENOPUS 
Investigating a Role for the Epicardium in Congenital Heart Disease  
The epicardium is a mesothelial sheet of cells surrounding the myocardium of 
the developing looped heart in many vertebrate organisms (Ho and Shimada, 1978; 
Viragh and Challice, 1981; Hirakow, 1992; Manner et al., 2001; Jahr et al., 2008; 
Pombal et al., 2008; Serluca, 2008). The epicardial structure arises from the pro-
epicardial organ (PEO), which is situated on the sinus venosus. These mesothelial 
cells cluster and bridge over towards the ventricular surface of the heart and migrate 
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onto the myocardial surface as an epithelial-like sheet. Subsequently, subsets of 
epicardial cells undergo epithelial-mesenchymal transition (EMT) and migrate into 
the sub-epicardial space and myocardium where they differentiate into various cell 
populations including fibroblasts and smooth muscle cells of the coronary 
vasculature (Manner et al., 2001; Lie-Venema et al., 2007; Winter and Gittenberger-
de Groot, 2007). The epicardium is thought to play a mitogenic role in cardiomyocyte 
growth and has been shown to be important for cardiac repair in adult zebrafish 
(Lepilina et al., 2006). Recently, adult human epicardium-derived cells (EPDCs) 
were demonstrated to have a paracrine role in improving mammalian cardiac 
function when co-transfected with cardiomyocytes into an infarcted murine heart 
(Winter et al., 2007; Winter et al., 2009). Thus, the epicardium may have the 
potential to stimulate cardiac repair and regeneration, given the right conditions. 
 
 Various congenital heart diseases display abnormalities that may arise from 
improper epicardium formation or differentiation of EPDCs. In avian embryos in 
which either the pro-epicardial organ is ablated or the epithelial-mesenchymal 
transition of EPDCs is disrupted, defects are seen in the compact layer of the 
myocardium, while the inner curvature of the heart is wider and often displays a 
double outlet right ventricle, indicative of a heart looping defect (Gittenberger-de 
Groot et al., 2000; Lie-Venema et al., 2005; Manner et al., 2005). Ventricular non-
compaction is also seen when genes involved in epicardium formation, e.g., Wt1 and 
RXRα, are knocked out in the mouse (Moore et al., 1998; Merki et al., 2005). In 
addition to their roles in regulating the development of the compact ventricular and 
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atrial myocardia, EPDCs are involved in the development of cardiac structures 
associated with the conduction system. The annulus fibrosus, which plays an 
important insulating role in the cardiac conduction system, is derived from the 
epicardium, and EPDCs also influence the formation of the peripheral Purkinje fiber 
network from ventricular cardiomyocytes (Eralp et al., 2006; Zhou et al., 2010). 
Electrophysiological cardiac defects, such as Wolff-Parkinson-White syndrome and 
Mahaim tachycardia, may therefore have an origin in improper epicardium or EPDC 
formation. 
 
     EPDCs also contribute cells to the atrioventricular cushions and valves, and 
disrupting epicardium formation can lead to aberrant valve formation (Gittenberger-
de Groot et al., 1998; Gittenberger-de Groot et al., 2000; Perez-Pomares et al., 
2002; Manner et al., 2005). It is conceivable that disorders in which the valve leaflet 
has not fully delaminated - for example, Ebstein’s anomaly (tricuspid valve leaflet) - 
might result from defects in epicardial patterning or signaling (Attenhofer Jost et al., 
2005; Lie-Venema et al., 2007). Ventricular non-compaction may also be indicative 
of an epicardial defect as shown by mouse knockout models of genes involved in 
epicardium formation, e.g., Wt1 and RXRα, or in PEO ablation studies in chick 
(Moore et al., 1998; Manner et al., 2005; Merki et al., 2005; Sucov et al., 2009). 
Interestingly, the Fog-2 knockout mouse, which has an epicardial defect phenotype, 
displays many of the anomalies described above - including tricuspid atresia, thin 
myocardium, double outlet right ventricles, and VSD (Svensson et al., 2000; 
Tevosian et al., 2000; Clark et al., 2006). 
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To date, little is known about how the epicardium develops and functions in 
Xenopus embryos. Scanning electron microscopy has demonstrated the presence of 
the PEO on the right side of the septum transversum in Xenopus embryos, similar to 
other vertebrates (Jahr et al., 2008). Furthermore, genes characteristic of the 
vertebrate PEO and epicardium are conserved in Xenopus (Jahr et al., 2008). The 
Xenopus model lends itself to studying the epicardium and potential defects in valve 
formation and conduction systems due to the ease of manipulating gene function 
and the established techniques of tissue explanting, antisense MO microinjection, 
lineage tracing, and transgenics. Recent advances in live imaging have enabled 
researchers to utilize the Xenopus model to visualize cardiac development in real 
time and to use non-invasive electrical recording, Doppler optical cardiograms, and 
optical coherence tomography to study heart structure, conduction, and blood flow to 
determine the role of the epicardium in these processes (Bartlett et al., 2004; 
Mariampillai et al., 2007; Yelin et al., 2007; Kieserman et al., 2010).  !
In Vivo Imaging of the Developing Xenopus Heart  
Xenopus embryos are very well-suited for live imaging of dynamic 
developmental processes due to their large size and external development. Because 
of the large size of the embryos, individual cells in the embryo are larger, which 
allows visualization of the subcellular localization and dynamics of a given 
fluorescent fusion protein. For example, live confocal imaging has been successfully 
used to demonstrate the dispersal of individual fluorescent myeloid cells throughout 
the Xenopus embryo (Kieserman et al., 2010). A combination of transgenesis and 
advanced imaging tools makes this type of approach feasible in the living animal. 
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Yolk opacity in the early Xenopus embryo presents a challenge for imaging of 
deeper tissues. However, cells and/or deep tissues can be visualized easily after 
microsurgery and subsequent culture of tissue explants. High resolution imaging of 
the structure and function of the developing myocardium will be critical to complete 
our understanding of how the heart develops in three and four dimensions, and thus 
how developmental defects can arise in this system. 
 
Historically, the morphology of the Xenopus embryonic heart has been 
studied in fixed embryos with a combination of confocal microscopy and 3D 
reconstruction of serial sections through the heart (Kolker et al., 2000; Mohun, 
2000). As even slight morphological or dynamic changes in the heart can result in 
myocardial dysfunction, it is of vital importance to examine these changes in vivo in 
the developing embryo. One area in which this is particularly relevant is in the 
characterization of defects in the cardiac conduction system. Human CHD is often 
complicated by atrioventricular conduction abnormalities. However, a thorough 
understanding of the defects in embryonic heart contraction as they result from a 
genetic or morphological abnormality is lacking due to the difficulty of examining 
these defects in vivo. It has recently been demonstrated that the Xenopus embryo is 
amenable to noninvasive live video analysis of the conduction system, allowing one 
to examine the properties of chamber contraction in vivo (Bartlett et al., 2004). 
Moreover, Xenopus cardiac electrophysiology shares many characteristics with the 
human conduction system, making it an ideal model in which to analyze the 
physiology of cardiac conduction defects. As a proof of principle, this methodology 
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has been used to examine the microscopic timing of heart contraction in embryos 
injected with two human Nkx2.5 mutants and resulted in the identification of a 
number of conduction defects including a delay in the AV interval and a distinct 
tachycardia (Bartlett et al., 2007). This type of study, when applied to other human 
mutations such as those in Tbx5 that cause Holt-Oram Syndrome, can improve our 
understanding of these complex human pathologies. !
Protein Interactions and Biochemical Function 
As discussed previously, transgenesis has primarily been used to study the 
regulation of gene expression and has revealed much about the transcriptional 
regulation of cardiac development. However, it has been used relatively little as a 
tool for isolating protein complexes. Because protein complexes mediate the 
majority of cellular processes, knowledge of the composition and function of cardiac-
specific protein complexes will provide key insights into their tissue-specific activity 
in the heart. With the advent of proteomics-based approaches to identify 
endogenous protein complexes, there are a variety of convenient in vivo tags such 
as GFP that can be used to genomically label any protein of interest. Thus, the 
generation of transgenic Xenopus lines that express tagged versions of proteins will 
provide virtually unlimited material for applications such as mass spectrometry and 
protein localization studies.  Additionally, tagged proteins carrying known CHD-
causing mutations could be utilized to characterize changes in their ability to form 
complexes with other cardiac proteins. As discussed previously, deficiencies in 
members of cardiac transcriptional complexes often lead to congenital heart 
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malformations, illuminating the need to investigate the functional role of these 
complexes during cardiac development. !
Genetic Approaches in Xenopus tropicalis 
To date, most studies that have used Xenopus as a model system to examine 
cardiac development have used the pseudotetraploid species Xenopus laevis and 
have relied upon well-established nucleic acid microinjection techniques for 
depletion or over-expression of proteins in the developing embryo. As our 
understanding of the genetic basis of inherited cardiac disease increases, there will 
be a greater need to use genetic approaches in Xenopus. Genetic techniques 
enable precise experimental manipulation that can be used to gain a deeper 
understanding not just of individual gene functions, but also of the interconnectivity 
between genes in genetic networks (through enhancer/suppressor gene interaction 
studies, for example). These interconnections, coupled with variation in the genetic 
background, may ultimately explain the range of disease type and severity often 
observed in patients with particular CHDs (Basson et al., 1994; Newbury-Ecob et al., 
1996; Sznajer et al., 2007). The use of loss-of-function or gain-of-function alleles of 
endogenous genes that are generated by mutagenesis also circumvents the 
undesirable features of MO-based inhibition and mRNA-based expression that result 
from the inherent limitations in controlling where and when MOs or mRNAs are 
active in the embryo. Specifically, the role of mutations that affect the biochemical 
function of a protein can be examined without inappropriately expressing the mutant 
protein in cells in which the native protein is not expressed, or at times at which it 
would not normally be present. 
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 The diploid Xenopus tropicalis is much more amenable to genetic analysis 
than the pseudotetraploid X. laevis. Fortunately, the vast majority of reagents and 
techniques developed by researchers for X. laevis can be adapted for use with X. 
tropicalis, primarily due to the extremely close similarities between the two species 
at the genetic and embryonic levels. Even complex reagents such as microarrays 
developed in one Xenopus species have been shown to be usable in both, although 
species-specific reagents are becoming increasingly available (Chalmers et al., 
2005). A key factor encouraging researchers to adopt X. tropicalis is the availability 
of a high-quality genome sequence and the resources that have stemmed from it, 
including a simple-sequence repeat map of more than 1,500 polymorphic markers 
that allows mutations to be mapped to relatively small regions of the genome 
following their isolation in forward genetic screens (Xu et al., 2008; Hellsten et al., 
2010) (http://tropmap.biology.uh.edu/index.html). The first two mutations mapped in 
X. tropicalis, Muzak and Dicky Ticker, both affect cardiac function and are located in 
the myosin heavy chain gene myh6 and the muscle-specific chaperone gene 
unc45b, respectively (Abu-Daya et al., 2009; Geach and Zimmerman, 2010). These 
early successes validate X. tropicalis as a model in which novel cardiac genes can 
be identified through phenotype-based forward genetic screens. The primary 
importance of this work will be to gain a better understanding of the developmental 
genetics of cardiac cell type differentiation and morphogenesis. However, studying 
the effects of mutations in disease-associated genes is also likely to advance our 
understanding of the etiology of congenital heart abnormalities. 
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Table A1.1. Xenopus models of human congenital heart disease. 
 
Gene 
Name Disease 
Cardiovascular 
Manifestations 
Xenopus 
Model 
Xenopus Cardiac 
Phenotype Refs 
Tbx1 DiGeorge 
Syndrome 
TOF, persistent truncus 
arteriosus 
overexpression of 
dominant 
negative  
unlooped heart, 
pericardial edema 
(Ataliotis et al., 
2005) 
Tbx5 Holt-Oram 
Syndrome 
ASD, VSD, cardiac 
conduction system 
defects 
overexpression of 
dominant 
negative 
 
protein depletion 
unlooped heart 
 
 
unlooped heart, loss of 
cardiac cells 
(Horb and 
Thomsen, 
1999) 
 
(Brown et al., 
2005) 
Tbx20 NA ASD, VSD, valve 
disease, pulmonary 
hypertension, 
cardiomyopathy, TOF 
protein depletion unlooped heart, 
pericardial edema, loss 
of cardiac cells 
(Brown et al., 
2005) 
Nkx2.5 NA ASD, cardiac 
conduction system 
defects 
overexpression 
 
overexpression of 
dominant 
negative  
 
overexpression of 
mutant mRNA 
enlarged heart 
 
reduced heart 
 
 
ASD, cardiac 
conduction system 
defects 
(Cleaver, 1996) 
 
(Fu, 1998; 
Grow and 
Krieg, 1998) 
 
(Bartlett et al., 
2007) 
Gata4 NA ASD protein depletion partial fusion of heart 
fields, cardiac bifida, 
abnormal cardiac 
looping 
(Haworth et al., 
2008) 
Shp2 Noonan 
Syndrome 
ASD, VSD, pulmonary 
stenosis, hypertrophic 
cardiomyopathy 
chemical 
inhibition 
unfused heart fields, 
loss of cardiac cells 
(Langdon et al., 
2007) 
Zic3 Heterotaxy cardiac looping 
defects, ASD, VSD, 
transposition of the 
great arteries, double 
outlet right ventricle, 
ventricle and aortic 
arch defects 
overexpression abnormal cardiac 
looping 
(Kitaguchi et al., 
2000; Kitaguchi 
et al., 2002) 
Pitx2 Axonfeld-
Reiger 
Syndrome 
ASD, pseudotruncus 
arteriosus, mitral valve 
and intraventricular 
septal defects 
overexpression 
 
overexpression of 
dominant 
negative  
 
protein depletion 
abnormal cardiac 
looping 
 
abnormal cardiac 
looping 
 
 
abnormal atrial 
septation, defects in 
atrial and ventricular 
chamber position, 
restriction of ventricular 
development 
(Campione et 
al., 1999) 
(Campione et 
al., 1999) 
 
(Dagle et al., 
2003) 
Chd7 CHARGE 
Syndrome 
TOF, atrioventricular 
canal defects, aortic 
arch defects 
protein depletion 
 
 
overexpression of 
mutant mRNA 
defects in neural crest 
cell migration 
 
abnormal positioning of 
truncus arteriosus and 
OFT 
(Bajpai et al., 
2010) 
 
(Bajpai et al., 
2010) 
TOF, Tetralogy of Fallot; ASD, atrial septal defects; VSD, ventricular septal defects; NA, Not Applicable; OFT, 
outflow tract 
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Appendix 2 
Immunoisolation of protein complexes from Xenopus 
 
Preface 
 This work was published as an in-depth technical article as part of the series 
Xenopus Protocols: Post-Genomic Approaches (ed. Stefan Hoppler and Peter D. 
Vize) in the journal Methods in Molecular Biology. It is based on a collaboration 
between our laboratory and Ileana Cristea’s group at Princeton University to 
optimize the immunoisolation of protein complexes from Xenopus embryonic tissue. 
I contributed a western blot demonstrating assessment of isolation efficiency of a 
GFP-tagged protein and to the writing of the manuscript itself. The article was 
conceived and finalized by Frank Conlon and Ileana Cristea. 
 
Conlon F.L., Miteva Y., Kaltenbrun E., Waldron L., Greco T.M., and Cristea I.M. 
(2012) Immunoisolation of protein complexes from Xenopus. Methods in Molecular 
Biology, vol 917: 369-390. 
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ABSTRACT 
The immunoaffinity isolation of protein complexes is an essential technique 
for the purification and concentration of protein complexes from cells and tissues. In 
this chapter we present the methodologies for the purification of proteins and protein 
complexes from Xenopus laevis and Xenopus tropicalis. Specific to this protocol are 
the techniques for the cryolysis of Xenopus cells and tissues, a procedure that limits 
contamination from yolk proteins while preserving endogenous protein complexes, 
the methodologies for immunoaffinity purification of proteins using magnetic beads, 
and the protocols for western blot analysis. In addition, the procedures in this 
chapter can be extended to use with proteomic analysis of protein complexes as 
presented in the following chapter. 
 
INTRODUCTION 
It is becoming increasingly clear that many forms of human disease are 
associated with defects in genes that are required for early steps in embryonic 
development. Moreover, the molecular and cellular pathways through which these 
genes function can be elucidated using established model systems such as the 
African clawed frog, Xenopus. Xenopus has numerous advantages as a model 
system in which to identify and characterize cellular and developmental processes 
particularly in regards to proteomic-based approaches. Most critically, unlike the 
mouse, the Xenopus embryo develops externally and the embryo is relatively large 
and is amenable to surgical manipulations, allowing defined regions to be excised 
and cultured in simple salt solutions. These classical approaches are complemented 
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by molecular techniques that allow the ectopic expression, overexpression, or 
knock-down of specific gene transcripts in the early embryo, and transgenic 
technologies.  
 
 Complementary to these approaches are emerging biochemical approaches. 
In this regard, Xenopus offers a unique model system for the identification and 
characterization of protein complexes in vivo. However, the use of these approaches 
has been limited due to the lack of optimized protocols for isolation of early stage 
Xenopus tissues and the large abundance of yolk proteins. As shown in Figure A2.1, 
this chapter describes methods for conducting immuno-precipitation of endogenous 
protein complexes in Xenopus laevis and Xenopus tropicalis which combines the 
cryogenic lysis of tissues with immunoisolation on magnetic beads. An overview of 
the approach is shown in Figure A2.1. Collectively, these approaches function to 
preserve endogenous protein complexes, limit problems associated with yolk 
platelets, and proved a specific isolation of a given protein. 
 
METHODS AND EQUIPMENT 
Obtaining Xenopus laevis embryonic tissue 
1. Fine watchmaker’s forceps such as Dumont number 5 forceps. 
2. X. laevis embryos cultured to desired stage of development (Nieuwkoop, 1994) 
3. 10X Modified Barth’s Saline (MBS), pH 7.8: 880 mM NaCl, 10 mM KCl, 10 mM 
MgSO4, 50 mM HEPES pH 7.8, 25 mM NaHCO3. 1X MBS is made by mixing 
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100 mL of 10X stock solution with 700 µL 1 M CaCl2 and adjusting the volume 
to 1 L with dH2O. Store at room temperature. 
4. 1% agarose plates for dissections: Weigh 1 g agarose and transfer to 250 mL 
Erlenmeyer flask containing 100 mL dH2O. Heat flask in microwave until 
agarose has completely dissolved. Cool molten agarose until cool enough to 
hold flask. Pour a layer of agarose into small plastic petri dishes (5 cm). Allow 
agarose to set. Store plates at 4°C. 
5. Plastic transfer pipettes 
6. Liquid nitrogen 
7. Syringe needle (19G1½) 
8. 50 mL conical tubes 
9. A dissecting microcope (e.g. Leica MZ6) 
 
Tissue lysis and protein extraction 
1. Retsch MM 301 Mixer Mill with 2 X 25 mL jars and 2 X 20 mm (tungsten 
carbide or stainless steel) grinding balls (Retsch, Newtown, PA). 
2. Liquid nitrogen, Styrofoam container and a pair of long forceps 
3. Windex 
4. Methanol 
5. 50 mL conical tubes 
6. Ultrapure water   
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Immunoaffinity purification of protein complexes 
Conjugation of magnetic beads 
Unless otherwise stated all solutions can be stored at room temperature 
1. Dynabeads M-270 Epoxy (Invitrogen).  
2. Affinity purified antibodies against a protein of interest or tag (e.g., anti-GFP 
antibodies as shown below for the isolation of GFP-tagged proteins), or 
Immunoglobulin G (for isolation of Protein A-tagged proteins).   
3. 0.1 M Sodium Phosphate buffer, pH 7.4:  Prepare as 19 mM NaH2PO4, 81 mM 
Na2HPO4 in water and adjust pH to 7.4, if necessary. Filter sterilize (0.2 µm 
filter (Millipore)). Store at 4°C.   
4. 3 M Ammonium Sulfate: Prepare in 0.1 M Sodium Phosphate buffer, pH 7.4. 
Filter sterilize (0.2 µm filter (Millipore)).   
5. 100 mM Glycine-HCl, pH 2.5: Prepare in water. Adjust pH to 2.5 with HCl. Filter 
sterilize (0.2 µm filter (Millipore)). Store at 4°C.    
6. 10 mM Tris, pH 8.8: Prepare in water. Adjust pH to 8.8 with HCl. Filter sterilize 
(0.2 µm filter (Millipore)). 
7. 100 mM Triethylamine: Prepare fresh in water. CAUTION: toxic and extremely 
flammable. Must handle in a chemical hood and dispose of appropriately.   
8. DPBS, pH 7.4 (Dulbecco's Phosphate-Buffered Saline (1X), liquid), (Invitrogen): 
Store at 4°C. 
9. 0.5% Triton X-100: Prepare in DPBS. Store at 4°C. 
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10. 0.02% Sodium azide (NaN3): Prepare in DPBS. Store at 4°C. CAUTION: NaN3 
is a toxic solid compound. Must handle in a chemical hood and dispose of 
appropriately.   
11. Rotator (at 30°C)   
12. Magnetic separation tube rack (Invitrogen) 
13. Tube shaker (Tomy shaker) 
14. Round bottom 2 mL Safe-Lock tubes (Eppendorf) 
15. Ultrapure water (e.g., from a Milli-Q Integral Water Purification System) 
 
Immunoaffinity purification 
1. Frozen tissue powder (see section Obtaining Xenopus laevis embryonic tissue) 
2. Optimized lysis buffer (See section Tissue lysis and protein extraction) 
prepared fresh prior to each experiment.  
3. Magnetic beads conjugated with antibodies (see section Conjugation of 
magnetic beads) 
4. 50 mL conical tubes 
5. Polytron for tissue homogenization (e.g., PT 10-35 Polytron from Kinematica) 
6. Centrifuge and rotor, compatible with 50 mL conical tubes and capable of 8000 
x g at 4°C 
7. Tube rotator at 4°C 
8. Ultrapure dH2O 
9. Round bottom eppendorf tubes (Fisher) 
10. Axygen Maxymum Recovery microcentrifuge tubes, 1.5 mL (VWR)  
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11. Bar magnets (for conical tubes) and magnetic separation rack (for eppendorf 
tubes) (Invitrogen) 
12. Ammonium hydroxide, 14.8 M (Sigma). Store at 4°C. 
13. Base elution buffer: Mix 4.826 mL of ultrapure H2O, 5 µL of 0.5 M EDTA, pH 
8.0, and 169 µL of ammonium hydroxide. Prepare fresh before use. 
14. 4X LDS elution buffer: Dissolve 0.666 g of Tris-HCl, 0.682 g of Tris-Base, 0.8 g 
of LDS, and 0.006 g of EDTA (free acid) in ultrapure dH2O to a final volume of 
10 mL.  Aliquot and store at -20°C. 
15. 10X Reducing Agent (Invitrogen) 
16. 1M iodoacetamide (IAA) (Sigma): Dissolve 0.185 g of iodoacetamide in 1 mL 
HPLC grade water. Dispense into 50 x 20 ml aliquots and store at -20°C 
17. Heat block at 70°C 
 
Assessment of immunoaffinity purification: Sample preparation 
1. Reserved fractions (from section Basic elution of immunoisolates) 
a. Cell pellet (step 7) 
b. Input Supernatant (step 7)  
c. Flow-through (step 11) 
d. Primary eluate (step 21)  
e. Secondary eluate (step 18) 
2. Ultrapure dH2O 
3. Acetone (-20°C) 
4. 1.7 mL eppendorf tubes (Fisher) 
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5. Microcentrifuge 
6. NuPAGE 4-12% Bis-Tris pre-cast SDS-PAGE gel, 10 well (Invitrogen) 
7. Xcell SureLock Mini-Cell electrophoresis system (Invitrogen) 
1. 20X NuPAGE MOPS SDS Running Buffer (Invitrogen) 
8. 4X NuPAGE LDS Sample Buffer (Invitrogen) 
9. 10X Reducing Agent (Invitrogen) 
10. Heat block at 70°C 
 
Assessment of immunoaffinity purification: SDS-PAGE and western blot analysis 
1. Prepared fractions (from section Assessment of immunoaffinity purification: 
Sample preparation) 
a. Cell pellet (step 1) 
b. Input supernatant (step 2)  
c. Flow-through (step 3) 
d. Secondary eluate (step 4)  
e. Primary eluate (step 5) 
2. NuPAGE 4-12% Bis-Tris gel, 10 well (Invitrogen) 
3. Xcell SureLock Mini-Cell electrophoresis system (Invitrogen) 
4. 20X NuPAGE MOPS SDS Running Buffer (Invitrogen) 
5. 1X Running Buffer: Dilute 20X NuPAGE MOPS SDS Running Buffer in 700 mL 
of ultrapure water. 
6. Precision Plus Protein Dual Color Molecular Weight Standards (BioRad) 
7. 4X NuPAGE LDS Sample Buffer (Invitrogen) 
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8. 10X Reducing Reagent (Invitrogen) 
9. PVDF membrane (BioRad) 
10. Methanol 
11. Transfer apparatus (e.g. Mini Trans-blot Cell from BioRad) 
12. 10X Transfer Buffer: Dissolve 144 g glycine and 30.3 g Tris base in final 
volume of 1 L dH2O. Prepare 1L of 1X Transfer Buffer containing 20% 
methanol. Chill at 4°C for 30min before use. 
13. 2 x Whatman filter paper and 2 x sponges for transfer 
14. 20X TBST: 200 mM Tris-HCl pH 8, 3 M NaCl, 2% Tween-20 in dH20. Dilute to 
1X with dH20 for use. 
15. Blocking Buffer: 5% non-fat dry milk powder in 1X TBST. 
16. Appropriate primary and secondary antibodies, diluted in Blocking Buffer 
17. Autoradiography cassette (FisherBiotech Cat# FBCA 57) 
18. ECL chemiluminescent substrate kit (Thermo Scientific) 
19. Autoradiography film (Kodak) 
 
METHODS AND PROCEDURES 
Obtaining Xenopus laevis embryonic tissue 
 Of all the proteins in X. laevis embryonic tissue, yolk proteins are among the 
most abundant, especially at earlier developmental stages when the embryo is still 
dependent on yolk for nutrients. The abundance of yolk proteins can be problematic 
when performing immunoaffinity purifications, as these proteins can nonspecifically 
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react with antibodies and mask a less abundant interaction. For this reason, it is 
desirable to remove as much of the yolk from the embryo as possible. 
 
1. Fill a 1% agarose plate with cold 1X MBS. Transfer X. laevis embryos to MBS in 
agarose plate. 
2. Using fine forceps and a dissecting microscope, remove as much of the yolk as 
possible from the rest of the embryo. Using a plastic transfer pipette, transfer the 
embryo to a new agarose plate containing fresh 1X MBS. Keep tissue on ice 
until all dissections are completed. Collect appropriate number of embryos for 
each immunopurification to be performed (See Note 1). 
3. Using a syringe needle, poke 4 holes in the cap of a 50 mL conical tube. 
Remove cap and secure tube into a rack in a styrofoam cooler. Fill cooler and 
tube with liquid nitrogen. 
4. Using a plastic transfer pipette, drop embryos one by one into liquid nitrogen in 
conical tube (see Note 4). When finished, replace the cap and screw on tightly. 
Remove the tube from the cooler (using a paper towel for protection) and invert 
to remove the liquid nitrogen. Store frozen tissue at -80°C. 
 
Tissue lysis and protein extraction 
 Tissue lysis can be carried out utilizing several approaches, including 
homogenization in a detergent-containing lysis buffer, passage through a needle 
(different needle gauges can be tested for efficiency of lysis), and cryogenic tissue 
disruption using traditional mortar and pestle or a Mixer Mill. While the procedures 
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described below for immunoaffinity purification of protein complexes utilize as 
starting material tissue disrupted cryogenically using a Mixer Mill, the other types of 
tissue lysis can also be incorporated. We prefer the type of cryogenic disruption 
described below as it leads to an increased efficiency of extraction (i.e., isolation of 
the targeted protein) and decreased level of non-specific associations. This method 
has provided us with a reliable and effective means of cell lysis for isolating varied 
protein complexes (Cristea et al., 2005; Cristea et al., 2006; Carabetta et al., 2010; 
Goldberg et al., 2010; Moorman et al., 2010; Greco et al., 2011). In circumstances 
that require a mild tissue lysis, such as the maintenance of intact organelles or large 
structures, e.g postsynaptic densities (Selimi et al., 2009), cryogenic disruption may 
not be the method of choice.  
 
Cryogenic tissue disruption 
1. Clean one spatula, the Retsch Mixer Mill jars, and the grinding balls 
sequentially with ultrapure dH2O, Windex, ultrapure dH2O, and 100% methanol. 
Allow all parts to dry completely in a chemical hood. 
2. Cool the jars and balls in liquid nitrogen (e.g., using a Styrofoam container filled 
with liquid nitrogen). Once cooled (i.e., liquid nitrogen no longer appears to be 
bubbling) remove them from the liquid nitrogen container using a pair of long 
forceps and place the frozen tissue into the jar. The tissue can fill up to a 
maximum of one third of the total volume of the jar for optimal cryogenic 
grinding (e.g., ~7 g frozen tissue pellets per 25 mL jar). Add the chilled ball on 
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top of the tissue (use one ball per jar), close the jar, and place it back into the 
liquid nitrogen container to cool. 
3. Place the filled jars in the Retsch Mixer Mill holders. If only one jar contains 
frozen tissue for grinding, then use the other empty jar (without a ball) as a 
balance. Grind the tissue using 20 cycles of 2 minutes 30 seconds each at a 
frequency of 30 Hz. Place the jars in liquid nitrogen in between cycles to cool, 
and ensure that the jars are still tightly closed.  
4. Open the jar and use a chilled spatula to transfer the frozen tissue powder to a 
50 mL conical tube kept on dry ice. Work as quickly as possible to avoid 
thawing of the ground sample. Periodically chill the spatula in liquid nitrogen. 
Store the powder at -80°C until immunopurification is to be performed. 
 
Optimization of lysis buffer and isolation conditions 
Successful isolation of a protein of interest and its interacting partners is 
dependent on several criteria including protein abundance and subcellular 
localization, sample amount, affinity of the antibody used for immunoaffinity 
purification, efficiency of bead conjugation, and lysis buffer conditions for 
immunoaffinity purification. During the cell lysis and protein isolation steps it is 
crucial to extract and preserve the targeted protein with its interactions in a soluble 
fraction. Therefore, the lysis buffer conditions utilized prior and during the affinity 
purification have to be optimized for each protein of interest before proceeding with 
larger scale immunoaffinity purifications for proteomics studies.  This can be done by 
performing small scale experiments (i.e., 20 embryos per immunopurification) that 
! 287!
use western blotting to assess 1) the efficiency of protein solubilization (see 
procedure below) and 2) efficiency of isolation (see section Assessment of 
immunoaffinity purification). It is recommended to compare at least three lysis buffer 
conditions with varied levels of stringency. Generally, the stringency of a lysis buffer 
is determined by the concentrations and combinations of detergents and salts. Table 
A2.1 provides examples of frequently used detergents, and Table A2.2 lists several 
lysis buffers that differ slightly in their compositions and were successfully utilized in 
immunoaffinity purifications of protein complexes from varied species.  
 
1. Split cryogenically ground tissue into equal small aliquots (e.g., 0.1 g) (see Note 
2). Ensure that the tissue power does not thaw during the weighing. 
2. Place the small aliquots on ice (4°C) and add a different lysis buffer (5 mL 
buffer per 1 g cells) to each sample.  
3. Homogenize the tissue powder in the buffer by vortexing for 1 min with 
intermittent cooling. This step is different than the usual homogenization for 
immunoaffinity purifications, which uses a polytron and a larger volume for the 
starting material. 
4. Separate the soluble and insoluble fractions by centrifugation at 8000 x g at 
4°C for 10 minutes. Recover soluble fraction and label “supernatant” 
5. Wash the pellet in water and discard supernatant. Extract pellet by sequential 
sonication then boiling at 95°C for 5 min in 50 mM Tris-HCl, pH 7.4, containing 
2% SDS.  Centrifuge at 20,000 x g for 10 min.  Recover supernatant and label 
“Pellet”. 
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6. Assess the levels of bait protein in the supernatant and pellet fractions (5 – 
10% aliquots) using western blotting and antibodies against either the affinity 
tag (if present) or the endogenous protein. 
7. To proceed with a larger scale immunoaffinity purification for proteomics 
analyses, select the lysis buffer condition that provides the highest proportion of 
bait protein in the soluble fraction, at the lowest necessary stringency. This will 
allow for a balance between an efficient extraction of the protein of interest and 
maintenance of interacting partners (see Note 3). 
 
Immunoaffinity purification of protein complexes 
Conjugation of magnetic beads 
This protocol has been optimized for conjugation of Dynabeads M-270 Epoxy, 
however it can also be applied for conjugation of other types of magnetic beads with 
larger or smaller diameters. In such cases, it is important to adjust the amount of 
antibody used for conjugation, depending on the bead capacity of binding. This 
protocol can be utilized for conjugating beads with high-affinity purified in-house 
developed antibodies as well as commercially available ones, provided their storage 
buffer doesn’t hinder covalent conjugation to Epoxy.   
 
It is best to start this protocol in the late afternoon and perform all washing 
steps (Step 7-10) in the morning of the following day. Unless otherwise stated all 
steps should be performed at room temperature. Do not allow the beads to dry out 
(i.e., do not keep the beads without a washing solution in between the steps).  
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1. Weigh out the necessary amount of magnetic Dynabeads in a round-bottom 
tube.  
a. Round-bottom tubes are preferred to avoid the trapping of beads in conical-
shape tubes during the conjugation.  
b. The necessary amount of beads is dependent on the purpose of the 
experiment and the abundance of the protein that will be immunoaffinity 
purified. An approximate guidance: 1-2 mg beads are appropriate for small-
scale optimization experiments, 5-7 mg beads are usually sufficient for 
performing single immunoaffinity purifications, and 10-20 mg beads are 
suitable for highly abundant proteins. 
2. Add 1 mL Sodium Phosphate buffer pH 7.4 to the beads; mix by vortexing for 
30 sec, followed by 15 min on a tube shaker (vigorous setting).  
3. Place the tube on a magnetic rack. After all the beads settle towards the 
magnetic side, discard the buffer.  
4. Remove the tube from the rack. Add 1 mL Sodium Phosphate buffer pH 7.4. 
Mix by vortexing for 30 sec and remove the buffer in the same manner as 
above. 
5. Remove the tube from the rack. Add, in this order, the necessary amount of 
antibodies, Sodium Phosphate buffer, and Ammonium Sulfate solution.  
a. The optimal total volume during the beads conjugation (that includes the 
antibody, Sodium Phosphate buffer, and Ammonium Sulfate solution) is ~ 20 
µl/mg beads  
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b. As a guideline of amounts of antibodies or IgG that we routinely use: 8-10 µg 
Ab/mg beads for commercially available antibodies and IgG, and 3-5 µg 
Ab/mg beads for purified high-affinity antibodies (e.g., in-house developed 
anti-GFP antibodies).  
c. The 3 M Ammonium Sulfate solution is added last and will be one third of total 
volume to give a final concentration of 1 M. 
d. For example, to conjugate 18 mg beads, use a total volume of 360 µL. For 
this, add 54 µg antibody to beads (if using 3 µg Ab/mg beads), then add 0.1 
M Sodium Phosphate Buffer (volume 0.1 M Sodium Phosphate Buffer = 360 
µL – volume of antibody used – 66.7 µL 3M Ammonium Sulfate), then add 
66.7 µL of 3 M Ammonium Sulfate. 
6. Secure the tube with parafilm and rotate bead slurry overnight on rotator at 
30°C. 
7. The next morning, place the tube with bead slurry on a magnetic rack. Remove 
and reserve the supernatant to assess the efficiency of bead conjugation by 
SDS-PAGE (See Note 4).  
8. Wash the beads sequentially with the following buffers. For each wash, gently 
resuspend the beads in 1 mL of the buffer, then place the tube on the magnet 
and remove buffer. “FAST” indicates that buffer should not be in contact with 
beads for longer than it takes to resuspend them:  
a. 1 mL of Sodium Phosphate buffer 
b. 1 mL 100 mM Glycine-HCl, pH 2.5 (FAST) 
c. 1 mL 10 mM Tris-HCl pH 8.8 
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d. 1 mL 100 mM Triethylamine solution (FAST) 
e. 4 x 1 mL DPBS 
f. 1 mL DPBS containing 0.5% Triton X-100. Leave the tube on a Tomy 
shaker (gentle setting) for 15 min.  
g. 1 mL DPBS 
9. Beads can be used immediately or stored at 4°C in DPBS containing 0.02% 
NaN3. For beads stored for future use, measure the final volume of the bead 
slurry (the bead size will contribute to the final volume) and make a note of the 
volume required for one mg beads as this will permit known aliquots of beads to 
be removed for multiple immunoaffinity purifications. Beads should be used 
within 2 weeks of conjugation. After 1 month of storage, their efficiency for 
isolation decreases by approximately 40%. 
 
Immunoaffinity purification: Basic elution of immunoisolates 
It is important to prepare all necessary reagents beforehand. Carry out all 
procedures on ice unless otherwise noted. At several steps during the protocol 
aliquots of samples (indicated with “RESERVE”) are taken to assess bait protein 
extraction and isolation efficiency (see section Assessment of immunoaffinity 
purification). 
 
Day 1 
1. Prepare appropriate volume of optimized lysis buffer as determined in section 
3.2.2. Pre-cool to 4°C. Add protease inhibitors just before use. Prepare 10 mL 
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of wash buffer per sample (used in steps 6, 11 – 13), which is usually identical 
in composition to the optimized lysis buffer, except protease and phosphatase 
inhibitors cocktails are not included. 
2. Incubate the frozen tissue powder on ice for 1 - 2 min, but do not thaw. Proceed 
immediately to step 3.  
3. Resuspend the frozen tissue powder in appropriate volume of lysis buffer by 
first adding a small amount of lysis buffer and swirling homogenate to solubilize 
pellet. Continue to add lysis buffer and gently mixing by hand until tissue 
powder has been completely solubilized (see Note 5).  
4. Run Polytron 10 sec in ultrapure dH2O to wash. Ensure that the tissue 
homogenate occupies ≤ 1/3 of the conical tube volume. Subject tissue lysates 
to Polytron homogenization for 2 x 15 second (speed = 22.5k), resting the 
sample on ice for a few minutes between homogenizations. If processing 
additional samples, rinse and run Polytron in ultrapure dH2O to wash out 
excess lysate.  When finished, perform a final rinse with methanol.  
5. Centrifuge the lysate at 8000 x g at 4°C for 10 minutes.  
6. During centrifugation, place tube containing antibody-conjugated magnetic 
beads on a magnetic rack for 30 – 60 secs. Discard the storage buffer and 
wash with 3 x 1 mL wash buffer by gently pipeting up and down to resuspend 
the beads. Do not vortex antibody-conjugated beads. Suspend beads in 100 – 
200 mL of wash buffer. 
7. Carefully pour the clarified lysates (supernatant) into new 50 mL conical tubes 
(see Note 6). RESERVE (i) the cell pellet and (ii) 40 mL of the input 
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supernatant (See section Assessment of immunoaffinity purification for 
analysis).   
8. Gently flick tube of antibody-conjugated beads to mix beads in solution.  Pipet 
the appropriate amount of beads into the clarified lysates. 
9. Rotate the lysates with beads on a rotator at 4°C for 1 hour. Do not use longer 
incubation times as this promotes the accumulation of non-specific binding and 
loss of weak interacting partners. 
10. During incubation, prepare base elution buffer and 1X LDS elution buffer (see 
Note 7). 
11. Attach a bar magnet to the lysates/bead suspension tube using a rubber band. 
Incubate on ice for 5 min. RESERVE the flow-through (unbound) fraction by 
pouring the supernatant into a clean conical tube (see section Assessment of 
immunoaffinity purification for analysis) 
12. Resuspend the beads in 1 mL of wash buffer and transfer the bead slurry to a 
round-bottom eppendorf tube.  
13. Place on a magnetic rack for 30 sec to pellet the beads and discard wash 
buffer.  Perform this procedure between all subsequent wash steps. 
14. Wash the beads 3 x 1 mL wash buffer. On the third wash, transfer the bead 
slurry to a clean round-bottom eppendorf tube, then pellet beads and discard 
wash buffer. 
15. Wash the beads 2 x 1 mL with wash buffer.  
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16. Add 1 mL DPBS to beads and transfer slurry to clean round-bottom eppendorf 
tube. Repeat wash once with 1 mL of DPBS to remove residual detergent. 
Quantitatively remove DPBS wash. 
17. Add 750 ml of base elution buffer. Incubate at RT for 20 min while shaking (see 
Note 8).  
18. Place the tube on the magnetic rack and transfer the eluate to an Axygen 
microcentrifuge tube. Freeze primary eluate in liquid nitrogen and evaporate to 
dryness overnight by vacuum centrifugation. 
19. Perform a second elution from the beads by suspending the beads in 40 µL of 
1X LDS elution buffer containing 50 mM DTT, incubating at 70°C for 10 min, 
and then at RT for 10 min while shaking. Place the tube on a magnetic rack and 
transfer the eluate to a clean microcentrifuge tube. RESERVE 10% (4 µl) of the 
secondary eluate in a clean microcentrifuge tube (see section Assessment of 
immunoaffinity purification for analysis). Freeze remaining 90% of secondary 
eluate in liquid nitrogen and store at -20°C. 
20. Proceed to Assessment of immunoaffinity purification to prepare reserved 
samples for Western blot analysis.  Continue with step 21 the following day. 
 
Day 2 
21. Remove dried eluate from the Speedvac.  
a. If performing SDS-PAGE-in-gel digestion (see Note 4), suspend dried eluate 
in 40 mL of 1X NuPAGE sample buffer containing 1X reducing agent and 
heat at 70°C for 10 min. RESERVE 10% (4 µl) of the eluate in a clean 
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microcentrifuge tube. Add 4 ml of 1 M iodoacetamide to remaining 90% of 
primary eluate and incubate 30 min at RT protected from light. Freeze in 
liquid nitrogen and store at -20°C or proceed immediately to proteomic 
analysis (see (Greco et al., 2012) 
b. If in-solution digestion is to be performed (see Note 4), suspend dried eluate 
in 40 mL of 1X LDS elution buffer containing 50 mM DTT and heat at 70°C 
for 10 min. RESERVE 10% (4 µl) of the eluate in a clean microcentrifuge 
tube. Freeze remaining 90% of primary eluate in liquid nitrogen and store at -
20°C or proceed immediately to proteomic analysis (see (Greco et al., 2012). 
 
Immunoaffinity purification: Alternate procedure (detergent elution of 
immunoisolates; see Note 7) 
 
Day 1 
1. Perform steps 1 – 16 as described above, except preparation of base elution 
buffer can be omitted (step 10). 
2. Add 40 µl of 1X LDS elution buffer to beads. Incubate 10 min at 70°C, then 10 
min at RT while shaking. 
3. Pellet beads on magnetic rack and transfer primary eluate to an Axygen 
microcentrifuge tube.  
4. Repeat Steps 2 and 3, transferring secondary eluate to an Axygen 
microcentrifuge tube.  
5. Add 2.0 mL of 1 M DTT to primary and secondary eluates. Heat at 70°C for 10 
min.  RESERVE 10% (4 µl) of eluates in clean microcentrifuge tubes.  
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6. If performing in-gel digestion (see Note 8), add 4 µl of 1 M iodoacetamide to 
remaining 90% of eluates and incubate at RT for 30 min protected from light. If 
performing in-solution digestion (see Note 8), proceed directly to step 7. 
7. Freeze remaining 90% of eluates in liquid nitrogen and store at -20°C or 
proceed immediately to proteomic analysis (see (Greco et al., 2012). 
 
Assessment of immunoaffinity purification: Sample preparation 
Reserved sample aliquots from section Immunoaffinity purification are 
prepared for SDS-PAGE and Western blot analysis. The recommended amount of 
each aliquot analyzed is provided as a starting point, and may need further 
optimization for differences in input material and bait protein abundance.  
 
1. Cell Pellet  
a. Wash the cell pellet with 1.0 mL dH2O. Homogenize washed cell pellet in 
1.0 mL of 2% SDS, transfer to microcentrifuge tube, and heat at 70°C for 10 
min. Centrifuge at maximum speed for 5 minutes at RT (see Note 9). 
b. Remove aliquot of SDS-soluble pellet fraction that corresponds to an 
identical percent of the input supernatant. For example, assuming a 40 µL 
aliquot of input supernatant was reserved from a total lysis volume of 10 mL, 
a 4 µL aliquot of the pellet sample should be removed.  
c. Dilute aliquot of SDS-soluble pellet fraction to a final volume of 60 µL 
containing 1X NuPAGE LDS Sample Buffer/1X Reducing Agent. 
2. Input Supernatant 
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a. Dilute 40 µL of reserved input supernatant to a final volume of 60 µL 
containing 1X NuPAGE LDS Sample Buffer/1X Reducing Agent. 
3. Flow-through (see Note 10) 
a. Transfer 10% of flow-through to clean tube. Slowly add 4 volumes of -20°C 
acetone. Vortex briefly. Incubate at -20°C for at least 1 hr. 
b. Centrifuge at 3000 x g at 4°C for 10 min. Pour off supernatant 
c. Briefly wash pellet with 4 volumes of 80% acetone/20% dH2O and discard. 
d. Air dry pellet for 5 min, then partially solubilize in 40 µL of 1X NuPAGE LDS 
Sampler Buffer/1X Reducing Agent by gentle agitation. 
4. Secondary Eluate 
a. Dilute 4 µL (10%) of the secondary eluate into a final volume of 40 µL 1x 
NuPAGE LDS Sample Buffer/1X Reducing Agent. 
5. Primary Eluate (prepared the following day, see Note 11) 
a. Dilute 4 µL (10%) of the primary eluate into a final volume of 40 µL 1x 
NuPAGE LDS Sample Buffer/1X Reducing Agent. 
6. Heat all samples at 70°C for 10 minutes. Freeze the samples at -20°C until 
ready to proceed with SDS-PAGE and western blot analysis. 
 
Assessment of immunoaffinity purification: SDS-PAGE and western blot analysis 
In this protocol the efficiency of immunoaffinity isolation of the bait protein is 
assessed by comparing 5 samples reserved at progressing stages of the 
immunoaffinity purification procedure: 1) cell pellet, 2) input supernatant, 3) flow-
through, 4) secondary eluate, and 5) primary eluate (see section Immunoaffinity 
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purification). While the amount of sample prepared (see section Sample preparation) 
is sufficient for duplicates analyses, the protocol below details a single experiment. A 
representative western blot is shown below (Figure A2.2A) indicating efficient 
isolation (no protein remaining in the flow-through) and recovery of the intended 
GFP-tagged bait protein (a majority of the protein was in the primary eluate). 
 
1. Set up the Xcell SureLock Mini-Cell electrophoresis system:  
a. Remove the white strip and the upper comb from the NuPAGE 4-12% Bis-
Tris pre-cast SDS-PAGE gel and rinse wells with ultrapure dH20. Place the 
gel in the apparatus, using a buffer dam for the opposing side, then lock the 
assembly in place.  
b. Fill the inner chamber with 200 mL and the outer chamber with 500 mL of 
1X Running Buffer. 
2. Thaw fractions if previously frozen and load into wells as follows: Lane 2, 10 µL 
Molecular Weight Standards; Lane 3, 30 µl of input supernatant; Lane 4, 30 µl 
of cell pellet; Lane 5, 20 µl of primary eluate; Lane 6, 20 µl of secondary eluate; 
Lane 8, 20 µl of flow-through; Empty lanes, 20 µL of 1X LDS Sample Buffer. 
3. Electrophorese for 5 min at 100 V, then 45 - 50 min at 200 V, or until the dye 
front has migrated all the way down the gel. 
4. While the gel is running, cut 2 pieces of Whatman filter paper and one PVDF 
membrane to the appropriate gel size. Always handle the membrane with 
tweezers.   
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5. Pre-wet PVDF in methanol and soak along with 2 transfer sponges, 2 filter 
papers, in pre-cooled 1X Transfer Buffer at least 15 min at 4°C. 
6. Open gel cassette to expose gel and discard the wells.  Working with wet 
gloves, transfer gel (by the thick ridge at the bottom) into a plastic tray 
containing 1X Transfer buffer.  Remove bottom ridge.   
7. Assemble a WB “sandwich” in the tray with pre-soaked items. Layer them in a 
transfer cassette as follows, starting from the clear side of the cassette: 
sponge, filter paper, PVDF membrane, SDS-PAGE gel, filter paper (gently roll 
out any bubbles using a 15ml conical tube), sponge. Close the sandwich and 
place into transfer apparatus with black side of cassette (gel side) facing black 
(anode) side transfer core. Place ice tray and stir bar into apparatus. Pour ice-
cold 1X Transfer Buffer into the apparatus until it covers fully the cassette.   
8. Transfer at 100 V for 1.5 hrs at 4°C while stirring. 
9. Open transfer cassette and discard the filter papers and gel. Verify the pre-
stained Molecular Weight Standards transferred to the membrane.  
10. Wash PVDF membrane with 1X TBST, discard, then add Blocking Buffer and 
incubate for 1 hour at RT on a rocking platform. Do not let the membrane dry. 
11. Discard Blocking Buffer and add the primary antibody diluted in Blocking Buffer. 
Incubate for 1-2 hours at RT or overnight at 4°C.    
12. Wash the membrane 3 x 20 mL in 1X TBST for 5 min while rocking at RT. 
13. Add the secondary horseradish peroxidase-conjugated antibody diluted in 
Blocking Buffer. Incubate for 1 hour at RT.  
14. Wash the membrane 4 x 20 mL in 1X TBST for 5 min while rocking at RT.   
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15. Mix ECL chemiluminescence substrates in 1:1 ratio (a total volume of 1 mL is 
usually sufficient to cover the membrane). Using tweezers, place the 
membrane on a dry plastic surface and apply the ECL solution, incubating for 1 
minute. Blot off the excess substrate and place the membrane between a sheet 
protector or Saran-wrap and tape into a film cassette. 
16. Carefully place a piece of autoradiography film on top of the membrane and 
close the cassette avoiding any film shifts as this will result in smeared bands. 
An initial exposure of 30 sec will indicate whether subsequent exposures of 
longer or shorter duration are required.  
 
Appropriate controls 
To assess the specificity of immunoaffinity isolation it is critical to have a 
control sample analyzed in parallel, beginning from tissue lysis through the isolation 
of the target protein. The controls described below account for non-specific binding 
of proteins to magnetic beads, antibody, and affinity tag (when present).   
 
GFP-tagged 
Often the bait protein is expressed as a GFP fusion protein. Here, parallel 
isolations of the GFP-tagged protein and GFP alone are highly desirable. If the GFP-
tagged protein is stably overexpressed by mRNA injection into embryos, it is 
necessary to generate a GFP-only tissue/animal in the same manner as the GFP 
fusion protein, i.e. mRNA injection of a GFP-only expression construct. Moreover, all 
treatment conditions and experimental variables, such as lysis buffer composition, 
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should be identical between the two isolations. Thus both the tag alone and the 
fusion protein can be immunoaffinity purified using identical preparations of 
antibody-conjugated magnetic beads. If lysis buffer conditions or other isolation 
variables are altered, such as incubation time of sample with antibody, an additional 
control should be performed. 
 
FLAG-tagged 
 If the bait protein is tagged with FLAG, then a more appropriate control 
(compared to the GFP tag), is the respective cell/tissue/animal but under wild type 
conditions. For both FLAG-tagged and wild-type conditions, magnetic beads 
conjugated with an antibody against the FLAG tag should be utilized. Although this 
doesn’t control for proteins that bind non-specifically to FLAG itself, non-specificity 
due to the antibody and beads can be determined.    
 
Endogenous, non-tagged protein 
In many experiments it is essential to immunoaffinity purify the bait protein at 
an endogenous level of expression (under its native promoter). Here, the control 
sample will use the identical cell/tissue/animal as for the experimental condition. In 
contrast to an affinity tag, the beads for the negative control are conjugated with 
either non-specific IgG or an IgG that lacks reactivity towards the endogenous bait 
protein. The control protein isolation will reveal interactions that bind non-specifically 
to the antibody and magnetic beads. A representative western blot from an 
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immunoisolation of endogenous Shp2 from X. tropicalis embryos is shown in Figure 
A2.2B.   
 
NOTES      
1. The number of embryos needed for each immunopurification is dependent on a 
number of criteria including protein abundance and solubility as well as the 
affinity of the antibody used for immunoisolation. For this reason, the optimal 
number of embryos and resulting amount of tissue must be optimized 
individually for each protein studied. Generally, 20-50 embryos per 
immunoisolation is a good starting point for small-scale experiments and may be 
scaled up for larger immunoaffinity purifications for proteomics studies. 
 
2. If starting directly with a small amount of tissue, the sample could be ground 
using round-bottom eppendorf tubes or used directly for incubation with the 
various lysis buffers. While performing the cryogenic grinding is preferred to 
mimic the conditions that will be utilized for protein isolation, direct resuspension 
in lysis buffer is an alternative that can adequately guide selection of an optimal 
buffer composition. 
 
3. The balance between extraction efficiency and maintenance of interacting 
partners can be further optimized by increasing the stringency of the buffer 
used to wash the magnetic beads relative to the buffer used for tissue 
homogenization. 
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4. To test the efficiency of bead conjugation, prepare the following samples for 
SDS-PAGE analysis: 1) Dilute >1 µg neat antibody with 2.5 µL 10x Reducing 
Agent and 6.25 µL 4x NuPAGE LDS Sample Buffer. Bring the sample to 25 µL 
total volume with dH2O. 2) Calculate the amount of bead supernatant that is 
equivalent to the amount of neat antibody in the previous sample, assuming that 
no antibody successfully conjugated to the beads. Dilute this amount with 2.5 µL 
10X Reducing Agent and 6.25 µL 4X NuPAGE LDS Sample Buffer. Bring 
sample to 25 µL with ultrapure H2O. Heat samples for 10 minutes at 70°C. 
Centrifuge the samples at 20,000 x g for 3 minutes at room temperature and 
load onto an SDS-PAGE gel. Stain the gel with SimplyBlue SafeStain and look 
for a reduction in the amount of antibody in the lane containing the bead 
supernatant. Refer to Cristea et al. 2005 (Cristea et al., 2005) for the expected 
amount of unbound antibody resulting from differing amounts of antibody used 
in the conjugation. 
 
5. After suspending tissue powder in lysis buffer, the solution may be slightly 
turbid, but should be devoid of tissue “clumps”.  Do not proceed to Polytron 
(step 4) until a homogenous suspension is observed. If necessary, additional 
rotation for 10 – 20 min at 4°C can be performed.  
 
6. If insoluble particles are present in supernatant after centrifugation, a pipet can 
be used to selectively transfer supernatant to clean 50 mL conical tube. 
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7. The base elution buffer is preferred as significantly less background protein 
contamination is observed under these elution conditions. However, if low 
recovery of bait protein is observed, e.g. when a high affinity antibody is used, 
an “Alternate Procedure” can be followed that uses a harsher detergent-based 
elution buffer (see above). 
 
8. The selection of an in-gel or in-solution digestion approach depends largely on 
the properties and nature of the proteins within the samples, e.g. pI, molecular 
weight, hydrophobicity, complexity, dynamic range, and total yield. In general, 
for high complexity and large yield and/or dynamic range of protein abundances, 
an in-gel approach is often desired. For further discussion, see (Greco et al., 
2012). 
 
9. For viscous samples, brief sonication can be used to aid solubilization of cell 
pellet. 
 
10. As the flow-through fraction often has higher protein concentration, the percent 
of material analyzed may need to be adjusted to prevent overloading of the SDS 
gel.  For NuPAGE gels of 1.0 mm thickness, between 100 – 150 mg is 
recommended.  
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11. If base elution buffer is used, processing of the primary eluate and its reserved 
fraction is not performed until the day after the immunoisolation was started (see 
section Immunoaffinity purification: Base elution, step 20).  
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 Figure A2.1. Immunoisolation of protein complexes from Xenopus. 
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Figure A2.2. Assessment of isolation efficiency and specificity of 
immunoaffinity purification. (A) A GFP-tagged bait protein was isolated and eluted 
with the alternate detergent-based procedure. 10% of the following fractions were 
analyzed to assess the efficiency of isolation: FT, flow-through; PE, primary eluate; 
SE, secondary eluate. The majority of bait protein was found in the primary eluate. 
(B) Immunoaffinity purification of endogenous Shp2 protein from 100 stage 40 
Xenopus tropicalis whole embryos. As a control for the specificity of the Shp2 
antibody, a second immunopurification was performed using anti-V5 antibody-
conjugated beads. 
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Table A2.1. Examples of detergents commonly used for cell lysis and their 
properties. 
Detergent' Properties' Notes'
Triton'X0100' • Nonionic&detergent&&
• pH&6.0&to&8.0&(5%&aqueous&solution)&&
• Critical&micelle&concentration&(CMC):&0.22@
24&mM&&
• Soluble& at& 25°C& in& all& proportions;& Soluble&
in& water,& benzene,& toluene,& xylene,&
trichloroethylene,& ethylene& glycol,& ethyl&
ether,& ethanol,& isopropanol,& ethylene&
dichloride&&
• Depending& on& the& utilized&
concentration,& Triton& is&
considered& a& relatively&
mild,& non@denaturing&
detergent.& Many& enzymes&
remain&active&in&0.1%@0.5%&
Triton& X@100& solution& (e.g.&
Proteinase& K& is& still& active&
in&1%&solution).&&
• Can& be& used& to& preserve&
protein@lipid&interactions&
Sodium'
deoxycholate'
(DOC)'
• Anionic&detergent&&
• pH&5.0&to&9.0&(1%&aqueous&solution)&
• CMC:& 2@6& mM& (0.083& to& 0.249%,& w/v).&
Micelle& Molecular& Weight:& 2000& g&
(average),&at&concentrations&above&2&mM&&
• Soluble& at& 20°C;& Soluble& in& water& in& less&
than&5%&solution&
• Common& component& of&
RIPA&lysis&buffer.&
• Suitable& for& isolating&
membrane& associated&
proteins,& and& liposome&
preparation.& Disrupts&
protein@lipid&interactions.&&
Digitonin' • Nonionic&detergent&
• pH:&data&not&available&
• CMC:& <0.5& mM,& at& 20@25°C.& Micelle&
Molecular&Weight:&70,000&g&(average)&&
• Soluble& in& water& at& ~5%& (w/v);& Must& be&
heated& to& 95@98°C& first,& then& cooled& to&
room& temperature.& Soluble& in& ethanol& at&
10&mg/mL&
• Suitable& for& analyzing&
membrane@bound&proteins&
and&solubilizing&lipids.&
Octyl0beta0
glucoside'
• Nonionic&detergent&
• pH:&data&not&available&
• CMC:& 23@25& & mM& (0.6716& to& 0.7300%,&
w/v);&Micelle&Molecular&Weight:&8000&g&
• Soluble&in&water&
• Suitable& for& studying&
membrane@associated&
proteins&
• Readily& integrated& with&
mass&spectrometry&studies&
(i.e..,&does&not& interfere&as&
much& as& other& detergents&
with& ionization& in& MALDI&
MS&experiments)&
Nonidet'P040' • Nonionic&detergent&
• pH&5.0&to&8.0&(5%&aqueous&solution)&&
• CMC:&0.059&mM&(20@25C)&&
• Soluble&in&water&
• Milder& alternative& to&
Triton& X@100;& depending&
on& the& concentration& it&
may&not&penetrate&nuclear&
membranes.&
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Table A2.2. Examples of lysis buffers used for immunoaffinity purification of 
protein complexes. 
Bait' (GFP0
tagged)'
Description'&'
Localization'
Species'&'
Sample'type' Optimized'Lysis'Buffer''' Ref.'
Apl1&& beta@adaptin&of&&
AP@2&complex;&
cellular&
membrane&&&
&
'
S.#cerevisiae#
cells#
20& mM& K@HEPES,& pH& 7.4,& 110& mM&
KOAc,& 2& mM& MgCl2& ,& 0.1%& Tween,&
0.4%& Triton,& 200& mM& NaCl,& 1/100&
(v/v)& protease& inhibitor& mixture& (20&
mg/mL& PMSF& +& 0.4&mg/mL& pepstatin&
A),&and&1/200&(v/v)&protease&inhibitor&
cocktail)&
(Cristea&
et&al.,&
2005)&
Nup37&& Member&of&
nuclear&pore&
complex;&
subunit&of&
Nup107@160&
subcomplex&
Homo#sapiens#
cells#
20& mM& K@HEPES,& pH& 7.4,& 110& mM&
KOAc,&2&mM&MgCl2,&0.1%&Tween,&0.5%&
Triton,& 200& mM& NaCl,& 1/100& (v/v)&
protease&inhibitor&mixture&(20&mg/mL&
PMSF& +& 0.4&mg/mL& pepstatin& A),& and&
1/200& (v/v)& protease& inhibitor&
cocktail)&
(Cristea&
et&al.,&
2005)&
HDAC5& Histone&
deacetylase&5;&
Nucleus&and&
Cytoplasm&
&
Homo#sapiens#
cells#
20& mM& HEPES@KOH,& pH& 7.4,& 0.1& M&
potassium& acetate,& 2& mM& & MgCl2,&
0.1%& Tween@20,& 1& μM& & ZnCl2,& 1& μM&&
CaCl2,& 0.5%& Triton& X@100,& 250& mM&
NaCl,& 4& μg/mL& DNase,& 1/100& (v/v)&
protease& and& phosphatase& & inhibitor&
cocktails&
(Greco&et&
al.,&2011)&
PAP&I& poly(A)&
polymerase&I;&
Cytoplasm&and&
inner&
membrane&
Escherichia#coli#
cells&
20&mM&HEPES,&pH&7.4,&0.11&M&KOAc,&2&
mM& MgCl2,& 0.1%& Tween@20& (v/v),& 1&
µM& ZnCl2,& 1& µM& CaCl2,& 1%& Triton& X@
100,& 0.5%& Deoxycholate,& 150& mM&
NaCl,& 1:100& protease& inhibitor&
cocktail,& 1:200&
phenylmethylsulphonyl&fluoride&
(Carabett
a&et&al.,&
2010)&
H3& Histone&3&
isoforms;&
Nucleus&
Mus#musculus#
ES&cells#
20&mM& K@HEPES,& pH& 7.4,& 110&mM& K@
acetate,&0.1%&Tween&20,&0.5%&Triton,&
300& mM& NaCl,& and& 1/100& (v/v)&
protease&inhibitor&cocktail&
(Goldber
g&et&al.,&
2010)&
nsP3& Sindbis&
nonstructural&
protein&3;&
Cytoplasm&
Sindbis@infected#
Rattus#
Norvegicus#
cells&&
20& mM& K@HEPES,& pH& 7.4,& 110& mM&
KOAc,& 2& mm&MgCl2,& 0.1%& Tween& 20,&
1%& Triton,& 0.5%& deoxycholate,& 500&
mM&NaCl,& 25& units/mL& DNase,& 1/100&
(v/v)&protease&inhibitor&mixture&&
(Cristea&
et&al.,&
2006)&
PSD& (via&
VGluRδ2)&
postsynaptic&&
densities;&
cerebellar&
excitatory&
synapses&
Mus#musculus#
tissue&
10&mM&HEPES,&pH& &7.4,&2&mM&CaCl2& ,&
132& mM& NaCl,& 3& mM& KCl,& 2& mM&
MgSO4,& 1.2& mM& NaH2PO4,& 0.5%&&
Triton& & X@100,& 1/100& (v/v/)& protease&
inhibitor&cocktail&
(Selimi&et&
al.,&2009)&
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